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Abstract
Background: Congenital hyperinsulinism (CHI) is a clinically heterogeneous condition.
Mutations in seven genes (ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1 and
HNF4A) are known to cause CHI, with mutations in HNF4A being the most recent
identified genetic aetiology. Recessive mutations in ABCC8/KCNJ11 cause severe
medically unresponsive hyperinsulinaemic hypoglycaemia (HH). Recently, dominant
mutations in these genes have been described that cause mild, medically responsive HH.
Controversy exists on whether these dominant ABCC8/KCNJ11 mutations predispose to
diabetes mellitus in adulthood or not. The phenotype and prevalence of the genetic
subgroups in a large cohort of patients has not been studied previously.
Aims: The aims of this thesis include:
1. To investigate genotype/phenotype correlations in a large cohort of patients with
CHI by comparing different genetic aetiologies
2. To examine the prevalence and phenotype of patients with HH resulting from
HNF4A gene mutations
3. To study the phenotype of dominantly inherited KATP channel mutations causing
CHI and functionally characterize the novel dominant mutations identified
Methods: 300 patients with biochemically confirmed CHI were recruited. Detailed clinical
information was collected prior to genotyping. ABCC8 and KCNJ11 genes were
sequenced in all patients with CHI that were unresponsive to diazoxide, the mainstay of
medical treatment in CHI. Mutations in the GCK, GLUD1 and HADH genes were sought in
patients with diazoxide responsive CHI with hyperammonaemia (HI/HA) (or leucine
sensitivity (GLUD1)), raised 3-hydroxybutyryl-carnitine (HADH) or positive family history
and/or delayed presentation (GCK). If no mutations were identified and in all other patients
with diazoxide responsive CHI (and where diazoxide responsiveness was not known);
ABCC8, KCNJ11 and HNF4A genes were sequenced. The clinical characteristics of
patients with the different genetic aetiologies identified were collated and the phenotypic
characteristics of the patients found to have a HNF4A mutation were compared with the
phenotypic characteristics of patients with transient and/ or diazoxide responsive CHI and
a KATP mutation (n= 27), GLUD1 mutation (n= 13) or a HADH mutation (n=3). The one-way
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analysis of variance (ANOVA) test was used to compare the phenotypic data followed by
LSD post-test to test for statistical significance.
Protein sensitivity was investigated in patients with a HADH mutation (n=3). Upon
confirmation of protein sensitivity, leucine tolerance test were conducted in these patients
to understand the mechanism of protein sensitivity.
The phenotype of ten families with dominant ABCC8/KCNJ11 mutations and the
prevalence of diabetes mellitus in the adult mutation carriers were also studied in detail.
Functional consequences of six novel dominant KATP channel mutations (five ABCC8 and
one KCNJ11) were examined by reconstituting the KATP channel in HEK293 cells and
evaluating the effect of drugs (diazoxide, glibenclamide) and metabolic poisoning on the
channels using 86Rb flux assay.
Results: Mutations were identified in 146/300 patients (48.6%). Mutations in the
ABCC8/KCNJ11 were the commonest genetic cause identified (n=117, 39%). Among
diazoxide unresponsive patients (n=105), mutations in these two genes were identified in
92 (87.6%); of whom 63 patients had recessively inherited mutations while four patients
had three novel dominantly inherited ABCC8 mutations (G1485E, D1506E and M1514K).
Among the diazoxide responsive patients (n=183), mutations were identified in 51 patients.
These include mutations in the ABCC8(n=25), KCNJ11(n=3), HNF4A(n=7), GLUD1(n=16)
and HADH(n=3). No mutations were identified in 132 (72%) patients in this group.
Heterozygous missense mutations were detected in 15 patients with HI/HA, two of which
are novel (N410D, D451V). In addition, a patient with a normal serum ammonia
concentration (21µmol/l) was heterozygous for a novel missense mutation P436L.
Functional analysis of this mutation confirmed that it is associated with a loss of GTP
inhibition. Seizure disorder was common (43%) in our cohort of patients with a GLUD1
mutation.
The study identified a novel homozygous missense mutation (M188V) in the HADH gene
in a patient with normal acylcarnitines and urine organic acids. Hydroxyacyl-Coenzyme A
dehydrogenase activity was significantly decreased compared with controls (index patient
mean 26.8 ± SEM 4.8mU/mg protein vs. controls 48.0 ± 8.1; p=0.029) in skin fibroblasts.
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This patient and two other children with CHI due to HADH gene mutations were severely
protein sensitive. The three children also demonstrated marked leucine sensitivity.
HNF4A mutations were identified to cause persistent CHI in addition to transient CHI,
reported previously. 3/8 children with an HNF4A mutation did not have a diabetic parent.
Children with HNF4A mutations had increased birth weight (median +2.4 SDS) and
presented early (median of day 1). Patients with a KATP channel mutation were also large
at birth (birth weight SDS ranged between -1.96 to +4.66) with an early age of presentation
(ranging from 1 day to 365 days). In contrast, patients with a GLUD1/ HADH mutation
were diagnosed later (mean of 157 and 125 days respectively) and were of normal birth
weight (mean birth wt SDS of -0.11 and -1.09 respectively).
Study of the phenotype of the dominant ABCC8/KCNJ11 mutations identified an increased
prevalence (57%) of diabetes in the adult mutation carriers. Functional studies on the
novel ABCC8/KCNJ11 mutations showed no 86Rb efflux when the mutant channels were
activated, thus confirming the pathogenicity of the mutations.
Conclusions: A genetic diagnosis was possible in only 48.6% of patients with mutations
in the ABCC8 gene being the commonest cause.
Recessively inherited mutations in the ABCC8/ KCNJ11 are associated with diazoxide
unresponsive disease. However, the phenotype associated with dominant ABCC8/
KCNJ11 mutations is variable, ranging from mild medically responsive CHI to severe early
onset CHI requiring a near total pancreatectomy. In adults, dominant ABCC8/ KCNJ11
mutations may also be an important cause of dominantly inherited early onset diabetes
mellitus.
Patients with hyperinsulinism due to mutations in the GLUD1 gene have a high risk of
epilepsy and may have normal serum ammonia concentrations. Hence GLUD1 mutational
analysis may be indicated in patients with leucine sensitivity; even in the absence of
hyperammonaemia.
Mutations in the HADH gene are associated with protein induced HH due to leucine
sensitivity, suggesting a novel biochemical pathway by which HADH regulates leucine
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induced insulin secretion. Patients with CHI due HADH gene mutations may have normal
acylcarnitines and urine organic acids. Hence, sequencing of HADH must be considered in
patients with diazoxide responsive HH from consanguineous families, even in the absence
of these features.
In this large series, HNF4A mutations were the third common cause of diazoxide
responsive CHI causing both transient and persistent HH, even in the absence of a family
history of diabetes. HNF4A sequence analysis must hence be considered in all patients
diagnosed with HH in the first week of life, irrespective of a family history of diabetes
mellitus.
Future Work: The vast majority of patients with diazoxide responsive CHI had no
mutations identified suggesting other novel mechanisms of insulin secretion.
Understanding the genetic aetiology of CHI in this large cohort of patients will provide
novel insights into pancreatic beta-cell physiology and have implications for
hypoglycaemia and diabetes mellitus.
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1Chapter 1- Introduction
The Physiology of Blood Glucose Control and the Role of Insulin
Glucose is the principal fuel for most mammalian cells and their metabolic needs. The
brain, under normal conditions, uses glucose as an obligatory substrate. Since the brain
has a limited supply of endogenous glucose and glycogen, it relies on a sustained and
continuous supply of glucose from the blood (Jones et al., 1975). Hence the maintenance
of normoglycaemia (fasting blood glucose concentration of 3.5-5.5mmol/L) is important for
the normal functioning of the brain; especially during active periods of brain development
and growth in infancy and childhood. Conditions that cause hypoglycaemia in childhood
can therefore cause permanent damage to the brain with long term neuro-developmental
deficits and have enormous implications for children and their carers.
Blood glucose concentration is tightly regulated by maintaining a balance between glucose
production and glucose utilisation. In normal individuals blood glucose remains in a narrow
range despite periods of feeding and fasting. This equilibrium is maintained by a complex
interplay of glucose, insulin and counter-regulatory hormones that include glucagon,
catecholamines, growth hormone and cortisol. This chapter describes the pathways
involved in glucose production and utilisation, the role of insulin in regulating the balance
between them and details the complex regulation of insulin secretion.
1.1 Glucose production
Ingested carbohydrates are broken down to form monosaccharides which are then
transported to liver and converted into glucose. Apart from ingested carbohydrates,
glucose is also produced by the following processes:
2Glycogenolysis: This involves the breakdown of stored glycogen to release glucose.
Glycogenolysis occurs in liver and muscle (where glycogen is stored) in response to
glucagon and/ or adrenaline secretion. This maintains the blood glucose concentration
during fasting and provides the brain with a ready source of glucose. The first step
involves activation of glycogen phosphorylase that phosphorylates glucose molecules in
the glycogen chain to form glucose 1-phosphate, which is converted to glucose 6-
phosphate. This is then converted to glucose by glucose-6-phosphatase. Glucagon and
insulin control glycogenolysis by their opposing actions on these two enzymes.
Gluconeogenesis: This involves the synthesis of glucose from non-carbohydrate sources
such as lactate, pyruvate, glycerol and amino acids (especially alanine). This process
mainly occurs in the liver and to some extent in the kidneys. Glycogenolysis begins within
2–3 h after a meal in humans while gluconeogenesis assumes a much greater importance
with prolonged fasting. The rate of gluconeogenesis is controlled principally by the
activities of certain unidirectional enzymes, such as phosphoenolpyruvate carboxykinase
(PEPCK), fructose-1,6-bisphosphatase and glucose-6-phosphatase (G6Pase). The genes
encoding these proteins are tightly controlled at the transcriptional level by key hormones,
particularly insulin, glucagon and glucocorticoids. In the fasted state, insulin levels drop
while glucagon secretion goes up resulting in increased glycogenolysis and
gluconeogenesis. In the fed state; insulin increases, suppressing glycogenolysis and
hepatic glucose production.
31.2 Glucose utilisation
Glucose is utilised by nearly all peripheral tissues. It enters the cells via two different types
of membrane associated carrier proteins, the sodium-coupled glucose transporters (SGLT)
and glucose transporter facilitators (GLUT). The distribution of these transporters varies in
different tissues and depends upon the kinetic properties of the transporters and the
requirement of the tissues. It is beyond the scope of this thesis to discuss each of the
transporters and the complex mechanism occurring at the cell level that leads to glucose
entry in the cell. A few important aspects of glucose transport are discussed instead.
GLUT1 and GLUT3 transporters facilitate the uptake of glucose in the brain. GLUT1 is
mainly expressed in the microvasculature of the brain and is responsible for transfer of
glucose across the blood brain barrier, while GLUT3 is predominantly expressed in the
neurons of the brain. In rats, hypoglycaemia has been shown to increase the expression of
GLUT1 mRNA (Simpson et al., 1999).
GLUT2, a low-affinity glucose transporter is predominantly expressed in the pancreatic ß-
cells, liver, kidney, and small intestine. This transporter plays an important role in
maintaining blood glucose concentrations because of its role in glucose absorption from
the intestinal lumen, reabsorption of glucose in kidneys, glucose sensing in the pancreatic
ß-cells and glucose uptake and release in the hepatocytes. The kinetic properties of
GLUT2 allow transport of glucose within these tissues even at high blood glucose
concentrations. Hence in these tissues glucose utilisation is not dependent on the number
and activity of the glucose transporters but on the blood glucose concentration (Brown
2000).
4GLUT4 is an insulin-sensitive glucose transporter, most abundantly found in the skeletal
and cardiac muscle and adipose tissue (James et al., 1989) and is the main glucose
transporter in these tissues. Insulin stimulation transports GLUT4 present in the
cytoplasmic vesicles to the cell membrane, increasing the glucose uptake in these tissues
(James et al., 1989).
After entry into the cells, glucose undergoes three metabolic fates:
1) Glycolysis- catabolism of glucose in the cells to produce adenosine triphosphate
(ATP)
2) Glycogenesis- storage as glycogen (in the liver and muscle)
3) Conversion to fatty acids and storage as triglycerides (in adipose tissue)
These fates are dependent upon the blood glucose concentration, length of fasting and the
hormonal milieu. Among the hormones that play a role, the principal hormone is insulin.
The following section gives a brief description about the synthesis, actions and regulation
of insulin secretion and its role in glucose physiology.
1.3 Insulin: Structure and Synthesis
Insulin is a hormone produced in the ß-cells of the islets of Langerhans in the pancreas. It
is a 51 amino acid polypeptide consisting of two chains (A & B) that are connected by
disulphide bridges and has a molecular weight of 5.8 kDa.
Preproinsulin is the primary precursor molecule that consists of a signal peptide, the A and
B chains of insulin and a connecting peptide (or C-peptide) (Steiner et al., 1967). It is
processed in the endoplasmic reticulum to proinsulin by removal of the signal peptide.
Proinsulin is then folded for the disulfide bonds to be formed between the A and B chains.
It is then transported to the Golgi apparatus where it is packaged into secretory vesicles.
5These vesicles contain endopeptidases that catalyse the conversion of proinsulin to form
mature insulin. The C-peptide is liberated from the centre of the proinsulin sequence and
the ends (the A chain and B chain) are connected by disulfide bonds. Insulin and c-peptide
are stored together in the secretory vesicles and are released by exocytosis on
appropriate stimulation.
1.4 Physiological actions of insulin
Insulin is an anabolic hormone. It decreases glucose production and increases glucose
utilisation by the following effects on carbohydrate, fat and protein metabolism (figure 1.1):
i. Effect on carbohydrate metabolism: Insulin inhibits the release of glucose from
stored glycogen in the liver (glycogenolysis). It also inhibits gluconeogenesis
directly by inhibiting the key gluconeogenic enzyme PEPCK, and indirectly by
inhibiting the release of free fatty acids (FFA) from adipose tissue. It activates
enzymes for glycogenesis (conversion of glucose to glycogen) and glucose
utilisation (glycolysis) (Radziuk and Pye, 2001). Insulin also facilitates glucose
uptake in skeletal muscle and adipose tissue by its action on the glucose
transporter (GLUT-4) (Scheepers et al., 2004). In the absence of insulin, GLUT-
4 glucose transporters are removed from the cell membrane and stored in
cytoplasmic vesicles. Finally, insulin activates hexokinase, which
phosphorylates glucose to form glucose-6-phosphate. This facilitates glucose
transport through the GLUT-2 transporter in the hepatocytes and keeps the
intracellular concentrations of glucose low.
6ii. Effect on lipid metabolism: Insulin inhibits the mobilisation of FFA/ glycerol from
adipose tissue. It stimulates free fatty acid synthesis (lipogenesis) and its
conversion to triglycerides in the liver. Insulin has also been shown to increase
cholesterol synthesis by increasing the key enzyme involved in cholesterol
synthesis, ß-hydroxy-ß-methylglutaryl coenzyme- A (HMG-CoA) reductase
(Lakshmanan et al., 1973).
iii. Effect on protein metabolism: Insulin reduces the release of amino acids from
muscle by inhibiting proteolysis. It also increases the uptake of amino acids into
liver and muscle and stimulates their conversion to protein.
Figure 1.1: Summary of the effects of insulin. Insulin reduces blood glucose
concentration by inhibiting glycogenolysis, gluconeogenesis, lipolysis and ketogenesis
and by enhancing the uptake of glucose by insulin sensitive tissues.
Insulin
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71.5 The regulation of insulin secretion
As insulin is the principal hormone that controls blood glucose concentration, the
regulation of insulin secretion plays a key role in maintaining normoglycaemia. Insulin
secretion in turn is controlled by a number of stimuli which include nutrients, hormones and
neurotransmitters. Glucose is the major stimulus for insulin secretion such that a rise in
blood glucose concentration leads to an increase in insulin secretion and vice-versa. After
a meal, when the blood glucose concentration increases, insulin secretion is stimulated
leading to a drop in blood glucose by mechanisms described above (figure 1.1). In
between meals, when there is no dietary glucose intake, there is less insulin and more
glucagon secreted. This stimulates glycogenolysis, gluconeogenesis and stops
glycogenesis to maintain the blood glucose concentration.
1.5.1 Nutrient induced insulin secretion
1.5.1.1 Glucose stimulated insulin secretion (GSIS):
Glucose induces a biphasic pattern of insulin release. First-phase insulin release occurs
within the first few minutes after exposure to an elevated glucose concentration; this is
followed by a more sustained second phase of insulin release.
In the pancreatic ß-cells, glucose enters the cytoplasm through facilitative glucose
transporters, especially the glucose transporter 2 (GLUT2) (Johnson et al., 1990;
Scheepers et al., 2004). GLUT2 has a high Km for glucose (approximately 40mmol/L) and
is expressed predominantly in the liver, kidney, ß-cells of the pancreas and intestinal
mucosal cells. The high Km for glucose of GLUT2 allows glucose transport by pancreatic
ß-cells and hepatocytes in proportion to the blood glucose concentration (Gould et al.,
1991; Scheepers et al., 2004). This, along with the glucose sensing abilities of the enzyme
8glucokinase, leads to the control of insulin secretion by the pancreas and the uptake or
release of glucose by hepatocytes as required, to regulate blood glucose concentration.
Glucose entry into the cells is followed by phosphorylation by the highly glucose specific
enzyme, glucokinase. Glucokinase acts as a glucose sensor and due to its high Km, it
does not saturate under physiological basal glucose levels. This allows the pancreatic ß-
cells to adjust the rate of insulin secretion and hence this is thought to be the rate limiting
step for insulin secretion (Matschinsky, 2002). Following phosphorylation, glucose is
metabolized to pyruvate (glycolysis) which then enters the Kreb’s cycle to produce ATP.
ATP triggers closure of the adenosine triphosphate-sensitive potassium channels (KATP)
channels located on the ß-cell membrane which leads to insulin release. The structure of
the KATP channels and the mechanism by which the channels couple metabolic signals
generated from glucose metabolism to insulin secretion is discussed below.
1.5.1.1.1 Overview of KATP channels and their role in GSIS:
The KATP channels are hetero-octameric complexes comprising of four inwardly rectifying
potassium channels (Kir6.2) and four sulphonylurea receptor 1 (SUR1) subunits. The
Kir6.2 forms the pore of the channel and the SUR1 (an ATP Binding Cassette Transporter)
acts as a regulatory subunit (Inagaki et al., 1995) (figure 1.2 b). KATP channels are
regulated by adenine nucleotides to convert changes in cellular metabolic levels into
membrane excitability. Each subunit of the KATP channel is known to be differentially
regulated. The Kir6.2 subunit determines the biophysical properties of the channel
complex including K+ selectivity, rectification, inhibition by ATP and activation by acyl-CoAs
(Tucker et al., 1998). The sulfonylurea receptors endow KATP channels with sensitivity to
the stimulatory actions of magnesium-nucleotides and KATP channel openers (e.g.
9diazoxide, nicorandil) and the inhibitory effects of sulphonylureas and glinides (Aguilar-
Bryan L et al., 1999).
The molecular topology of SUR1 consists of three transmembrane domains- TMD0,
TMD1 andTMD2; each of which consist of five, five, and six membrane spanning regions
respectively (Conti et al., 2001). SUR1 also has two nucleotide binding domains (NBD-1
and NBD-2) on the cytoplasmic side (figure 1.2 a) with which it senses changes in the
intracellular ATP/ADP ratio and transmits the signal to the pore. NBD1 appears to be the
principal site for ATP binding, whereas NBD2 binds MgADP (Conti et al., 2001). NBD-1
and NBD-2 are located in the loop between TMD1 and TMD2 and in the C-terminus,
respectively. These binding domains cooperate with each other in mediating the nucleotide
regulation of the pore function (Ueda et al., 1999). NBDs of SUR contain highly conserved
motifs among ABC proteins: Walker A motif, Walker B motif, ABC signature motif (also
known as linker sequence or LSGGQ motif), and an invariant glutamine and histidine
residue (also known as the Q-loop and H-loop, respectively). Walker A and Walker B
motifs are directly involved in nucleotide binding (Matsuo et al., 2005).
10
Figure 1.2A: Schematic outline of the components of the ß-cell KATP channel. The KATP
channel is composed of two proteins: SUR1 which consists of 17 transmembrane domains
with two intracellular nucleotide binding (NBD) motifs. Two N-linked glycosylation sites are
present on amino acids 10 and 1049. Kir6.2 has 3 transmembrane segments.
Figure 1.2B: illustrating the hetero-octameric arrangement of the KATP channel.
(Figure adapted from James et al., 2009.)
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KATP channels can only function if they are assembled and correctly transported to the cell
membrane surface (trafficking). The assembly and trafficking of KATP channels are
intricately linked processes. Only octameric KATP channel complexes are capable of
expressing on the cell membrane surface. For example both Kir6.2 and SUR1 possess an
endoplasmic reticulum (ER) retention signal (RKR) that prevents the trafficking of each
subunit to the plasma membrane in the absence of the other subunit (Zerangue 1999).
Coexpression of two subunits masks these retention signals, allowing them to move to the
plasma membrane. The retention signal is present in the C terminal region of Kir6.2 and in
an intracellular loop between TMD1 and NBD-1 in SUR1. Truncation of the C-terminus of
Kir6.2 deletes its retention signal, allowing functional expression of Kir6.2 in the absence
of SUR1 subunit (Tucker et al., 1997). In addition to these retrograde signals, the C
terminus of SUR1 has an anterograde signal, composed in part of a dileucine motif and
downstream phenylalanine, which is required for KATP channels to exit the ER/cis-Golgi
compartments and transit to the cell surface (Sharma et al., 1999). Deletion of as few as
seven amino acids, including the phenylalanine, from SUR1 markedly reduces surface
expression of KATP channels (Babenko et al., 1998). Thus, one function of SUR is as a
chaperone protein, to facilitate the surface expression of Kir6.2.
There is also some evidence that Kir6.2 provides a reciprocal service for SUR1 (Clement
et al., 1997).The SUR1 protein shows a high-affinity binding capacity to the sulfonylurea
glibenclamide, indicating that SUR1 confers sulfonylurea binding (Inagaki et al., 1996).
The sulfonylurea drugs (glibenclamide and tolbutamide) inhibit the channels and are used
in the treatment of non-insulin-dependent (type II) diabetes mellitus. The other class of
drugs, known as potassium channel openers (e.g. diazoxide), activate the channel and are
used to suppress insulin secretion.
In euglycaemic conditions, the KATP channels are open which allows potassium efflux from
the pancreatic ß-cell. This keeps the ß-cell membrane at a negative potential at which
voltage-gated calcium (Ca2+) channels are closed. An increase in the blood glucose
concentration leads to production of ATP. The increase in the ATP/ ADP ratio triggers
closure of the KATP channels leading to the depolarisation of the ß-cell membrane. This in
turn leads to the opening of the voltage gated Ca2+ channels and Ca2+ ion influx. The entry
of calcium ions triggers exocytosis of insulin (figure 1.3).
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Apart from the above described KATP channel-dependent pathway, glucose also stimulates
insulin secretion via KATP channel independent pathways (Gembal et al., 1992). The KATP
channel-independent pathways act synergistically to augment the secretory responses to
increased intracellular calcium and lead to the second and more sustained phase of
glucose-stimulated insulin secretion. However the mechanisms of these pathways are
poorly defined. The two widely proposed theories are:
1. High glucose concentrations lead to increased citrate levels and increased malonyl-
CoA. This inhibits carnitine palmitoyl transferase-1 (CPT1) activity and leads to
suppression of fatty acid oxidation (Corkey et al., 1989, Prentki et al., 1992). It has been
proposed that the consequent accumulation of long chain acyl-CoAs in the extracellular
space enhances the release of insulin by unknown mechanisms (Prentki et al., 1992).
2. Glucose generates glutamate in the pancreatic ß-cell mitochondria which acts as a
signalling molecule for insulin secretion (Maechler and Wollheim, 1999). In support of this
theory, Maechler and Wollheim showed that glucose causes elevated intracellular
glutamate concentration and direct addition of glutamate to INS-1 cells led to insulin
secretion. However, these studies were performed on the INS-1 cell line that does not
have a KATP channel independent pathway. Furthermore, other studies performed on
pancreatic ß-cell islets did not show an elevation in intracellular glutamate levels following
exposure to glucose or that increased intracellular glutamate (following exposure to
glutamine) leads to insulin secretion (MacDonald and Fahein, 2000). In defence of the
theory, it has been pointed out that a) the alkalinising effect of glutamine may adversely
effect the cell and the affect of glutamate on insulin secretion and b) the findings in isolated
islets may not represent what actually happens in the pancreatic ß-cell (Rutter, 2001).
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It has also been proposed that adenine and guanine nucleotides, that control the KATP
channel dependent pathway, also control the KATP channel-independent pathway
(Detimary et al., 1996). The control of both pathways by the intracellular nucleotide
concentrations would explain the co-ordination between the two pathways. However this
has not been supported by a report that studied the effect of chronic leucine exposure on
islets. The study showed reduced glucose stimulated insulin secretion associated with a
reduction in ATP/ADP ratio on chronic exposure to leucine. However the KATP independent
insulin release remained unchanged despite the associated changes in the intracellular
nucleotides (Anello et al. 2001).
In summary, although it is widely accepted that the second phase of glucose-stimulated
insulin secretion is due to the KATP channel-independent pathways, the mechanisms
involved in this pathway are poorly understood.
Finally, glucose also stimulates translation of preformed mRNA encoding insulin and
increases the transcription of the insulin gene (Melloul et al., 1993).
1.5.1.2 Amino acid stimulated insulin secretion
Amino acids can, under appropriate conditions, enhance insulin secretion from primary
islet ß-cells and ß-cell lines. However, surprisingly little data exist on the molecular
mechanisms through which metabolism of amino acids impact on changes of ionic flux and
other processes leading to exocytosis of insulin. There are three fundamental mechanisms
by which amino acids may stimulate insulin secretion 1) direct depolarisation of the plasma
membrane by transport of cationic amino acids such as L-arginine, resulting in opening of
voltage-activated L-type Ca2+ channels; 2) co-transport with Na+, resulting in opening of
voltage-activated L-type Ca2+ channels; and 3) metabolism of the amino acid (e.g, L-
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leucine), resulting in an elevation of the ATP/ADP ratio, which results in membrane
depolarisation and Ca2+ influx following closure of the KATP channels.
The cationically charged amino acid, L-arginine has been shown to stimulate insulin
secretion by direct depolarisation of the plasma membrane and resultant rise in
intracellular Ca2+ concentrations (Smith et al., 1997; Herchuelz et al., 1984). However, as
L-arginine is found at a very low physiological concentration in the plasma, this mechanism
is probably not relevant in vivo. Other amino acids, which are co-transported with Na+, can
also depolarize the cell membrane as a consequence of Na+ transport and thus induce
insulin secretion by activating voltage-dependent calcium channels.
L-alanine is consumed at high rates in rat islets and in BRIN-BD11 cell lines and this is
enhanced in the presence of glucose (Dixon et al., 2003). L-alanine has been shown to
have an insulinotropic effect in cell lines and in rat islets (Brennan et al., 2002) which may
be due to co-transport with Na+ resulting in membrane depolarisation and increased
intracellular calcium (Dunne et al., 1990). L-alanine is also metabolized by BRIN-BD11
cells to give end products such as glutamate, aspartate, and lactate. (Brennan et al.,
2002). Hence insulinotropic action of L-alanine may be secondary to a combination of co-
transport with Na+ and ATP generation via metabolism.
L-Glutamine has also been shown to be consumed at high rates by both islets and BRIN-
BD11 ß-cells (Dixon et al., 2003). Although L-glutamine is rapidly taken up and
metabolized by islets, it alone does not initiate or potentiate insulin secretion. However, it
stimulates L-leucine stimulated insulin secretion via the GDH (glutamate dehydrogenase)
pathway. GDH is a highly allosteric enzyme and L-leucine is a potent activator of GDH. In
the presence of L-leucine, GDH activation leads to increased entry of glutamine into the
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TCA cycle and subsequent oxidation (Sener and Malaisse, 1980). It is known that glucose
inhibits glutaminolysis in ß-cells presumably via GTP-dependent allosteric inhibition of
GDH, resulting in accumulation of L-glutamate and thus product-dependent inhibition of
glutaminase, and as a result blocks leucine-stimulated insulin secretion (Gao et al., 1999).
The action of intracellular L-glutamate on insulin secretion has been the subject of
considerable debate (Newsholme et al., 2007). As discussed in section 1.5.1.1, confusion
over the importance of glutamate in glucose-stimulated insulin secretion has arisen as a
result of opposing findings: total cellular glutamate concentrations have been reported to
increase in response to elevated glucose, in human, mouse and rat islets as well as in
clonal ß-cells by some groups, causing increased insulin secretion (Maechler and
Wollheim, 1999; Rubi et al., 2001), whereas others reported no such change (Bertrand et
al., 2002).
L-Leucine stimulates insulin release in pancreatic ß-cells by a process that involves: (i)
increased mitochondrial metabolism by activation of GDH and (ii) an increase in ATP
production by transamination of leucine to α-ketoisocaproate and subsequent entry into
the TCA cycle via acetyl-CoA (Sener and Malaisse, 1980). It has also been reported that
leucine and α-ketoisocaproate stimulate insulin release via distinct mechanisms (Gao et
al., 2003).
In summary, although the exact mechanisms are not completely understood, it is clear that
amino acids play an important role in regulation of insulin secretion and stimulate or
synergistically increase insulin secretion by various mechanisms.
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1.5.1.3 The role of fatty acid metabolism and insulin secretion
Free fatty acids are important to the pancreatic ß-cell for its normal function, its capacity to
compensate for insulin resistance, and its failure in type 2 diabetes mellitus (McGarry
2002; Prentki et al., 2002). Both stimulatory and detrimental effects of free fatty acids on
pancreatic ß-cells have long been recognized (Haber et al., 2003; Yaney and Corkey,
2002). Acute exposure of the pancreatic ß-cell to both high glucose concentrations and
saturated free fatty acids results in a substantial increase of insulin release, whereas a
chronic exposure results in desensitisation and suppression of secretion. Reduction of
plasma free fatty acids levels in fasted rats or humans severely impairs glucose-induced
insulin release. Physiological plasma levels of free fatty acids are therefore important for
regulation of normal ß-cell function. However the key regulatory molecular mechanisms
controlling the interplay between glucose and fatty acid metabolism and thus insulin
secretion are not well understood. Several different mechanisms have been proposed by
which fatty acids or their metabolites regulate insulin secretion.
One mechanism involves the AMP-activated protein kinase/malonyl-CoA/long-chain acyl-
CoA (LC-CoA) signalling network in which glucose, together with other anaplerotic fuels,
increases cytosolic malonyl-CoA, which inhibits fatty acid partitioning into oxidation, thus
increasing the availability of LC-CoA for signalling purposes (Corkey et al., 2000). Another
mechanism involves glucose-responsive triglyceride (TG)/free fatty acid (FFA) cycling. In
this pathway, glucose promotes LC-CoA esterification to complex lipids such as TG and
diacylglycerol, concomitant with glucose stimulation of lipolysis of the esterification
products, with renewal of the intracellular FFA pool for reactivation to LC-CoA.
Diacylglycerol and LC-CoA may regulate increase insulin secretion by KATP channel
dependent and independent mechanisms (Corkey et al., 2000). The elevation of cytosolic
LC-CoA could potentiate insulin secretion by direct acylation of regulatory proteins.
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Alternatively, LC-CoAs may be converted to other bioactive metabolites, for example
diacylglycerol (DAG), which activate downstream effectors such as protein kinase C
(Prentki et al., 1992).
Finally, FFAs have been shown to stimulate insulin secretion via activation of the G-protein
coupled receptor GPR40 on the pancreatic ß-cell membrane (Itoh et al., 2003). GPR40 is
abundantly expressed in the ß-cells. In the presence of glucose, activation of GPR40 has
been shown to cause an increase in the the intracellular levels of Ca2+, leading to insulin
secretion (Shapiro et al., 2005). It is thought that this is mediated via increased
phospholipase C activity which leads to the production of inositol 1,4,5-trisphosphate (IP3)
and DAG. DAG can activate protein kinase C with subsequent insulin secretion while IP3
can cause the release of stored Ca2+ (Morgan and Dhayal, 2009). Activation of GPR40
also has an effect on the voltage-gated potassium channels (Kv channels). The Kv
channels play a role in membrane repolaristion and facilitate the closure of voltage
sensitive Ca2+ channels. Activation of GPR40 receptors have been shown to inhibit these
channels, enhancing membrane depolarization and increasing Ca2+ influx (Feng et al.,
2006).
1.5.1.3.1 The role of HADH in pancreatic ß-cell physiology
Mitochondrial Short-chain L-3-Hydroxyacyl-CoA dehydrogenase (HADH) is involved in the
second dehydrogenation step of the ß-oxidation pathway (figure 1.4). It catalyses the
conversion of L3-hydroxyacyl CoAs to 3-Ketoacyl CoAs, this reaction also utilises NAD+ as
cofactor producing NADH (He et al., 1999; Vredendaal et al., 1996). HADH is very highly
expressed in pancreatic ß-cells suggesting it has an important role in insulin secretion
(Agren et al., 1977). ß-cells express relatively low levels of other ß-oxidation enzymes
such as acyl-CoA dehydrogenase short, medium, and long chain and acetyl-coenzyme A
acyltransferase 2.
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Several studies have now shown that HADH has a pivotal role in regulating insulin
secretion (Hardy et al., 2007; Martens et al., 2007) and interacting with other genes which
are known to be important for ß-cell development and function (Lantz et al., 2004; Sund et
al., 2001). In one study suppression of HADH activity using siRNA caused a significant
increase in basal insulin secretion compared to untreated cells (Hardy et al., 2007). This
demonstrates for the first time that HADH is required directly in ß-cells for the regulation of
basal insulin release. The addition of diazoxide did not alter the enhanced basal insulin
secretion caused by suppression of HADH, indicating that HADH functions directly in ß-
cells to regulate a KATP channel independent pathway to insulin secretion.
In another study (Martens et al., 2007) based on rat ß-cells and in the ß-cell line INS1 832-
13, HADH silencing resulted in elevated insulin release at low and at high glucose
concentrations, which appeared not to be caused by increased rates of glucose
metabolism or an inhibition of fatty acid oxidation. These data indicated that the normal ß-
cell phenotype is characterized by a high expression of HADH and a low expression of
other ß-oxidation enzymes. Down-regulation of HADH causes an elevated secretory
activity suggesting that this enzyme protects against inappropriately high insulin levels and
hypoglycaemia (Martens et al., 2007).
HADH also interacts with key genes involved in pancreatic ß-cell function. For example
Foxa2 is able to bind and trans-activate the HADH gene (Lantz et al., 2004). ß-cell specific
Foxa2 knockout mice show a three fold down regulation of HADH (Lantz et al., 2004).
These mice have severe hyperinsulinaemic hypoglycaemia due to unregulated insulin
secretion. Foxa2 encodes a transcription factor (forkhead box A2) that has been
postulated to play a central role in ß-cell development due to its ability to bind to and
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transactivate pancreatic duodenal homeobox 1 (Pdx1) cis-regulatory elements in vitro
(Ben-Shushan et al., 2001).
Hence it is clear from the limited studies above that HADH has an extremely important but
unknown role in regulating insulin secretion. Understanding the molecular mechanisms of
how mutations in the HADH gene lead to unregulated insulin secretion will provide novel
insights into pancreatic ß-cell physiology.
1.5.2 Non-nutrient regulation of insulin secretion:
In addition to the regulation of insulin secretion by nutrients, a variety of hormones and
neurotransmitters also regulate insulin secretion and are thought to potentiate the nutrient
led insulin secretion.
1.5.2.1 Hormones
Hormones secreted from the other islet cells are known to regulate insulin secretion. For
example, somatostatin secreted by the delta (δ) cells inhibits insulin release. Somatostatin 
may exert an inhibitory effect on insulin secretion via various mechanisms. It has been
reported to inhibit insulin gene transcription (Redmon et al., 1994) and adenylate cyclase
(Seaquist et al., 1992) and may also act by activation of KATP channels. In contrast,
glucagon released by the alpha (α) cells of the islets is thought to stimulate insulin release. 
In a study on digested islets that caused α-cell loss, glucose induced insulin secretion was 
significantly reduced in comparison to normal islets (Li et al., 2002). Insulin secretion was
then shown to improve on application of exogenous glucagon, suggesting a paracrine
regulation of insulin secretion by glucagon. Insulin itself is thought to inhibit glucagon
secretion, supported by the decrease in glucagon response to hypoglycaemia in the
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presence of intraislet hyperinsulinaemia (Banarer et al., 2002). The actual decrease in
insulin secretion during hypoglycaemia is thought to be an important signal in glucagon
secretion (Israelian et al., 2005). Insulin may inhibit glucagon secretion via KATP channel
activation (Franklin et al., 2005). Gamma aminobutyric acid (GABA), a neurotransmitter is
a known inhibitor of glucagon secretion and insulin is also thought to exert its inhibitory
action on secretion of glucagon by stimulation of Type A GABA receptors in the α-cells (Xu 
et al., 2006).
In addition, the gastrointestinal hormones (incretins), glucagon-like peptide 1 (GLP-1) and
gastric inhibitory peptide (GIP) are known to stimulate insulin secretion. These gut
hormones account for the greater insulin secretion seen in response to an oral glucose
load in comparison with an intravenous load (Fehmann HC et al., 1995); called the incretin
effect. GLP-1 is secreted from the intestinal endocrine L-cells, mainly located in the distal
ileum and colon; while GIP is released from intestinal K-cells that are located more
proximally in the small intestine. The main stimulus for the secretion of the gut hormones is
a meal. GLP-1 and GIP have analogous effects on the pancreatic ß-cells. They exert their
insulotropic effect via various mechanisms that include- increase in cAMP, direct inhibition
of the KATP channels, direct effect on the Ca2+ channels and Ca2+ stores in the cells leading
to raised intracellular Ca2+ levels, effect on the voltage dependent K+ channels (Kv) and
prevention of ß-cell repolarisation and stimulation of exocytosis (Baggio and Drucker,
2007).
1.5.2.2 Neurotransmitters and neuropeptides
The islets of Langerhans are highly innervated by sympathetic, parasympathetic and
sensory nerves which store neurotransmitters and neuropeptides. The classical
neurotransmitters include acetylcholine (parasympathetic) and noradrenaline
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(sympathetic). The neuropeptides that are expressed in the islets and influence insulin
secretion include vasoactive intestinal peptide (VIP), pituitary adenylate cyclase activating
polypeptide (PACAP) and gastrin-releasing peptide (GRP) at the parasympathetic nerve
terminals and galanine and neuropeptide Y at the sympathetic nerve terminals.
Parasympathetic stimulation is known to stimulate insulin secretion and sympathetic
stimulation inhibits insulin secretion.
Acetylcholine and the parasympathetic neuropeptides (VIP, PACAP and GRP) are all
stimulated by vagal activation and are known to stimulate secretion of glucagon,
pancreatic polypeptide and somatostatin along with insulin (Ahren B, 2000). Acetylcholine
directly stimulates insulin secretion from the ß-cells via the muscarinic receptors. Binding
of an agonist to the muscarinic acid receptors activates the phosphoinositide pathway
which leads to insulin secretion via an increase in cytosolic Ca2+ levels and via activation
of protein kinase C (PKC) (Ahren, 2000). VIP and PACAP stimulate insulin secretion by
activation of adenylate cyclase and formation of cyclic AMP. cAMP has a stimulatory effect
on extracellular Ca2+ intake and may also have an insulotropic effect by its action on the
exocytosis machinery (Winzell and Ahren, 2007).
Noradrenaline inhibits insulin secretion via its effect on the α-2 adrenoceptors on the islet 
ß-cells. Activation of the α-2 adrenoceptors have been shown to decrease intracellular 
Ca2+ levels, decrease cAMP levels and also inhibit the exocytotic machinery, all inhibiting
insulin secretion. However, catecholamines could also stimulate insulin secretion by
activating the ß-2 adrenoceptors and by stimulating glucagon secretion (Ahren, 2000).
Adrenaline also suppresses insulin release and may exert its effect on the presynaptic
adrenoceptors. A study on isolated mouse pancreatic islets showed that the suppressive
effect of adrenaline on insulin release requires intact sympathetic nerve terminals;
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suggesting that adrenaline probably acts on the presynaptic adrenocoeptors and that its
action on insulin release may be mediated via the release of an inhibitory neurotransmitter
which may be noradrenaline or a pancreatic neuropeptide (Karlsson et al., 1997).
1.6 Summary
Insulin release is regulated by a complex interplay of nutritional, hormonal and neural
factors. Glucose is the major trigger for insulin secretion and along with the other nutrients
and gastrointestinal hormones provides the signal for insulin release in the prandial phase.
25
Chapter 2- Introduction
Hyperinsulinaemic Hypoglycaemia
Hypoglycaemia or low blood glucose concentration is a common endocrine and metabolic
problem encountered in childhood. Its particular importance in childhood stems from the
deleterious neurodevelopmental sequelae of reduced blood glucose supply to the brain.
The neurological outcome not only depends on the level and duration of hypoglycaemia;
but it also depends on the cause of the hypoglycaemia. The cause of hypoglycaemia also
determines the long term management of the child. The commonest cause of severe and
persistent hypoglycaemia is hyperinsulinaemic hypoglycaemia.
2.1 Hyperinsulinaemic Hypoglycaemia
Under normal physiology, the pancreatic ß-cells secrete the appropriate amount of insulin
to maintain normoglycaemia. The inappropriate secretion of insulin from pancreatic ß-cells
in relation to the blood glucose concentration leads to hyperinsulinaemic hypoglycaemia
(HH). This is a major cause of persistent and recurrent hypoglycaemia in the neonatal and
infancy period (Aynsley-Green et al., 2000). The inappropriate insulin secretion drives
glucose into insulin sensitive tissues (such as skeletal muscle, adipose tissue and the
liver) and simultaneously inhibits glucose production (via glycolysis and gluconeogenesis),
as well as suppressing fatty acid release and ketone body synthesis (inhibition of lipolysis
and ketogenesis). This metabolic “footprint” of insulin action (hyperinsulinaemic
hypoglycaemia, with inappropriately low fatty acid and ketone body formation) makes the
brain highly susceptible to hypoglycaemic brain injury. The brain is not only deprived of its
most important substrate (namely glucose) but also ketone bodies which form an
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alternative source of fuel. HH therefore is associated with a high risk of neurological
handicap, cerebral palsy and epilepsy (Tyrrell VJ et al., 2001, Meissner T et al., 2003).
Any patient with recurrent or persistent hypoglycaemia can potentially have
hyperinsulinism. A powerful clue to the dysregulated insulin secretion is the calculation of
the intravenous glucose infusion rate required to maintain normoglycaemia. An
intravenous glucose infusion rate of >8mg/kg/min (normal is 4-6mg/kg/min) is virtually
diagnostic of hyperinsulinism. Biochemically, HH is diagnosed by the demonstration of an
inappropriate concentration of serum insulin (and/or c-peptide) for the concentration of
blood glucose (spontaneous or provoked) with inappropriately low concentrations of serum
ketone bodies and fatty acids during the hypoglycaemic episode. A ‘normal’ concentration
of insulin is abnormal in the context of a low blood glucose concentration (Aynsley-Green
et al., 2000). There is no correlation between the serum insulin concentration and the
severity of the hypoglycaemia. In adults, ß-cells are exquisitely sensitive to the prevailing
blood glucose concentration such that insulin secretion is suppressed when the blood
glucose concentration reaches around 4mmol/L (Bolli and Fanelli, 1999). In the neonatal
period, the serum insulin concentrations have been reported to be higher and not as
closely linked to the blood glucose concentrations as in older children and adults (Hawdon
et al., 1993). Hence in some difficult cases the diagnosis of HH is not based on an isolated
serum insulin concentration but on the clinical presentation and the biochemical profile of
insulin action (low ß-hydroxybutyrate and fatty acid concentrations).
The counter-regulatory hormonal response to hypoglycaemia is blunted in some infants
with HH with inappropriately low serum cortisol and glucagon concentration (Hussain et
al., 2003; Hussain et al., 2005a). In some patients a positive glycaemic response (rise in
the blood glucose concentration of >1.5mmol/L) following an intramuscular/intravenous
injection of glucagon at the time of hypoglycaemia provides supportive evidence (Finegold
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et al., 1980). A glycaemic response to a subcutaneous dose of octreotide may also aid
diagnosis along with decreased serum concentrations of insulin growth factor binding
protein 1 (IGFBP-1) as insulin suppresses the transcription of the IGFBP-1 gene (Levitt
Katz et al., 1997). The diagnostic criteria for HH are summarized in table 2.1.
Table 2.1: Diagnostic biochemical features of hyperinsulinaemic hypoglycaemia
(published Kapoor et al., 2009c):
Glucose infusion rate >8 mg/kg/min
Laboratory blood glucose <3 mmol/L with
-detectable serum insulin/C-peptide
-suppressed/low serum ketone bodies
-suppressed/low serum fatty acids
-suppressed branch chain amino acids
Supportive evidence (when diagnosis is in doubt):
Positive glycaemic (>1.5mmol/L) response to intramuscular/ intravenous glucagon
Positive glycaemic response to a subcutaneous/intravenous dose of octreotide
Low levels of serum IGFBP1
2.1.1 Causes of Hyperinsulinaemic Hypoglycaemia
HH may be congenital (congenital hyperinsulinism CHI) due to mutations in genes
involved in regulating insulin secretion. Mutations in seven different genes (ABCC8,
KCNJ11, GLUD1, GCK, HADH, SLC16A1 and HNF4A) have been reported which lead to
unregulated insulin secretion. The next section in this chapter gives a detailed overview of
the mechanisms known to cause CHI.
HH may also develop secondary to certain risk factors (such as maternal diabetes mellitus,
birth asphyxia and intra-uterine growth retardation) (Collins et al., 1984) The HH observed
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in these groups is sometimes referred to as “transient”. Most newborns with these risk
factors will have HH that tends to last for a few days and then resolves. However a
subgroup of newborns with intra-uterine growth retardation (IUGR) and perinatal asphyxia
can have a protracted or prolonged form of HH that requires treatment with diazoxide,
persists for several months, and then resolves spontaneously (Fafoula O et al., 2006; Hoe
et al., 2006). At present it is not clear why some infants with perinatal asphyxia and IUGR
have protracted HH.
HH may occur in association with developmental syndromes (such as Beckwith-
Weidemann syndrome (BWS)) and rare metabolic conditions such as congenital disorders
of glycosylation (CDG syndromes). The most common syndrome associated with HH is
BWS. This syndrome is characterised by prenatal and/or postnatal overgrowth,
macroglossia, anterior abdominal wall defects, organomegaly, hemihypertrophy, ear lobe
creases, helical pits, renal tract abnormalities and a propensity to develop tumours. HH is
observed in about 50% of patients with BWS (Munns et al., 2001). In the vast majority of
patients with BWS the HH is usually transient and resolves spontaneously. However a
small number of patients (5% of cases), have persistent HH requiring medical therapy or
even sub-total pancreatectomy (Hussain et al., 2005b).
‘’Dumping syndrome’’ is a rare cause of HH, classically observed in infants in the post-
prandial phase following gastro-oesophageal surgery (Bufler et al., 2001). Another rare
cause of post prandial HH is due to mutations in the insulin receptor gene (Højlund et al.,
2004). An insulinoma, isolated or as a part of multiple endocrine neoplasia syndrome type
1 (MEN1), may present with HH (Grant et al., 2005). Finally, Munchausen by proxy can
present as factitious HH due to administration of insulin or anti diabetic drugs such as
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sulphonylureas. In some cases, this has led to misdiagnosis and consequent
pancreatectomy (Giurgea et al., 2005). The causes of HH are summarized in table 2.2.
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Table 2.2: Summary of the known causes of hyperinsulinaemic hypoglycaemia (published
Kapoor et al., 2009c):
Causes of Hyperinsulinaemic Hypoglycaemia
Congenital Hyperinsulinism (Mode of inheritance)
ABCC8 (Autosomal recessive and dominant)
KCNJ11 (Autosomal recessive and dominant)
GLUD1 (Dominant)
GCK (Dominant)
HADH (Recessive)
HNF4A (Dominant)
SLC16A1 (Exercise induced) (Dominant)
Secondary to (usually transient)
Maternal diabetes mellitus (gestational and insulin dependent)
Intrauterine growth retardation (IUGR)
Perinatal asphyxia
Rhesus isoimmunisation
Metabolic conditions
Congenital disorders of glycosylation (CDG), Type 1a/b/d
Tyrosinaemia type I
Associated with Syndromes
Beckwith-Wiedemann
Soto
Kabuki
Usher
Timothy
Costello
Trisomy 13
Mosaic Turner
Central Hypoventilation Syndrome
Other causes
Dumping syndrome
Insulinoma (sporadic or associated with Multiple Endocrine Neoplasia (MEN) Type 1)
Insulin gene receptor mutations
Factitious HH (Munchausen-by-proxy)
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2.2 Congenital Hyperinsulinism
Congenital Hyperinsulinism (CHI) is a clinically, genetically, morphologically and
functionally heterogeneous condition. Children with CHI may present with non-specific
symptoms of hypoglycaemia such as poor feeding, lethargy and irritability or severe
symptoms such as apnoea, seizures or coma. The age of presentation is variable with the
severe forms typically presenting in the neonatal period and the milder forms presenting
later in infancy or childhood with recurrent symptoms of hypoglycaemia. Symptoms
generally develop after a period of fasting or when the child is unwell. However, some
forms of CHI demonstrate protein and/ or leucine sensitivity and symptoms are manifested
or aggravated in the post-prandial period following a protein rich meal rather than a fast
(Hsu et al., 2001). Macrosomia is a common feature in infants, reflecting fetal
hyperinsulinaemia; however not all babies with CHI are macrosomic.
CHI occurs due to defects in key genes involved in regulating the secretion of insulin from
ß-cells. So far, mutations in seven different genes (ABCC8, KCNJ11, GLUD1, GCK,
HADH, SLC16A1 and HNF4A) that lead to dysregulated secretion of insulin have been
described (Hussain, 2008a). An understanding of the genetic mechanisms leading to CHI
has helped in understanding the heterogeneity and the clinical management of this
condition. However, mutations in these seven genes account for only 50% of the cases
with CHI and the genetic basis of the remaining 50% is still unknown. Both sporadic and
familial forms of CHI have been recognised. Sporadic CHI has an estimated incidence of 1
in 27,000 in Ireland and 1 in 50,000 in Finland (Otonkoski et al., 1999). However, in
communities where consanguinity is a common factor, the incidence can be as high as 1
in 3,000 (Otonkoski et al., 1999).
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CHI is not only clinically and genetically heterogeneous; but is also varied in its
histopathological forms. Histologically, it has been classified into a diffuse form where the
pancreatic ß-cells show increased nuclear size throughout the pancreas on haematoxylin
and eosin (H&E) staining; and a focal form characterized by the presence of a focal
adenomatous hyperplasia with no nucleomegaly confined to a single region of the
pancreas (figure 2.1). Recently, atypical forms of the disease have also been described
where the histology cannot be classified into the diffuse or focal forms (Hussain et al.,
2008b).
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Figure 2.1: The two major histological subgroups of CHI. A: Diffuse CHI affects the entire
pancreas while the focal form is localised to a single region of the pancreas. (Figure
adapted from Kapoor et al., 2009c). B: Histological appearances of diffuse CHI vs focal
CHI. In diffuse CHI, enlarged ß-cell nuclei (indicated by arrows) are visualised on H&E
staining throughout the pancreas.
Diffuse disease
Entire pancreas is affected A focal
A
BFocal disease
area of the pancreas is affected
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2.2.1 The genetic mechanisms causing CHI
As discussed in section 1.1.5.1.1, the pancreatic ß-cell adenosine triphosphate-sensitive
potassium channels (KATP channels) play a pivotal role in glucose stimulated insulin
secretion (GSIS). The channels couple glucose metabolism to membrane electrical activity
and insulin release in pancreatic ß-cells. The SUR1 and Kir6.2 proteins are encoded by
the ABCC8 and KCNJ11 genes, respectively. Activating mutations in these genes are
known to cause neonatal diabetes mellitus (Flanagan et al., 2007). Therefore, it is not
surprising that inactivating mutations in these two genes lead to CHI. The molecular
mechanisms causing CHI due to mutations in these genes and other genes known to
cause CHI are discussed below.
2.2.1.1 ABCC8 and KCNJ11 gene mutations
A. Recessive inactivating mutations in ABCC8 and KCNJ11
The ABCC8 gene consists of 39 exons and spans more than 100kb of genomic DNA
(Aguilar-Bryan et al., 1995). The human SUR1 cDNA contains a single open reading frame
that encodes for 1,582 amino acids with a molecular weight of 177kDa (GenBank
NM_000352.2). Kir6.2 consists of a single exon encoding for a protein of 390 amino acids
(GenBank NM_000525.2). The ABCC8 and KCNJ11 genes are both located on
chromosome 11p15.1, separated by only a small stretch of 4.5 kb of DNA (Aguilar-Bryan
et al., 1995). Missense, frameshift, nonsense, insertions/deletions (macrodeletion), splice
site and regulatory mutations have been reported in ABCC8 and KCNJ11. So far more
than 150 mutations have been reported in ABCC8 and 25 in KCNJ11 (Flanagan et al.,
2009). In the Ashkenazi Jewish population two common mutations (F1388del and c.3992–
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9G>A) account for 90% of all cases of CHI (Nestorowicz et al., 1996) whereas in the
Finnish population, two founder mutations have been reported (V187D and E1507K)
(Otonkoski et al., 1999; Huopio et al., 2000). Recessive inactivating mutations in ABCC8
and KCNJ11 usually cause severe CHI which in the vast majority of patients is
unresponsive to medical therapy (with diazoxide- the mainstay of medical treatment in
CHI). However some recessively inherited mutations may be milder and may respond to
treatment with diazoxide (Dekel et al., 2002). The molecular basis of recessive inactivating
ABCC8 and KCNJ11 mutations involves multiple defects in KATP channel biogenesis and
turnover, in channel trafficking from the endoplasmic recticulum and Golgi apparatus to the
plasma membrane and alterations of channels in response to both nucleotide regulation
and open-state frequency. Compound heterozygous mutations may result in complex
interactions (Muzyumba et al., 2007) and the response to treatment is likely to be
dependent on the combined effect of the two mutations.
i. Defects in channel biogenesis and turnover
The mechanisms that control the maturation and assembly of KATP channels are not well
understood. Pulse-labeling studies have shown that when Kir6.2 is expressed individually,
it is either degraded rapidly (about 60% is lost with a half life of 36 min) or it assembles
very slowly into a long-lived species (half life of 26 h) (Crane et al., 2004). Expressed
alone SUR1 has a long half life of 25.5 h. When Kir6.2 and SUR1 are co-expressed, they
associate rapidly and the fast degradation of Kir6.2 is eliminated (Crane et al., 2004). Two
mutations, KCNJ11 (W91R) and ABCC8 (F1388del), identified in patients with the severe
form of CHI, profoundly alter the rate of Kir6.2 and SUR1 turnover, respectively (Crane et
al., 2004). Both mutant subunits associate with their respective partners but dissociate
freely and degrade rapidly suggesting that the mutations alter channel biogenesis and
turnover.
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ii. Defects in channel trafficking
Some mutations in ABCC8 (such as R1437Q(23)X, F1388del and R1394H) have been
shown to cause loss of channel activity due to a defect in the trafficking of the channel
subunits from the endoplasmic recticulum compartment to the cell surface (Dunne et al.,
1997; Cartier et al, 2001; Partridge et al., 2001 and Shyng et al., 1998). Trafficking of KATP
channels requires that the endoplasmic reticulum-retention signal, RKR, present in both
SUR1 and Kir6.2 is shielded during channel assembly. Mutations such as L1544P may
cause a trafficking defect by improper shielding of this RKR signal (Taschenberger et al.,
2002). In addition, an anterograde signal on the C-terminus has also been identified to
play an important role in the surface expression of the KATP channels (Sharma et al.,
1999). Hence mutations in ABCC8 that lead to C-terminal truncation may cause CHI by
preventing normal trafficking.
Mutations in KCNJ11 can also cause defective trafficking and truncated non-functional
proteins. For example the Kir6.2 mutation (Y12X) causes the synthesis of a truncated
nonfunctional protein (Nestorowicz et al., 1997) whereas another mutation (W91R) leads
to defective channel assembly with a rapid degradation in the endoplasmic reticulum (ER)
(Crane et al., 2004). Recently a new homozygous mutation H259R (KCNJ11) has been
shown to lead to a nonfunctional KATP channel with impaired trafficking to the cell
membrane (Marthinet et al., 2005).
iii. Defects of channel regulation
The SUR1 subunit plays a key role in determining the pharmacological regulation of KATP
channels with SUR1 acting as a conductance regulator of Kir6.2. The sensitivity of KATP
channels to changes in ATP, ADP, and guanosine (GTP, GDP) nucleotides involves both
subunits. The functional regulation of KATP channels is induced by changes in the ATP/ADP
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ratio. This involves cooperative interactions of nucleotides at both subunits with the actions
of ATP-induced inhibition of Kir6.2 being countered by the activation of ADP at SUR1.
Hence mutations that affect the regulation of the KATP channels by altering its sensitivity to
changes in ADP/ATP will lead to unregulated insulin secretion. Several mutations in
ABCC8 (for example R1420C, T1139M and R1215Q) have now been described that result
in the loss of ADP-dependent gating properties of the channel (Shyng et al., 1998; Matsuo
et al., 2000 and Nichols et al., 1996). Loss of ADP-dependent gating results in the
constitutive inhibition of KATP channels by ATP.
B) Dominant inactivating ABCC8 and KCNJ11 mutations
Dominant inactivating mutations in ABCC8 and KCNJ11 have been described which lead
to CHI (Huopio et al., 2000; Thornton et al., 2003; Lin et al., 2006 and Pinney et al., 2008).
However the phenotype of patients with dominant inactivating mutations in ABCC8 and
KCNJ11 seems to be much milder to that of patients with recessive inactivating ABCC8
and KCNJ11 mutations. Patients with dominant mutations seem to be responsive to
medical therapy with diazoxide, may present later than those with recessive mutations and
do not require a pancreatectomy (Pinney et al., 2008). In one large study of 16 families
with dominant CHI caused by mutations in ABCC8 or KCNJ11 all of the mutations were
conservative single–amino acid changes, allowing for normal channel formation at the
plasma membrane (Pinney et al., 2008). Whereas recessive mutations cause near
absence of KATP channel activity (have defects in channel biogenesis or trafficking of
mature functional channels to the plasma membrane) dominant mutations demonstrate
normal channel assembly with their respective wild type partner and normal trafficking of
assembled channels to the plasma membrane when expressed in vitro.
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A dominant missense CHI causing mutation F55L (KCNJ11) has also been shown to
greatly reduce the open probability of KATP channels in intact cells without affecting channel
expression (Lin et al., 2006). It was shown that the low channel activity was due to
reduced channel response to membrane phosphoinositides and/or long-chain acyl-CoAs,
as application of exogenous phosphatidylinositol-4, 5-bisphosphate (PIP2) or oleoyl-CoA
restored channel activity similar to that seen in wild type channels.
C) The genetic basis of focal CHI
CHI presents as two different morphological forms: a diffuse form with functional
abnormality of islets throughout the pancreas and a focal form with focal islet cell
adenomatous hyperplasia, which can be cured by partial pancreatectomy (Rahier et al.,
2000). Focal CHI is characterized by nodular hyperplasia of islet-like cell clusters,
including ductuloinsular complexes and hypertrophied insulin cells with giant nuclei (Rahier
et al., 2000; Goossens et al., 1989). The genetic aetiology of focal CHI is distinct from that
of diffuse CHI. Focal adenomatous hyperplasia involves the specific loss of the maternal
chromosome 11p15 region (loss of heterozygosity or LOH) and a constitutional mutation of
a paternally inherited allele of the genes ABCC8/KCNJ11 encoding the KATP channel
(Verkarre et al.,1998; de Lonlay et al., 1997; Fournet et al., 2001; Fournet et al., 2000). It
has been recently demonstrated that the LOH results from paternal uniparental disomy
(UPD) of chromosome 11p15.5-11p15.1 (Damaj et al., 2008). The UPD unmasks the
paternally inherited KATP channel mutation at 11p15.1 (figure 2.2) which leads to
uncontrolled secretion of insulin.
LOH studies have shown that the affected region encompasses two regions of interest: the
11p15.5 region, subject to imprinting, and the 11p15.1 region containing the ABCC8/
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KCNJ11 genes, which are not imprinted (de Lonlay et al., 1997). The 11p15.5
chromosome region involved contains an imprinted domain, including several imprinted
genes characterized by mono-allelic expression (Giannoukakis et al., 1993; Lee et al.,
1997; Matsuoka et al., 1995 and Zhang et al., 1992). These include four maternally
expressed genes (H19 a candidate tumour suppressor gene, P57KIP2 a negative
regulator of cell proliferation, KVLQT1 the gene coding for the potassium channel involved
in the long QT syndrome, HASH2 a transcription factor and one paternally expressed gene
the insulin-like growth factor 2 (IGF2) (Giannoukakis et al., 1993; Zhang et al., 1992; Hao
et al., 1993; Hatada et al., 1996 and Guillemot et al., 1995). The imbalance between
imprinted genes (increased IGF2 and diminished H19 and P57KIP2) gives rise to the
increase in the proliferation of the affected ß-cell, a striking feature of focal adenomatous
hyperplasia not observed in the diffuse form (Fournet et al., 2001). H19 seems directly or
indirectly to modulate cytoplasmic levels of the product of the IGF2 allele and thus the H19
gene seems to be an antagonist to IGF2 in trans (Fournet et al., 2001).
The probability for this somatic chromosomal event to occur in a foetus carrying a
heterozygous mutation of ABCC8/KCNJ11 of paternal origin is < 1% (Fournet et al., 2001).
Recently it was demonstrated that individual patients with focal CHI may have more than
one focal pancreatic lesion due to separate somatic loss of the maternal allele
encompassing the 11p15 region (Giurgea et al., 2006).
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Fig 2.2: Genetic aetiology of a focal lesion (figure adapted from James
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2.2.1.2 Activating mutations in GLUD1 (Glutamate Dehydrogenase) gene: the cause
of Hyperinsulinism/ Hyperammonaemia (HI/HA) syndrome
Hyperinsulinism hyperammonaemia (HI/HA) syndrome (OMIM 606762) describes a form
of CHI whereby patients have recurrent symptomatic HH associated with a raised serum
ammonia concentration. HI/HA is the second most common form of CHI. Patients typically
present with postprandial HH following the ingestion of a protein meal (due to leucine
hypersensitivity) (Stanley et al., 1998) though they can have fasting hypoglycaemia as
well. Zammarchi et al. (1996) first described a family with leucine sensitive hypoglycaemia
associated with a raised serum ammonia level. Then Weinzimer et al. (1997) described
two more unrelated patients with a similar clinical and biochemical phenotype. Later,
Stanley et al. (1998) were able to show that mutations in the GLUD1 gene (which encodes
for the intra-mitochondrial enzyme glutamate dehydrogenase, GDH) form the molecular
and biochemical basis of the HI/HA syndrome and explain the link between leucine
hypersensitivity and the hyperammonaemia.
Glutamate dehydrogenase (GDH) is highly expressed in the pancreas, liver, kidney and in
the brain (Hudson et al., 1993). It plays a key role in intermediary metabolism regulating
protein synthesis and degradation. By an oxidative deamination reaction GDH converts
glutamate to α-ketoglutarate and ammonia using NAD+ (nicotinamide adenine
dinucleotide) and NADP+ as co-factors (Li et al., 2009). The α-ketoglutarate is channelled 
into the citric acid cycle as a substrate to increase the ATP/ADP (adenosine triphosphate/
adenosine diphosphate) ratio. The increased ATP/ADP ratio causes the closure of the
pancreatic ß-cell KATP channels with depolarisation of the ß-cell membrane, increased
calcium entry and subsequent insulin exocytosis. The activity of GDH is under complex
allosteric regulation by effectors such as ADP (adenosine diphosphate), GTP (guanine
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triphosphate) and leucine (Fang et al., 2002). In the HI/HA syndrome activating
(heterozygous missense single amino acid substitutions) mutations in the GLUD1 gene
generally make GDH insensitive to repression by high energy phosphate compounds like
GTP and in rare cases increase basal GDH activity (Yorifuji et al., 1999 and Fujioka et al.,
2001). The loss of inhibition by GTP increases the rate of oxidation of glutamate in the
presence of leucine, thereby increasing insulin secretion. The clinical picture is hence
characterized by postprandial hypoglycaemia following a protein meal (fasting
hypoglycaemia may also occur).
Human GDH is a homohexamer, with two trimeric subunits. Each subunit further is
composed of three domains; the glutamate binding domain, the NAD binding domain, and
the antenna domain (Smith et al., 2001). The NAD+ and glutamate-binding domains of
bovine GDH are similar to those of the bacterial forms of the enzyme, while the antenna
domain is unique to mammals (Rajagopalan et al., 1999). The GTP binding site lies
between the antenna and NAD binding domain while the ADP binding site lies behind the
glutamate binding domain and under the pivot helix (Smith et al., 2002). Missense
mutations causing HI/HA were first described to occur in exons 11 and 12 that form the
hinge and antenna regions of GDH and lie close to the binding site for GTP (Stanley et al.,
1998 and Stanley et al., 2000). Mutations were then described in exons 6 and 7 that lie in
the GTP binding region (Miki et al., 2000; Santer et al., 2001). Finally, mutations in exon
10 were described located in the α-helix of the antenna like structure of the GDH (Fujioka 
et al., 2001; Yorifuji et al., 1999). Most cases of HI/HA syndrome occur sporadically
(Stanley et al., 2000); though familial cases of dominantly inherited mutations are also
described (Santer et al.,2001). These locations and the mutations described so far are
depicted in figure 2.3A/B.
4Figure 2.3A/ 2.3B: 2.3A: Cartoon showing location of known mutations along a
representation of the GLUD1 gene, the different colours signify the subunits of the protein.
2.3B. Representation of the structure of the GDH monomer, six of these make up the
functional hexamer. The blue region interacts with GTP and ADP, the yellow structure is
the pivot helix, the green region represents the antenna and the purple region represents
the glutamate binding domain.
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Most of the described mutations are at residues that directly bind with GTP, impairing the
inhibition of GDH by GTP. However mutations occurring in residues that do not directly
bind with GTP are also known to cause impaired GTP inhibition. It is postulated that these
mutations either impair the communication between the subunits that is essential for GTP
inhibition or have a deleterious effect on the complex motion of the protein causing loss of
GTP binding (Smith et al., 2008). Islets isolated from mice that express the mutant GDH in
pancreatic ß-cells show an increased rate of glutaminolysis, increased insulin release in
response to glutamine, and increased sensitivity to leucine-stimulated insulin secretion (Li
et al., 2006). Transgenic GDH mice expressing the H454Y mutation have a similar
phenotype to humans with fasting hypoglycaemia as well as demonstrating leucine and
glutamine stimulated insulin secretion (Li et al., 2006).
The exact mechanism causing the hyperammonaemia remains unknown. It is possible that
the hyperammonaemia is the result of increased GDH activity in the hepatocytes leading
to either an increase in the production of ammonia from glutamate and/ or a depletion of
glutamate with reduction in the production of N-acetylglutamate, an allosteric activator
essential for the first step of ammonia detoxification (Kelly and Stanley 2001). N-
acetylglutamate regulates the activity of carbamyl phosphate synthetase 1 (CPS) which
produces urea from ammonia. These high levels of ammonia are resistant to treatment
with drugs such as sodium benzoate, N-carbamyl glutamate or to protein restriction. The
hyperammonaemia observed in these patients seems to be asymptomatic compared to
patients who have hyperammonaemia due to other metabolic disorders such as the urea
cycle disorders (Kelly and Stanley 2001). Figure 2.4 shows the postulated biochemical
pathways leading to hyperinsulinaemia in the pancreas and hyperammonaemia in the
liver.
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Patients with HI/HA develop seizures and other neurological complications more frequently
than other patients with CHI (Raizen et al., 2005; Bahi- Buisson et al., 2008a; Bahi-
Buisson et al., 2008b). In a cohort of patients with HI/HA, 77% of patients were reported to
have a learning disability and 50% developed epilepsy (Bahi- Buisson et al., 2008b) in
comparison with a prevalence of 26-44% of developmental delay and 25% of epilepsy in
all forms of CHI (Menni et al., 2001; Meissner et al., 2003). The frequency of seizures at
presentation may be due to the effect of hypoglycaemic brain injury or the
hyperammonaemia, or may be due to increased GDH activity in the brain (Bahi-Buisson et
al., 2008a). A study done on patients with HI/HA who developed epilepsy showed that
they had structurally normal brain MRI scans, except for one patient who had frontal
atrophy (Bahi- Buisson et al., 2008b). Mutations in exon 6 and 7 of the GLUD1 gene have
been reported to be associated with the development of epilepsy in childhood in patients
with HI/HA compared with mutations in exons 11 and 12 (Bahi- Buisson et al., 2008b).
Treatment of seizures with anticonvulsants such as carbamezapine or oxcarbezapine can
worsen seizure frequency and therefore should be used with caution (Raizen et al., 2005).
HI/HA is characterised by having mild to moderate hypoglycaemia which is usually
responsive to diazoxide treatment at minimal doses (5-15mg/kg/day) in the majority of
cases. In some patients protein restriction will also help in the management of the
hypoglycaemia. It also has been shown that carbohydrate ingestion prior to ingestion of
protein may reduce the leucine hypersensitivity of these patients (Kelly et al., 2001).
However there has been a case reported of severe hypoglycaemia in a patient with a
GLUD1 gene mutation who was resistant to medical treatment and required a
pancreatectomy (MacMullen et al., 2001).
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In summary the HI/HA syndrome occurs due to activating mutations in the GLUD1 gene.
These mutations remove the inhibitory effect of GTP on the enzyme GDH and in turn
increase enzyme activity by leucine. Patients typically present with HH following the
ingestion of a protein meal (leucine hypersensitivity). The characteristic biochemical
finding is hyperammonaemia, which is unaffected by feeding, fasting or pharmacological
intervention. Patients with HI/HA syndrome have a high risk of developing epilepsy.
Dietary protein restriction and pharmacological intervention with diazoxide is the mainstay
of treatment.
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2.2.1.3 Activating mutations in Glucokinase (GCK) gene
Glucokinase (hexokinase IV or D) is one member of the hexokinase family of enzymes.
The name, glucokinase, is derived from its relative specificity for glucose under physiologic
conditions. Glucokinase is a key regulatory enzyme in the pancreatic ß-cells. It operates
as a monomer and phosphorylates glucose on carbon 6 with MgATP as a second
substrate to form glucose-6-phosphate (G6P) as a first step in the glycolytic pathway. It
plays a crucial role in the regulation of insulin secretion and has been termed the
pancreatic ß-cell glucose sensor on account of its kinetics, which allows pancreatic ß-cells
to change glucose phosphorylation rate over a range of physiological glucose
concentrations (4–15mmol/L) (Matschinsky, 2002). These kinetic characteristics are the
enzyme’s low affinity for glucose (concentration of glucose at which the enzyme is half
maximally activated, 8–10mmol/L), positive cooperativity for glucose, and lack of inhibition
by its product G6P (Matschinsky, 2002). The enzyme has at least two clefts, one for the
active site, binding glucose and MgATP and the other for a putative allosteric activator.
Glucokinase activity is closely linked to the KATP and calcium channels of the ß-cell
membrane, resulting in a threshold for glucose-stimulated insulin release of approximately
5mmol/L, which is the set point of glucose homoeostasis (Zelent et al., 2005).
Heterozygous inactivating mutations in GCK cause maturity-onset diabetes of the young
(MODY), homozygous inactivating GCK mutations result in permanent neonatal diabetes
whereas heterozygous activating GCK mutations cause CHI (Glaser et al., 1998; Gloyn et
al., 2003; Cuesta-Munoz et al., 2004). A number of heterozygous GCK mutations have
been reported in sporadic cases (de novo mutations) or families with dominantly inherited
CHI. Activating GCK mutations increase the affinity of GCK for glucose and alter (reset)
the threshold for glucose stimulated insulin secretion. All reported activating mutations
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cluster in a region of the enzyme which has been termed the allosteric activator site and is
remote to the substrate-binding site. The allosteric site of GCK is where small molecule
activators bind, suggesting a critical role of the allosteric site in the regulation of GCK
activity (Ralph et al., 2008). Both GCK activators and activating mutations increase
enzyme activity by enhancing the affinity for glucose (Heredia et al., 2006). There is no
evidence to suggest that over expression of GCK (increased gene dosage effect) is a likely
cause of CHI (Van de Bunt 2008).
The clinical symptoms and course of patients with GCK mutations cover a broad spectrum
even within the same family with the same mutation, implicating a complex mechanism for
GCK regulation. Most of the GCK mutations reported to date cause mild diazoxide
responsive CHI. However a “de novo” mutation in GCK (Y214C) was described in a patient
with medically unresponsive CHI (Cuesta-Munoz et al., 2004). This mutation was located
in the putative allosteric activator domain of the protein and functional studies of purified
recombinant glutathionyl S transferase fusion protein of GK-Y214C showed a sixfold
increase in its affinity for glucose with the threshold for GSIS predicted to be 0.8mmol/L, as
compared with 5mmol/L in the wild-type enzyme. Recently, three patients were described
where diazoxide therapy was effective in the patient with the M197I mutation, ineffective in
the patient with the ins454A mutation and only partially effective in the patient with the
W99L mutation (Sayed et al., 2009). The threshold for GSIS was estimated to be
1.1mmol/L for the ins454A mutation, 2.2mmol/L for the W99L mutation and 3.5mmol/L for
the M197I mutation, accounting for the heterogeneity in the phenotype. In the largest study
performed to date on a pool of patients (n=108) who were negative for mutations in the
ABCC8 and KCNJ11 genes the prevalence of CHI due to mutations in GCK was estimated
to be about 7% (Christesen et al., 2008).
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2.2.1.4 Loss of function mutations in Hydroxyacyl-CoA Dehydrogenase (HADH)
gene
HADH encodes for the enzyme L-3-hydroxyacyl-Coenzyme A dehydrogenase (HADH),
(previously known as Short-chain L-3-Hydroxyacyl-CoA dehydrogenase SCHAD), which is
an intra-mitochondrial enzyme that catalyses the penultimate step in the ß-oxidation of
fatty acids, the NAD+ dependent dehydrogenation of 3-hydroxyacyl–CoA to the
corresponding 3-ketoacyl-CoA. Human HADH encodes a 314-amino acid protein with 8
exons and spans approximately 49 kb (Vredendaal et al., 1996). It is composed of a 12-
residue mitochondrial import signal peptide and a 302-residue mature HADH protein with a
calculated molecular mass of 34.3kD (Vredendaal et al., 1998).
Loss-of-function mutations in the HADH gene are associated with CHI (Clayton et al.,
2001; Molven et al., 2004; Hussain et al., 2005c). The clinical presentation of all patients
reported is heterogeneous, with either mild late onset intermittent HH or severe neonatal
hypoglycaemia. All reported cases so far have presented with increased 3-
hydroxyglutarate in urine and hydroxybutyrylcarnitine in blood which may be used as
diagnostically useful markers for HADH deficiency. In the first patient reported sequencing
of the HADH genomic DNA from the fibroblasts showed a homozygous mutation
(c.773C>T) changing proline to leucine at amino acid 258 (Clayton et al., 2001). Analysis
of blood from the parents showed they were heterozygous for this mutation. Western blot
studies showed undetectable levels of immunoreactive HADH protein in the patient’s
fibroblasts. Expression studies showed that the P258L enzyme had no catalytic activity.
This patient presented with intermittent hypoglycaemia at 4 months of age.
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A novel, homozygous deletion mutation (deletion of the six base pairs CAGGTC at the
start of HADH exon 5) was found in the second patient who presented with severe
neonatal hypoglycaemia (Molven et al., 2004). The mutation affected RNA splicing and
was predicted to lead to a protein lacking 30 amino acids. The observations at the
molecular level were confirmed by demonstrating greatly reduced HADH activity in the
patients’ fibroblasts and enhanced levels of 3-hydroxybutyryl-carnitine in their plasma.
Urine metabolite analysis showed that HADH deficiency resulted in specific excretion of 3-
hydroxyglutaric acid. Finally the third patient reported to date was found to be
homozygous for a splice site mutation (IVS6-2 a>g) in the HADH gene with western
blotting with an anti-HADH antibody indicating a decrease in the amount of
immunoreactive protein in fibroblasts from the patient consistent with the observed
decrease in enzyme activity (Hussain et al., 2005c). This patient presented at 4 months of
age with HH that responded to treatment with diazoxide.
The molecular mechanism of how loss of function in the HADH gene leads to unregulated
insulin secretion is still unclear. Several recent studies in rodents have begun to give some
insight into how HADH regulates insulin secretion and its interaction with other genes
involved in ß-cell development and function (Hardy et al., 2007; Martens et al., 2007; Lantz
et al., 2004). The normal ß-cell phenotype is characterized by a high expression of HADH
and a low expression of other ß-oxidation enzymes. Down-regulation of HADH causes an
elevated secretory activity suggesting that this enzyme protects against inappropriately
high insulin levels and hypoglycaemia (Hardy et al., 2007; Martens et al., 2007). Hence
HADH seems to be a negative regulator of insulin secretion in ß-cells. Further studies will
be required to fully understand the biochemical pathways by which defects in HADH lead
to dysregulated insulin secretion.
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2.2.1.5 Mutations in the promoter region of SLC16A1 gene: the cause of exercise
induced hyperinsulinism (EIHI)
In the glycolytic pathway glucose is metabolised to pyruvate which then enters in the
mitochondria. Pyruvate can be converted into lactate or enters into the tricarboxylic acid
(TCA) cycle, generating reducing equivalents. This leads to stimulation of the respiratory
chain and ATP synthesis. The transport of monocarboxylates such as lactate and pyruvate
is mediated by the SLC16A family of proton-linked membrane transport proteins known as
monocarboxylate transporters (MCTs). Fourteen MCT-related genes have been identified
in mammals and of these seven MCTs have been functionally characterized. Despite their
sequence homology, only MCT1–4 have been demonstrated to be proton-dependent
transporters of monocarboxylic acids (Halestrap and Price, 1999).
The SLC16A1 gene encodes for MCT1 that mediates the movement of lactate and
pyruvate across cell membranes. The SLC16A1 gene maps to chromosome 1p13.2-p12,
spans approximately 44 kb, and is organized as 5 exons intervened by 4 introns (Cuff and
Shirazi-Beechey, 2002; Garcia et al., 1994). The first of these introns is located in the 5’
UTR-encoding DNA, spans >26 kb, and thus accounts for approximately 60% of the entire
transcription unit (Cuff and Shirazi-Beechey, 2002). Analysis of a 1.5 kb fragment of the
MCT1 5’ flanking region shows an absence of the classical TATA-Box motif. However, the
region contains potential binding sites for a variety of transcription factors (Cuff and
Shirazi-Beechey, 2002).
Studies in whole rat and mouse islets have shown that pyruvate and lactate cannot mimic
the effect of glucose on insulin secretion despite active metabolism (Zhao and Rutter,
1998; Ishihara et al., 1999). This is postulated to be due to low expression of MCT in ß-
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cells. However over expression of LDH and MCT1 leads to pyruvate induced insulin
secretion (Ishihara et al., 1999). In exercise induced CHI there is increased expression of
MCT1 transporter in ß-cells due to dominant mutations in SLC16A1 (Otonkoski et al.,
2007). In these patients anaerobic physical exercise induces HH that is preceded by an
inappropriate increase in the circulating insulin concentration (Meissner et al., 2001;
Meissner et al., 2005). Affected patients become hypoglycemic within 30 min after a short
period of anaerobic exercise. A pyruvate load test causes a brisk increase in the serum
insulin concentration suggesting that pyruvate metabolism or transport is in some way
involved in signaling insulin secretion from ß-cells in these patients (Otonkoski et al.,
2003). A genome scan performed on two families with 10 affected patients first mapped
the gene to chromosome 1 (Otonkoski et al., 2007). Mutations in the promoter region of
SLC16A1 gene were confirmed in all patients. Studies on cultured fibroblasts from affected
patients showed abnormally high SLC16A1 transcript levels, although the MCT1 transport
activity was unchanged in fibroblasts (possibly reflecting additional posttranscriptional
control of MCT1 levels in extrapancreatic tissues).
The mutations identified in two separate pedigrees were in the binding sites of several
transcription factors (nuclear matrix protein 1, albumin negative factor (ANF) and AML-1a,
simian- virus-40-protein-1 (Sp1), upstream stimulatory factor (USF), myeloid zinc finger 1
(MZF1) and GATA-1–binding site). They resulted in increased protein binding to the
corresponding promoter elements and marked (3- or 10-fold) transcriptional stimulation of
SLC16A1 promoter-reporter constructs (Otonkoski et al., 2007). These studies suggested
that activating mutations in the promoter region of SLC16A1 induce increased expression
of MCT1 in the ß-cell (where this gene is not usually transcribed) allowing pyruvate uptake
and pyruvate-stimulated insulin release despite ensuing hypoglycaemia (Otonkoski et al.,
2007).
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2.2.1.6 Mutations in the HNF4A gene: a novel cause of CHI
HNF-4 (hepatocyte nuclear factor 4alpha) is a transcription factor of the nuclear hormone
receptor superfamily and is expressed in liver, kidney, gut, and pancreatic islets (Sladek et
al., 1990). In combination with other hepatocyte nuclear factors, HNF4 has been
proposed to form a functional regulatory loop that regulates the development and function
of the pancreas and the liver (Boj et al., 2001; Odom et al., 2004). In ß-cells, HNF4 has
been shown to be the most widely acting transcription factor and regulates several key
genes involved in glucose stimulated insulin secretion (Odom et al., 2004; Wang et al.,
2000) (figure 2.5).
Mutations in the HNF4A gene (encoding the hepatocyte nuclear factor 4alpha, HNF-4α) 
are a novel cause of transient and persistent HH, associated with macrosomia (Pearson et
al., 2007). Mutations in this gene are known to cause maturity onset diabetes of the young
type1 (MODY1), characterized by autosomal dominant inheritance and impaired glucose-
stimulated insulin secretion from pancreatic ß-cells (Yamagata et al., 1996).
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5: Figure published by Kulkarni et al. (2004) demonstrating the interaction of
the pancreatic ß-cells and the regulation of several target genes by the
on factors. HNF4 is the most widely acting transcription factor, regulating the
n of other transcription factors and that of several key genes involved in glucose
insulin secretion
4A gene is located on human chromosome 20q13.1-13.2. The gene has two
P1 and P2 with P2 being upstream to P1. At least nine isoforms (HNF4A1-9)
n to be produced by the gene by means of alternate splicing, polyadenylation
of poly(A) tail to the RNA molecule) and production of different transcripts by the
oters (Harries et al., 2008). The P1 derived isoforms are most abundant in the
ssues while the P2 promoter represents the major transcription site in ß-cells
Cited by Kulkarni et al., Science. 2004,303;1311-1312
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(Harries et al., 2008). Transfection assays with various deletions and mutants of the P2
promoter revealed the presence of functional binding sites for HNF1A, HNF1B, and IPF1
(Thomas et al., 2001). The HNF4 protein consists of an N-terminal ligand-independent
transactivation domain (amino acids 1-24), a DNA binding domain containing two zinc
fingers (amino acids 51-117), and a large hydrophobic portion (amino acids 163-368)
composed of the dimerization, ligand binding, cofactor binding, and ligand-dependent
transactivation domain (Hadzopoulou-Cladaras et al., 1997).
Transfection assays with various deletions and mutants of the P2 promoter revealed
functional binding sites for HNF1A, HNF1B, and IPF1 (Thomas et al., 2001). The HNF4
protein consists of an N-terminal ligand-independent transactivation domain (amino acids
1-24), a DNA binding domain containing two zinc fingers (amino acids 51-117), and a large
hydrophobic portion (amino acids 163-368) composed of the dimerization, ligand binding,
cofactor binding, and ligand-dependent transactivation domain (Hadzopoulou-Cladaras et
al., 1997).
Heterozygous mutations in the human HNF4A gene classically lead to maturity onset
diabetes of the young subtype 1 (MODY1). MODY is a type of monogenic diabetes that
usually presents in early adulthood and is characterized by autosomal dominant
inheritance and impaired glucose-stimulated insulin secretion from pancreatic ß-cells
(Yamagata et al., 1996). These mutations in the HNF4A gene cause multiple defects in
glucose stimulated insulin secretion and in expression of HNF4A dependent genes (Wang
et al., 2000; Stoffel and Duncan, 1997). Recently mutations in the HNF4A gene were
reported to cause macrosomia and transient HH (Pearson et al., 2007). In this
retrospective study the birth weight of the HNF4A mutation carriers compared to non-
mutation family members was increased by a median of 790 g. Transient hypoglycaemia
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was reported in 8/54 infants with heterozygous HNF4A mutations and documented HH in
three cases (Pearson et al., 2007).
At present it is unclear how heterozygous mutations in HNF4A lead to hypoglycaemia.
Using the conditional Cre-loxP-based inactivation system to delete HNF4A specifically in
the pancreatic ß-cell, Gupta et al studied glucose homeostasis in the adult mice (Gupta et
al., 2005). These mice were hyperinsulinaemic in fasted and fed state but also
paradoxically had impaired glucose tolerance with inadequate insulin secretion after
glucose stimulation. Cotransfection assays demonstrated that these mice had a 60%
reduction in the expression of the Kir6.2 subunit of the potassium channel. However two
further studies (Pearson et al., 2007; Miura et al., 2006) have reported no change in the
expression of Kir6.2 in HNF4A- deficient mice suggesting that this loss of expression of
Kir6.2 in the pancreatic ß-cell may not be the cause of the dysregulated insulin secretion.
Hence, it is unclear how heterozygous mutations in the HNF4A gene cause HH in the
newborn period followed by the opposite phenotype of MODY-1 in young adulthood.
In summary, several molecular mechanisms due to mutations in seven different genes are
known to cause CHI. These mechanisms are enlisted in table 2.3 and are schematically
represented in a cartoon model of the pancreatic ß-cell in figure 2.6.
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Table 2.3: The genes implicated in CHI with the gene loci, proteins affected and patterns
of inheritance (AD- autosomal dominant, AR- autosomal recessive) (James et al., 2009).
Gene (locus) #OMIM Protein Mechanism Inheritance
ABCC8
(11p15.1) 600509
Sulphonylurea receptor1
(SUR1)
Defects in KATP biogenesis and
turnover, trafficking and
nucleotide regulation
AR/ AD
KCNJ11
(11p15.1) 600937
Inward rectifying
potassium channel
(Kir6.2)
Defects in KATP biogenesis and
turnover, trafficking and
nucleotide regulation
AR/ AD
GLUD1
(10q23.3) 138130
Glutamate
dehydrogenase (GDH)
Loss of inhibition of GDH by GTP
and increased basal GDH activity AD
GCK
(7p15-13) 138079 Glucokinase
Increased affinity of GCK for
glucose AD
HADH
(4q22-26) 601609
3-hydroxyacyl-CoA
dehydrogenase Unknown AR
SLC16A1
(1p13.2-p12) 600682
Monocarboxylate
transporter 1 (MCT1) Increased expression of MCT1 AD
HNF4A
(20q12-13.1) 600281
Hepatocyte nuclear factor
4 alpha Unknown AD
Figure 2.6: Schematic representation of the known genetic causes of CHI (published
Kapoor et al., 2009c). The commonest causes of CHI are mutations in the genes (ABCC1
and KCNJ11) that encode the proteins of the KATP channels (SUR1 and KIR6.2),
respectively.
Loss of KATP
channel
function
K+ Ca2+
Voltage-gated calcium
channel
KATP channel
LPyruvate
Loss of HNF4A
function
?Mechanism
Increased
MCT-1
activity
eucine
ATP/ADP59
Glucose
Insulin
granule
exocytosis
Loss of
function
of HADH
Increased
GCK activity
Increased
GDH activity
-Ketoglutarate + NH3
Glutamate Glucose-6-phosphate
Fatty Acids
?Abnormal Metabolites
60
2.2.2 Clinical management of CHI
Early diagnosis and immediate meticulous management are the cornerstones for
preventing brain injury in patients with CHI. The mainstay of medical therapy is diazoxide-
a drug that binds to the intact SUR1 component of the KATP channels. It acts by keeping
the KATP channels open, thereby preventing depolarisation of the ß-cell membrane and
insulin secretion. Diazoxide therapy may sometimes be supplemented by dietary
manipulation in patients where a dietary trigger is established.
In patients that are unresponsive to diazoxide it is essential to differentiate focal from
diffuse disease as the surgical approaches are radically different. The precise preoperative
localisation and limited surgical removal of the focal domain “cures” the patient (Otonkoski
et al., 2006). In contrast, patients with diffuse disease may require a near total
pancreatectomy which will have lifelong implications (high risk of diabetes mellitus,
pancreatic exocrine insufficiency).
Some infants who fail to respond to diazoxide may be managed with long term
subcutaneous octreotide injections in combination with frequent feeding. Octreotide is a
long-acting analog of the natural hormone, somatostatin. Somatostatin inhibits insulin
release via activation of the somatostatin receptors (SSTR) which belong to the G-protein-
coupled receptor family. Five distinct SSTRs are known, SSTRs 1-5. Octreotide is known
to bind to SSTR2 and SSTR5, both of which mediate inhibition of insulin release from the
pancreatic islets (Singh et al., 2007). Octreotide is used in the short and long term
management of some patients with CHI. In the short term (with and without glucagon) it is
used to stabilise patients pending further investigations. Octreotide has been successfully
used in the long term management of some CHI patients in combination with frequent
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feeding (Glaser et al., 1989). The principle of this treatment is based on the fact that the
hypoglycaemia in some patients gradually gets milder over time. The long term medical
management of diffuse disease with frequent subcutaneous injections of octreotide and
frequent feeding may impose a huge burden and is extremely stressful on the family. A
gastrostomy is often required in these patients for the delivery of bolus and continuous
overnight feeds.
2.2.3 Clinical relevance of the molecular genetic classification:
Diazoxide is ineffective in diffuse forms of CHI due to recessively inherited inactivating
mutations in ABCC8 and KCNJ11 and in patients with focal CHI as it requires a functional
channel to act upon. All of the other forms of CHI are responsive to diazoxide, although
there are recent reports that CHI due to a mutation in the GCK gene can cause diazoxide
unresponsive disease (Cuesta- Munoz et al., 2004; Sayed et al., 2009).
The availability of rapid genetic analysis for mutations in ABCC8 and KCNJ11 allows early
confirmation of the diagnosis and identification of the majority of patients with diffuse
disease (homozygous or compound heterozygous mutations in ABCC8 and KCNJ11). This
information helps in predicting the likely course of the disease and institution of appropriate
treatment. Patients with a paternal mutation in ABCC8 and KCNJ11 (or those with no
mutations in these genes) potentially have focal disease and thus enables selection of
patients who require further imaging studies with 18F-DOPA-PET scan for precise pre-
operative localisation of the focal lesion. The clinical approach to this complex disease has
hence been transformed by the understanding of the molecular and histological
classification and is summarized in figure 2.7.
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The confirmation of a GLUD1 mutation informs clinicians of the protein sensitive nature of
hypoglycaemia and allows the manipulation of diet (protein restriction) as a useful
(sometimes mandatory) adjunct to diazoxide therapy in controlling recurrent
hypoglycaemic episodes.
The identification of a disease causing mutation in a proband has implications for other
family members too. In a dominantly inherited mutation, unless the mutation is ‘de novo’,
the proband’s siblings will have a 50% chance of inheriting the mutation. In contrast,
siblings of probands with recessively inherited mutations will have a 25% risk of inheriting
both the mutations and developing the disease. Furthermore, the identification of a HNF4A
mutation in a proband would identify infants who are at a risk of developing diabetes
(MODY) in adulthood. Unless the mutation has arisen de novo, one of the parents (and
potentially other family members) will also be heterozygous for the HNF4A mutation and at
risk of developing diabetes, if not already developed. A molecular genetic diagnosis in the
proband may therefore also be of benefit for other relatives.
Figure 2.7: Flow chart outlining the management cascade of CHI (Kapoor et al., 2009c).
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2.2.4 Aims of the thesis
As outlined in the introduction, the knowledge of the molecular genetic mechanisms
underlying the different subtypes of CHI has transformed the clinical management of the
patients and has provided unique insights into pancreatic ß-cell physiology. However, the
genetic basis of CHI and phenotypic characterisation of the sub groups is only just
beginning to be unravelled. Although CHI due to mutations in the KATP channel genes has
been well studied, novel aspects of the phenotypic variation are still emerging. For
example, controversy exists on whether these mutations are a risk for future development
of diabetes. This knowledge not only has implications for the patients and family members,
but also may help in understanding the pathophysiology of a common condition such as
diabetes mellitus.
The less well studied sub groups, where little is known about the molecular mechanisms
and the phenotype, include CHI due to mutations in the HADH and HNF4A genes. Further
understanding of the genotype-phenotype correlations due to these known and novel
causes of CHI will be very important for the diagnosis and subsequent management of
these patients. With the knowledge of the lacunae within the field of CHI, the aims of this
thesis include:
4. To investigate genotype/phenotype correlations in a large cohort of patients with
CHI by comparing different genetic aetiologies
5. To examine the prevalence and phenotype of patients with HH resulting from
HNF4A gene mutations
6. To study the phenotype of dominantly inherited KATP channel mutations causing
CHI and functionally characterize the novel dominant mutations identified
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Chapter 3- General Methods
This section gives an overview of the methodologies used throughout this thesis. Further
details are provided in the methods section for each chapter.
3.1 Ethical Approval
Ethical approval for the study was obtained from the Research Ethics Committee at the
Institute of Child Health and Great Ormond Street Children’s Hospital NHS Trust (GOSH)
in 2006 by Dr Hussain. In 2007, the protocol was amended and a ‘Parent Information
Sheet’ and ‘Proforma and Consent’ pack was designed (appendix 12.1-12.2) by me. I then
submitted a notice of substantial amendment to the Research Ethics Committee. This
notice was reviewed at the meeting of the Sub-Committee of the REC held on 24 April
2007 and was given a favourable opinion (appendix 12.3). The study was also exempted
from Site-Specific assessment at other NHS sites.
3.2 Recruitment of patients
Patients with congenital hyperinsulinism are referred to GOSH, a national centre for the
management of children with CHI. The study was discussed with all the patients referred
to the CHI service at GOSH who met the inclusion criteria. The information sheet was also
provided to the parents and an informed consent was obtained prior to recruitment.
A thorough assessment of the phenotype of each patient was carried out at the initial
admission/ referral. Along with this a blood sample (2-5 ml) for extraction of DNA was also
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collected. Blood samples from parents or any other family member were requested
depending on the family history.
Information regarding the study was disseminated to the neonatalogists in the UK via the
bulletin published by the BAPM (British Association of Perinatal Medicine). National and
international referring clinicians were also informed about the study. Hence, patients have
also been recruited from other NHS trusts in the UK and worldwide with the help of local
and international collaborators.
3.3 Inclusion Criteria
All patients with HH, usually defined as:
a. Hypoglycaemia (blood glucose concentration <3.0 mmol/L) with detectable
concentrations of insulin and/or C-peptide with
b. Glucose requirement of > 8mg/kg/min (intravenous glucose infusion rate of
>8mg/kg/min and
c. Inappropriately low concentrations of ketones and fatty acids during the
episode of hypoglycaemia
3.4 Exclusion criteria
All patients with a secondary cause of HH were excluded. This included patients with the
following risk factors:
– Perinatal asphyxia
– Intra-uterine growth restriction (IUGR)
– Rhesus isoimmunisation
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– Infant of diabetic mothers with HH <48 hours
3.5 Clinical and biochemical phenotyping
3.5.1 Data collection using a proforma
A proforma (see appendix 12.1) was designed to collect data on patients with CHI that met
the inclusion criteria. Apart from identifying details (name, date of birth, hospital number,
gender), personal data included ethnic background of the patients according to the Office
for National Statistics (ONS) classification (Office for National Statistics, 2003).
Phenotype assessment included a detailed clinical and biochemical profiling for each
patient. Clinical assessment included a thorough history with a focus on birth-weight,
gestational age, age at presentation, treatment details and family history of hypoglycaemia
or diabetes mellitus. Examination details of the patient (presence or absence of syndromic
features) were recorded. Biochemical assessment carried out at the time of investigating
hypoglycaemia whether at the primary referring hospital or at our center was also
recorded. This included serum insulin, c-peptide, ammonia and acylcarnitines.
Response to medical therapy and results of 18F-DOPA-PET scan, if applicable were also
documented. Finally, for the patients who required surgery, the type of the surgical
procedure and the results of the histological analysis of the pancreas were documented.
In cases where the child had been previously treated in the hospital and discharged, a
review of the medical records and telephone interviews were conducted to complete the
data collection. Home visits were also conducted to obtain blood samples from the patient
and/ or family members for genetic analysis.
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Children with CHI who had an established molecular diagnosis were not excluded from the
study. The phenotypic data on these children were retrospectively collected from them and
their medical case notes.
A database using Microsoft Access was created to allow ease of entry and access to the
data. The database has been designed, completed and updated by myself throughout the
period of the study.
3.5.2 Further phenotypic data
In some patients, the phenotype was further defined with the help of the following
provocation tests, as detailed in individual chapters:
a. Oral glucose tolerance test
b. Oral protein tolerance test
c. Leucine tolerance test
3.5.3 Statistics
In order to correct for the gestational age, birth weight standard deviation scores (birth
weight SDS) were calculated for each patient. The mean birth weight SDS and age of
presentation of patients with diazoxide responsive CHI due to a KATP channel mutation,
GLUD1 mutation, HADH mutation or an HNF4A mutation were compared using one-way
analysis of variance (ANOVA) followed by the Fisher's Least Significant Difference (LSD)
post-test to test for statistical significance (SPSS, version 16).
The one way ANOVA test is a common statistical test used to test the difference between
three or more groups. The test can be applied to test the equality of means between
samples that are independent and normally distributed. Prior to applying this test, it was
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ensured that the samples within the groups were normally distributed. The one way
ANOVA test showed that the mean birth weight SDS and age of presentation of the groups
were different. The LSD post-hoc test (which makes individual comparisons) was then
applied to understand where the differences were.
3.6 Molecular genetic testing
3.6.1 Sequence analysis of genes known to cause CHI
The DNA samples were analysed for mutations in genes known to cause CHI (ABCC8,
KCNJ11, HNF4A, GCK, GLUD1 and HADH genes) at the Diagnostic Molecular Genetics
Laboratory at Peninsula Medical School in Exeter under the supervision of the Consultant
Clinical Molecular Geneticist, Professor Sian Ellard. DNA was extracted from blood
samples by the staff at Peninsula Medical School using their standard protocol (appendix
12.3). The amplification of specific regions of DNA by polymerase chain reaction (PCR)
was the principal methodology used, followed by detection of mutation using DNA
sequencing.
Polymerase chain reaction (PCR): Initially, the DNA is denatured, separating the double
helix, allowing the primers to bind to their complementary DNA sequences. Primers extend
in the presence of DNA polymerase and deoxynucleotide triphosphates, allowing the
synthesis of a complementary DNA sequence. The process is repeated approximately 35
times resulting in over 2 million copies of the target DNA sequence.
Dideoxy Chain Termination Sequencing: Purified PCR products were sequenced using the
ABI Prism Big Dye Terminator Cycle Sequencing ready reaction kit 1.1 (Applied
Biosystems, Warrington, UK). The method utilises a single- stranded PCR product which
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acts as a template for the synthesis of a complementary strand of DNA. The sequencing
reactions contain a DNA polymerase, primer and four dideoxynucleotides which lack a 3’
hydroxyl group. Each ddNTP is labelled with a base specific fluorescent dye. The absence
of the 3’ hydroxyl group prevents phosphodiester bonding resulting in the formation of
many hundreds of oligonucleotide fragments which differ in length. The sequencing
reactions are then separated by size on a capillary sequencer (ABI 3730 Sequencer,
Applied Biosytems, Warrington, UK). The DNA sequence is generated by computer
software and analysed using either Staden software (hhtp://staden.sourceforge.net) or
Mutation Surveyorv2.61 (Softgenetics, State College, PA, USA).
The single exon of KCNJ11 gene was amplified in five patient samples by me using three
primer pairs (primer sequences published in Flanagan et al., 2006). I performed
sequencing in both directions using the BigDye Terminator Cycler Sequencing Kit v1.1
(Applied Biosystems, Warrington, UK) and analysed the five reactions on the ABI 3730
Capillary sequencer (Applied Biosystems). The sequences were then compared by me
with the published sequence (NM_000525) using the Staden analysis software. Analyses
of these five samples taught me the principles and details of the techniques employed
(primer designing, polymerase chain reaction, gel electrophoresis and sequencing) in
analysing the samples. Sequencing of the other patient samples and analysis was carried
out by the laboratory staff at Peninsula Medical School. Sequencing of genes known to
cause CHI is routinely carried out at this large Diagnostic Molecular Genetics Laboratory in
Exeter. After recruitment, detailed phenotyping and collection of DNA samples from the
patient and family members, I organized genetic testing at this laboratory where
sequencing of the genes was carried out by the diagnostic service.
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3.6.2 Sequencing strategy (Figure 3.1)
ABCC8 and KCNJ11 genes were sequenced in all patients with diazoxide unresponsive
CHI.
In patients with diazoxide responsive CHI,
i) mutations in GLUD1 were sought if the patient had hyperammonaemia or
leucine sensitivity
ii) HADH was sequenced if there was raised plasma 3-hydroxybutyrylcarnitine
iii) if no mutations were identified and in the absence of above features; KCNJ11,
ABCC8 and HNF4A genes were sequenced in that order
iv) Sequencing of GCK was considered if there was a positive family history of
hypoglycaemia or delayed presentation of hypoglycaemia
If it was not possible to establish whether a patient with CHI was diazoxide responsive or
not, KCNJ11, ABCC8 and HNF4A genes were sequenced in that order.
Sequencing of SLC16A1 was planned in case of a history of exercise induced
hypoglycaemia. However, no patients with EIHI were recruited during the study period.
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Figure 3.1: Schematic representation of the Experimental Design
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3.7 Functional analysis of novel mutations
The functional consequences of certain novel mutations identified in the ABCC8 or
KCNJ11 genes were undertaken under the supervision of Professor Tinker at the Rayne
Institute, University College London. Briefly, mutations were introduced into hamster SUR1
cDNA or mouse Kir6.2 cDNA using the QuickChange site-directed mutagenesis kit.
Functional consequences were then examined by reconstituting the KATP channel in
HEK293 cells and evaluating the effect of drugs (diazoxide, glibenclamide) and metabolic
poisoning on the channels using Rb86 flux assay. Western blotting was carried out to
confirm expression of the mutant proteins. The details of these techniques and the
statistics used for functional evaluation of the novel mutants are provided in chapter 9.
Through established collaboration with experts in functional characterisation of GLUD1
and HADH mutations (Dr Bernadette Chadefaux and Dr Simon Eaton respectively),
functional consequences of selected novel GLUD1 and HADH gene mutations were
investigated to provide insight into the mutational mechanisms.
74
Chapter 4- Overview of Results
Patient Recruitment and Prevalence of the Different Genetic
Aetiologies
Three hundred patients with CHI were recruited in this study, forming the largest cohort of
children with CHI in the world. As outlined in chapter 3, mutational analysis of various
genes known to cause CHI was carried out depending on the phenotype of the patient.
The patients were broadly classified into diazoxide responsive (n=183) and diazoxide
unresponsive (n=105) groups (figure 4.1), diazoxide responsiveness being defined as
normoglycaemia maintained during normal feeding volume and frequency with normal
fasting tolerance for age of the child. Twelve patients with CHI were not able to be grouped
within these two broad categories. These included patients with transient CHI that did not
require treatment with diazoxide (n=9) and 1 patient who was not treated with diazoxide
following an anaphylactic reaction to the drug.
Figure 4.1: Categorisation of the 300 recruited patients, according to their responsiveness
to diazoxide
Recruited:
300
Diazoxide
responsive:
183
Diazoxide
unresponsive:
105
Diazoxide
responsiveness
unknown:
12
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4.1 Diazoxide responsive CHI
The largest category of patients with CHI in this cohort included patients with diazoxide
responsive CHI. Of the 183 patients with diazoxide responsive disease, a genetic
diagnosis was possible in 51 patients (Fig 4.2).
Diazoxide responsive CHI
0
0%
16
9%7
4%
3
2%
25
14%
132
71%
No mutations
ABCC8/KCNJ11
HNF4A
GLUD1
HADH
GCK
Figure 4.2: Figure demonstrating the genetic aetiologies identified in patients with
diazoxide responsive CHI
168 patients had mutational analysis of the KATP channel genes, of which 25 were
identified to have a mutation in the KCNJ11 or ABCC8 genes. The phenotypic
characteristics of these patients are outlined in chapter 5.
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20 patients with diazoxide responsive CHI (19 patients with hyperammonaemia and 1 with
leucine sensitivity) had mutational analysis of GLUD1 gene, of which 16 were positive for a
mutation in this gene. The genotype-phenotype correlations of these patients are
discussed in chapter 6.
Of the 105 patients with diazoxide responsive CHI who had mutational analysis of the
HNF4A gene, 7 were identified to have a mutation in this gene. The phenotypic
characteristics of these patients are presented in chapter 8.
This cohort also contains 3 patients with a mutation in the HADH gene, of which 2 patients
were known to have CHI due to recessively inherited mutations in the HADH gene and
have been described previously (Clayton et al., 2001; Hussain et al., 2005c). The novel
phenotypic characteristics of the patients with HADH mutations causing CHI are presented
in chapter 7.
GCK was analysed in patients with a delayed age of presentation (> 6 months) if sufficient
DNA was available after analysis of the KCNJ11 and ABCC8 genes. No patients with GCK
mutation were identified on analysis of the DNA of 17 patients.
4.2 Diazoxide unresponsive CHI
In this cohort, there were 105 patients who did not respond to 1st line treatment with
diazoxide and required additional treatment measures. All of these patients had
sequencing of the ABCC8 and KCNJ11 genes. A significant proportion (92/105; 87.6%) of
these patients had a mutation in one of these genes. This included 10 patients with a
mutation in the KCNJ11 gene and 82 patients with a mutation in the ABCC8 gene. No
mutation in these genes were found in 13 patients (12.4%).
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4.3 Diazoxide responsiveness not known
There were 12 patients where it was not possible to establish whether they were
responsive to diazoxide or not. These included 11 patients who had transient HH (lasting
1-10 days) that was managed with supportive treatment (intravenous dextrose solutions)
alone. The remaining patient had a severe reaction to the first dose of diazoxide and
hence diazoxide was discontinued. A further attempt to re-start diazoxide was met with a
similar reaction where the child developed a generalized rash and difficulty in breathing.
Hence, diazoxide was not continued and the child underwent a partial pancreatectomy to
manage the HH. All these patients had sequencing of the ABCC8 and KCNJ11 genes and
a mutation in the ABCC8 gene was identified in two patients. Six patients had sequencing
of the HNF4A gene (DNA sample was insufficient for the remaining 4), of which one
patient with transient HH had an HNF4A mutation.
These results are summarized below in figure 4.3.
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Figure 4.3: Figure summarizing the results of mutational analysis of 300 patients with CHI:
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4.4 Discussion
In this cohort of patients, with the designed strategy of the order of sequencing and the
limitation of low DNA sample in some patients, a genetic diagnosis was possible in 48.6%
of patients. The vast majority of patients with an unknown genetic cause were diazoxide
responsive (132/154; 85.7%). This may be reflective of the sequencing strategy rather
than the actual prevalence of the genetic aetiologies. For example, GCK was only
sequenced in patients with a delayed age of presentation as patients with GCK-CHI were
initially reported to be diagnosed at a much later age (Glaser et al., 1998; Christensen et
al., 2002; Cuesta-Munoz AL et al., 2004). A recent study looking at the prevalence of GCK
mutation in patients with CHI reported five patients with GCK mutation who presented in
the neonatal period with hypoglycaemia (Christensen et al., 2008). Hence, this low
prevalence of GCK mutations in our group of patients with diazoxide responsive CHI may
be an underestimate and a thorough sequencing of all patients with diazoxide responsive
CHI and no mutations in the ABCC8/ KCNJ11 genes is indicated. Similarly, sequencing of
GLUD1 and HADH were limited to patients with specific phenotypic features
(hyperammonaemia for GLUD1 and abnormal plasma acyl carnitine profile for HADH). In
the chapters to follow, it will be clear that patients may have CHI due to mutations in these
two genes in the absence of these biochemical markers that were previously thought to be
diagnostic. Hence, sequencing of these two genes in this large cohort of patients with
diazoxide responsive CHI may also be indicated. This large cohort of patients with an
unknown aetiology forms a unique cohort for further studies investigating the known and
novel genetic causes of CHI.
Unlike the cohort with diazoxide responsive CHI, a genetic diagnosis was possible in the
vast majority of patients with diazoxide unresponsive CHI that underwent sequencing of
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the ABCC8 and KCNJ11 genes. A genetic diagnosis in this group of patients helps in the
clinical management by determining whether a patient may have focal disease that is
potentially curable by a limited pancreatectomy or whether the patient has diffuse disease
and is a candidate for near-total pancreatectomy (Kapoor et al., 2009c). Hence, the high
possibility of finding a KATP channel mutation in patients within this cohort confirms the
importance of rapid sequencing of the ABCC8 and KCNJ11 genes in these patients. Only
13/105 (12.4%) patients with diazoxide unresponsive patients did not have a mutation in
these genes. Mutations in the GCK gene have recently been described to cause medically
unresponsive CHI (Cuesta-Munoz et al., 2004; Sayed et al., 2009). Sequence analysis of
the GCK gene in this cohort of patients is hence indicated, prior to further research
investigating novel genetic aetiologies.
The patients identified to have a genetic mutation are varied in their phenotypes
depending on their genotypes. In the chapters to follow, I describe the phenotype of
patients with KATP channel mutations (chapter 5), GLUD1 mutations (chapter 6), HADH
mutations (chapter 7) and HNF4A mutations (chapter 8) and compare the clinical
characteristics of the patients according to their genetic aetiology (chapter 8).
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Chapter 5
Congenital Hyperinsulinism due to mutations in the ABCC8/
KCNJ11 genes
5.1 Background
Mutations in the ABCC8 gene were the first genetic cause identified and are the
commonest cause of CHI. So far over 150 mutations in the ABCC8 gene have been
identified that are distributed throughout the gene (Flanagan et al., 2009). Relatively, fewer
mutations have been described in the KCNJ11 gene (Flanagan et al., 2009). The
mutations are commonly recessively inherited and cause diazoxide unresponsive disease
in the vast majority of patients. However, there have been reports of dominantly inherited
mutations in these genes causing diazoxide responsive disease (Huopio et al., 2000;
Thornton et al., 2003; Pinney et al., 2008). Compound heterozygous mutations in the
ABCC8 have also been reported to cause diazoxide responsive disease (Dekel et al.,
2002). Mutations in these genes are also associated with the pathogenesis of focal CHI,
where a focal area of the pancreas is affected which is amenable to curative surgery.
The identification of an ABCC8 or KCNJ11 mutation in a patient helps to predict the likely
course and influences the management of the patient (Kapoor et al., 2009c). In patients
with medically unresponsive disease, rapid genetic testing of these genes identifies those
who have diffuse disease (homozygous/ compound heterozygous mutations) where a
near-total pancreatectomy may be considered. It also helps in identifying patients who may
have a focal lesion (single, paternally inherited mutation) that is potentially curable with
resection of the focal lesion.
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In this chapter, the phenotype and genotype of the 119 patients with a mutation in the
ABCC8/ KCNJ11 genes is discussed. This section reports several novel mutations
identified in these genes and summarises the associated clinical picture in each patient.
5.2 Methodology
Of the 300 patients recruited, 2 patients with known HADH mutations and 15 patients with
hyperammonaemia that screened positive for a GLUD1 mutation did not have sequence
analysis of the KATP channel genes. The remaining 283 patients had mutational analysis of
the KCNJ11 and ABCC8 genes, in that order. KCNJ11 was sequenced as outlined in
section 3.6.1. The coding regions and conserved splice sites of the ABCC8 gene were
amplified using 38 primer pairs (primer sequences published in Proks et al., 2006). PCR
products were sequenced using standard methods on an ABI 3730 (Applied Biosystems,
Warrington, UK) and compared to the published sequence (NM_000352.2) at Peninsula
Medical School, Exeter. When a mutation in the ABCC8/ KCNJ11 gene was identified, the
parents were tested (if available) to ascertain the mode of inheritance. Novel mutations
were confirmed by testing 500 control chromosomes, of mixed ethnicites (as are our
patients). In addition, these genes are also analysed by Peninsula Medical School in
patients with neonatal diabetes (>300 and increasing). These patients also serve as
additional controls, although ethnic differences cannot be guaranteed.
All the patients had standard clinical and biochemical phenotyping, as outlined in chapter
3. The patients positive for a mutation in the ABCC8 gene were categorized into those with
homozygous mutations, compound heterozygous mutations and single, heterozygous
mutations. The clinical data were tabulated, according to these categories summarizing
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the most pertinent clinical features, with particular emphasis on the responsiveness to
diazoxide therapy and outcome.
Clinical features of the patients with a KCNJ11 mutation were tabulated separately.
Data on ethnic backgrounds of the patients was also tabulated to study whether certain
mutations were more prevalent in certain ethnic populations. The Office for National
Statistics (ONS) classification was used to categorise ethnicity (Office for National
Statistics, 2003).
5.3 Results
Of the 119 patients with a mutation in the KATP channel gene, 106 patients had a mutation
in the ABCC8 gene while 13 patients had a KCNJ11 mutation.
5.3.1 KCNJ11 gene mutations
Thirteen different KCNJ11 mutations were identified; eleven of which are novel. The
genotype and phenotype of these patients is summarized in table 5.1. The mean age of
presentation of these patients was 4 days (median of 1 day) and the mean birth weight
SDS was +1.69 standard deviation score (SDS).
Diazoxide unresponsive disease:
Six patients had diazoxide unresponsive disease associated with homozygous mutations
in the KCNJ11 mutation. Four (table 1- patients 26, 323, 379 and 395) of these patients
underwent a near total pancreatectomy while two (67, 74) were treated conservatively with
octreotide. Diffuse disease was confirmed histologically in the four patients who underwent
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a near- total pancreatectomy and in patient 74 via a pancreatic tail biopsy. The histological
diagnosis was not established in patient 67.
Three patients (133, 244 and 365) with diazoxide unresponsive disease and a paternal
mutation in KCNJ11 had focal disease, confirmed on histological examination following a
limited/ sub-total pancreatectomy. One of the patients (148) with diazoxide unresponsive
disease who was heterozygous for a novel paternal mutation had diffuse disease requiring
a near total pancreatectomy.
Diazoxide responsive disease:
Three others who were heterozygous for a mutation in the KCNJ11 gene had diazoxide
responsive disease. Two (22 and 56) of these had transient disease, requiring diazoxide
therapy for 4- 6 months. Patient 56 has inherited the mutation from an unaffected mother
and the inheritance of the mutation in the second patient could not be determined
(mother’s DNA was negative and unable to obtain paternal DNA sample). The third patient
(285) has inherited the mutation from her affected father (who has a history of neonatal
hypoglycaemia), confirming dominant inheritance.
There were no common KCNJ11 mutations in our cohort and hence an intra-gene
genotype-phenotype correlation was not possible.
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Table 5.1: Summary of patients with a KCNJ11 gene mutation: Patients presented early (mean age of presentation was 1 day) and
were large at birth with a mean birth weight of +1.69 standard deviation score. The majority (10/13) were diazoxide unresponsive.
ID Genotype Type
of
mutation
Novel Inheritance Ethnicity Age of
presentation
(days)
Birth
weight
SDS
Management Histology/
18F-DOPA-
PET scan
Diazoxide responsive patients with a KCNJ11 mutation
56 R347H/N Missense Yes Maternal Asian Indian 1 -0.00 Diazoxide for 6 months n/a
22 R54H/N Missense Yes Not
determined
Black African 1 -0.27 Diazoxide for 4 months n/a
285 I284del/N Deletion Yes Paternal White British 1 +1.48 Continuing Diazoxide at
1.9 yrs
n/a
Diazoxide unresponsive patients with a KCNJ11 mutation
26 A161V/
A161V
Missense Yes Both parents Asian
Pakistani
2 +1.33 Near total pancreatectomy Diffuse
395 G40A/
G40A
Missense No Both parents Other Asian 1 +2.46 Near total pancreatectomy Diffuse
323 G132D/
G132D
Missense Yes Both parents Other Asian 1 +0.07 Near total pancreatectomy Diffuse
379 E51X/
E51X
Missense Yes Both parents White British 1 +4.73 Near total pancreatectomy Diffuse
74 H259Q/
H259Q
Missense Yes Both parents Asian
Pakistani
1 +1.3 Continuing octreotide at
5.7 yrs
Diffuse-
tail biopsy
67 A213T/
A213T
Missense Yes Both parents Asian
Pakistani
1 +3.22 Continuing octreotide at
5.5 yrs
n/a
133 E292K/N Missense Yes Paternal White British 1 +2.36 Near total pancreatectomy Focal
244 R136fs/ N Frameshift No Paternal White British 1 +2.2 Near total pancreatectomy Focal
365 R301H Missense Yes Paternal White British 50 +0.91 Resection of focal lesion Focal
148 T294M/N Missense Yes Paternal White British 1 +2.23 Near total pancreatectomy Diffuse
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5.3.2 ABCC8 gene mutations
Of the 106 patients with an ABCC8 gene mutation, 19 patients were compound
heterozygous, 38 patients were homozygous and 49 patients were heterozygous for a
mutation in the gene. A variety of missense, frameshift, nonsense, deletions and splice site
mutations, located throughout the gene, were identified. Sixty-eight novel mutations were
identified in this study. These mutations affected residues that were conserved across
species and were not found in the control chromosomes. An intragene genotype-
phenotype correlation was not possible due to the small numbers of mutations found in
common. The most common mutations were the splice site mutation IVS32-9G>A and the
missense mutation G111R, found in six patients each. However, even within these groups,
the mutations were either homozygous or heterozygous or compound heterozygous and
hence a true intra-gene genotype-phenotype was not possible.
5.3.2.1 CHI due to homozygous/ compound heterozygous mutations in ABCC8
(tables 5.2 and 5.33):
All the patients with recessively inherited CHI due to ABCC8 mutations were unresponsive
to diazoxide therapy (n= 57). Of these 57 patients, 38 patients underwent a near total
pancreatectomy and diffuse disease was confirmed histologically. The remaining 19
patients were treated conservatively with octreotide therapy. Diazoxide was used as an
adjunct in 7 patients and nifedipine was added to octreotide therapy in 1 patient.
The mean age of presentation of these patients was 20 days (median of 1 day) and the
mean birth weight SDS was +1.67 SDS.
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Table 5.2: Summary of the patients with compound heterozygous mutations in the ABCC8 gene: All of the 19 patients were
diazoxide unresponsive. Diffuse disease was confirmed in all the patients that underwent a pancreatectomy.
ID Genotype Type of
mutation
and location
(Exon/
Intron)
Novel Ethnicity Age of
Presentation
(day)
Birth
Weight
SDS
Diazoxide
responsive
Management Histology
213 c.1012-2A>G/
c.3870+7G>A
Splicing In
Intron 6 and
31
c.3870+7G>
A
White
Irish
1 +0.79 No Continuing
octreotide
N/A
20 G735E/R1215W Missense In
Exons 16 And
29
G735E White
British
1 +2.38 No Continuing
diazoxide +
octreotide
N/A
252 K329X /P1414L Nonsense In
Exons 6 and
35
K329X Other White 1 +1.4 No Continaquing
octreotide +
nifedipine
N/A
346 H125Q/E529K Missense in
Exons 3 and
10
E529K Other White 250 +1.51 No Continuing
diazoxide +
octreotide
N/A
104 R74Q/G111R Missense In
Exons 2 And 3
No Asian
Indian
1 +2.66 No Continuing
diazoxide
+octreotide
N/A
184 R74Q/G111R Missense In
Exons 2 And 3
No Asian
Indian
1 -0.58 No Continuing
Octreotide
N/A
23 V222M/E515K Missense In
Exons 5 And
10
Both Novel White
British
60 +1.58 No Continuing
octreotide
N/A
88 R168C/S606T Missense In
Exons 4 And
12
S606T Asian
Indian
1 +4.63 No Octreotide for 8
weeks
N/A
191 G70E/R1419H Missense In
Exons 2 And
35
No White
British
1 +4.53 No Near Total
Pancreatectomy
Diffuse
142 M429fs/H627fs Frameshift In
Exon 8 And 13
M429fs White
British
1 +1.56 No Near Total
Pancreatectomy
Diffuse
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138 [I320N;W739C]/
c.1176+2T>C
Two Missense
in Exons 6
And 16 and
Splicing In
Intron 7
All Three
Novel
White Irish 1 +2.05 No Near Total
Pancreatectomy
+ Octreotide
Diffuse
85 R1421C/T1532
A
Missense In
Exons 35 And
38
T1532A White
British
1 +2.89 No Near Total
Pancreatectomy
Diffuse
114 G1343E/c.2116
+3A>G
Missense In
Exon 10 And
Splicing In
Intron 15
No White
British
1 +1.57 No Near Total
Pancreatectomy
Diffuse
200 c.725delA/R143
7L
Framehsift In
Exon 5 And
Missense In
Exon 35
Both novel White
British
1 +1.63 No Near Total
Pancreatectomy
Diffuse
261 R16P/c.2116+3
A>G
Missense In
Exon1 And
Splicing In
Intron 15
R16P White
British
56 +0.79 No Near Total
Pancreatectomy
Diffuse
262 R16P/c.2116+3
A>G
Missense In
Exon1 And
Splicing In
Intron 15
R16P White
British
1 +2.72 No Near Total
Pancreatectomy
Diffuse
175 R248X/c.4311-
2A>G
Nonsense In
Exon 10 And
Splicing In
Intron 35
C.4311-
2A>G
White
British
4 +1.85 No Near Total
Pancreatectomy
Diffuse
155 R526C/S1482R Missense In
Exons 10 And
37
Both Novel White
British
1 +2.85 No Near Total
Pancreatectomy
Diffuse
231 V21D/c.1176+2
T>C
Missense In
Exon1,
Spilcing In
Intron 7
No White
British
1 Not known No Near Total
Pancreatectomy
Diffuse
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Table 5.3: Summary of the patients with homozygous mutations in the ABCC8 gene: Simlar to the patients with compound
heterozygous mutations, all of the 38 patients were diazoxide unresponsive. Diffuse disease was confirmed in all the patients that
underwent a pancreatectomy.
ID Genotype Type Exon/
Intron
Novel Ethnicity Age of
presentation
(Days)
Birth
Weight
SDS
Diazoxide
Responsive
Management Histology
31 c.1877del57/
c.1877del57
Frameshift Exon 13 Yes Asian
Pakistani
1 +1.01 No Near Total
Pancreatectomy
Diffuse
77 c.945delC/
c.945delC
Frameshift Exon 6 No Asian
Pakistani
1 +4.1 No Near Total
Pancreatectomy +
Octreotide
Diffuse
250 c.1672-5C>G/
c.1672-5C>G
Splicing Intron 11 Yes Asian
Pakistani
1 +1.85 No Near Total
Pancreatectomy
Diffuse
105 c.3871-1G>A/
c.3871-1G>A
Splicing Intron 31 Yes Asian Indian 2 +0.79 No Near Total
Pancreatectomy
Diffuse
102 c.3871-1G>A/
c.3871-1G>A
Splicing Intron 31 Yes Other Asian 30 -).86 No Near Total
Pancreatectomy
Not Known
193 E786del/
E786del
Deletion Exon 19 Yes Asian
Pakistani
3 +0.53 No Near Total
Pancreatectomy
Diffuse
292 G111R/
G111R
Missense Exon 3 No Asian Indian 1 +4.71 No Near Total
Pancreatectomy
Diffuse
321 G111R/
G111R
Missense Exon 3 No Asian Indian 1 +2.66 No Near total
pancreatectomy
Diffuse
291 G111R/
G111R
Missense Exon 3 No Asian Indian 1 +1.92 No Near total
pancreatectomy
Diffuse
243 [c.554delT;Q664l]/
[c.554delT;Q664l]
Frameshift-
C.554delt,
Missense
Q664l
Exons 4
and 14
Yes Asian
Bangladeshi
1 Not known No Near Total
Pancreatectomy
Diffuse
207 L1471Pfs/
L1471Pfs
Frameshift Exon 36 Yes Chinese 2 -1.59 No Near Total
Pancreatectomy
Not Known
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108 N32K/
N32K
Missense Exon1 Yes Other Asian 1 +2.59 No Near Total
Pancreatectomy
Diffuse
41 R1251X/
R1251X
Nonsense Exon 30 No Other Asian 1 +0.59 No Near Total
Pancreatectomy
Diffuse
61 R1494W/
R1494W
Missense Exon 37 No Other Asian 11 Not known No Near Total
Pancreatectomy
Post
Pancreatect
omy
62 Q1342X/
Q1342X
Nonsense Exon 33 Yes Other Asian 1 +1.29 No Near Total
Pancreatectomy
Not Known
63 Q1342X/
Q1342X
Nonsense Exon 33 Yes Other Asian 1 -0.92 No Near Total
Pancreatectomy
Not Known
208
Q1488X/
Q1488X
Nonsense Exon 37 Yes Chinese 1 +2.15 No Near Total
Pancreatectomy
Diffuse
290 A390E/
A390E
Missense Exon 7 Yes Other Asian 1 +4.75 No Near total
Pancreatectomy
Diffuse
303 IVS32-9G>A/
IVS32-9G>A
Splicing Intron 32 No Other Asian 120 +1.1 No Near total
pancreatectomy
Diffuse
205 IVS32-9G>A/
IVS32-9G>A
Splicing Intron 32 No Asian
Bangladeshi
1 -0.92 No Near Total
Pancreatectomy
Diffuse
183 G706S/
G706S
Missense Exon 15 Yes Black African 1 +3.24 No Near total
pancreatectomy
Diffuse
388 A736fs/
A736fs
Frameshift Exon 16 Yes Other Asian 1 +1.92 No Near Total
Pancreatectomy +
Octreotide
Diffuse
377 IVS32-9G>A/
IVS32-9G>A
Splicing Intron 32 No Other White 1 +2.44 No Near total
pancreatectomy
Diffuse
362 W1339X/
W1339X
Missense Exon 33 Yes Other Asian 1 +2.99 No Near total
pancreatectomy
Diffuse
266 IVS9+5G>A/
IVS9+5G>A
Splicing Intron 9 Yes Other Asian 1 Not known No Near Total
Pancreatectomy
Diffuse
343 IVS9+5G>A/
IVS9+5G>A
Splicing Intron 9 No Asian
Pakistani
1 +1.01 No Near total
pancreatectomy
Diffuse
64 IVS9+5G>A/
IVS9+5G>A
Splicing Intron 9 Yes Asian
Pakistani
1 Not known No Near Total
Pancreatectomy
Diffuse
65 IVS9+5G>A/
IVS9+5G>A
Splicing Intron 9 Yes Asian
Pakistani
1 +1.75 No Continuing
Diazoxide+
Octreotide at 6 years
N/A
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331 L362fs/
L362fs
Frameshift Exon 7 Yes Other Asian 1 +3.36 No Continuing
Octreotide at 2yrs
N/A
332 L362fs/
L362fs
Frameshift Exon 7 Yes Other Asian 1 +0.30 No Continuing
Octreotide +
Diazoxide at 1.8 yrs
N/A
333 N188S/
N188S
Missense Exon 4 No Other Asian 1 +0.57 No Continuing
Octreotide +
Diazoxide at 1.3 yrs
N/A
326 G1376R/
G1376R
Missense Exon 34 Yes Black African 14 +1.12 No Continuing
Octreotide at 1.5 yrs
N/A
327 Homozygous
deletion of exons
1-22
Deletion Exons 1-
22
No Other Asian 3 -0.81 No Continuing
Octreotide at 1.5 yrs
N/A
364 R74Q/
R74Q
Missense Exon 2 No Asian
Pakistani
540 +0.35 No Continuing
Octreotide at 2.4 yrs
Diffuse
302 R837X/
R837X
Nonsense Exon 21 No Other Asian 1 +0.12 No Continuing
Octreotide at 1.9 yrs
of age
N/A
234 Q822X/
Q822X
Nonsense Exon 20 Yes Other Asian 1 +0.8 No Octreotide For 10
Weeks
N/A
69 IVS32-9G>A/
IVS32-9G>A
Splicing Intron 32 No Other White 2 +4.07 No Octreotide- Till 1
Year
N/A
152 E490X/
E490X
Nonsense Exon 10 No Asian
Pakistani
1 +1.52 No Continuing
Octreotide +
Diazoxide at 5.4 yrs
of age
N/A
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5.3.2.2 CHI due to heterozygous mutations in ABCC8 (table 5.4):
Forty-nine patients were heterozygous for a single mutation in ABCC8. This is a
heterogeneous group of patients that includes 25 patients with diazoxide unresponsive
CHI and 22 patients with diazoxide responsive CHI. A single mutation in the ABCC8 was
also identified in 2 patients where the diazoxide responsiveness is not known as they had
transient CHI that resolved without trial of diazoxide therapy. This includes patient 172 who
is heterozygous for a novel dominantly inherited mutation (G1479A) that arose de novo,
and patient 281 who is heterozygous for the R1539Q mutation known to cause mild,
dominantly inherited CHI (Pinney et al., 2008). The clinical phenotype of these and other
patients with mild, dominantly inherited CHI is detailed in chapter 9.
Diazoxide unresponsive CHI with a single mutation in ABCC8:
Of the 25 patients with diazoxide unresponsive CHI and a single mutation in the ABCC8
gene, 19 patients had a paternal mutation, 3 had a de novo mutation, 1 had a maternally
inherited mutation and in 2 patients (with histologically confirmed focal disease), the
inheritance was not established due to unavailability of the paternal DNA.
Of the 19 patients with a paternal mutation, 12 patients had confirmed focal disease
(confirmed histologically or via an 18-F-DOPA PET scan) that was managed by resection
of the focal lesion/ limited pancreatectomy. However, six patients had diffuse disease with
a mutation inherited from an unaffected father. Two of these (patient 97 and 270) are
heterozygous for the same novel mutation (A1263T). One other patient with a paternally
inherited mutation was treated conservatively with octreotide and it was not determined
whether they had a focal lesion or not.
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Four patients with three novel dominant mutations (D1506E (c.4518C>A), G1485E
(c.4454G>A) and M1544K (c.4541T>A)) were identified to cause severe diazoxide
unresponsive diffuse disease requiring a near total pancreatectomy. The D1506E mutation
was identified in two patients from different families. Testing of the parents demonstrated
that the mutation had arisen de novo in one (patient 57) and from an affected mother in the
other patient (patient 295). The mother of patient 295 had diazoxide unresponsive CHI for
which she underwent a sub-total pancreatectomy at 5 weeks of age. Post operatively she
continued to have HH that was managed on a combination of subcutaneous octreotide
injections and frequent high calorie carbohydrate feeds until she outgrew the HH at 11
years of age. Testing of the maternal grandparents confirmed that the mutation had arisen
de novo in the mother. The G1485E and M1544K mutations were each identified in one
patient (patients 9 and 300). Testing of their unaffected parents demonstrated that the
mutations had arisen de novo.
Diazoxide responsive CHI with a single mutation in ABCC8:
There were 22 patients who had diazoxide responsive CHI associated with a single
mutation in the ABCC8 gene. The patients in this category have varying durations of HH,
ranging from transient disease of 4 weeks duration (patient 185) to persistent disease
continuing diazoxide therapy at 10.7 years of age (pt 194). Similar to the other groups of
patients with an ABCC8 mutation, the mean age of presentation in this group was early at
35.5 days of age (median of 1 day) and the mean birth weight SDS was 1.27 SDS.
This category includes 11 patients (four related and seven unrelated) with seven different
dominantly inherited mutations occurring in NBD2 area of the SUR1 protein. Five of these
mutations are novel. The clinical phenotype of these patients and the functional
characterisation of the mutations are detailed in chapter 9. Apart from the patients with
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dominantly inherited mutations, there are 11 patients where a single mutation was
inherited from an unaffected parent, seven (A309G, A355T, V601I, A726T, E1443D,
A1303V, A1185E) of which are novel.
CHI due to a single mutation in ABCC8, where diazoxide responsiveness was not known:
Two patients (patients 281 and 172) with mutations G1479A and R1539Q in ABCC8 had
mild CHI limited to the neonatal period that did not require treatment with diazoxide. The
R1539Q mutation is known to be a dominant mutation (Pinney et al., 2008) while the
G1479A mutation is a novel dominant mutation. The genotype and phenotype of the
patients with mild CHI due to dominantly inherited mutations in the KATP channel genes are
described in detail in chapter 9.
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Table 5.4: Summary of the patients heterozygous for a mutation in ABCC8: Twenty-three novel mutations were identified. A paternal
mutation was associated with both focal and diffuse disease. Dominantly inherited mutations were identified to be associared with
both diazoxide responsive and unresponsive disease.
ID Mutation Exon/intron Novel Ethnicity Inheritance Age of
Presentation
(days)
Birth
weight
SDS
Management Histology/
PET
Diazoxide unresponsive CHI due to heterozygous mutations in ABCC8
378 L1171fs Frameshift in
exon 28
Yes White Irish Paternal 1 +3.16 Resection of focal lesion Focal- Giant
lesion
236 M1V Missense in
exon1
No White
British
Not
determined
1 +2.4 Subtotal pancreatectomy Focal
203 c.580-1G>C Splicing in intron
4
Yes White
British
Not
determined
2 -1.13 Subtotal pancreatectomy Focal
356 A1493T Missense in
exon 37
No White Irish Paternal 1 +2.15 Resection of the focal lesion Focal- Giant
260 E128K Missense in
exon3
No White
British
Paternal 14 +1.27 Subtotal pancreatectomy Focal
304 c.2669_2675d
elAGCTACA
Frameshift
deletion
Yes White
British
Paternal 1 +2.5 Resection of focal lesion Focal
197 R934X Nonsense in
exon 23
No White Irish Paternal 2 +2.6 Resection of focal lesion Focal
235 S12X Nonsense in
exon 1
Yes White
British
Paternal Not known -0.87 Resection of focal lesion Focal
136 R1494W Missense exon
37
No White
British
Paternal 1 +0.45 Subtotal pancreatectomy Focal
230 R74W Missense in
exon 2
No Other
White
Paternal 1 +0.48 Resection of focal lesion Focal
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110 Q1373X Nonsense in
exon 33
Yes Other
Asian
Paternal 70 +1.54 Subtotal pancreatectomy Focal
86 c.1629-2A>C Intron 10 Yes White
British
Paternal 1 +1.73 Resection of focal lesion Focal
182 G111R Missense in
exon 3
No Asian
Indian
Paternal 3 -1.98 Resection of focal lesion Focal
129 H627fs Frameshift in
exon 13
No White Irish Paternal 1 +0.78 Resection of focal lesion Focal
211 H627fs Frameshift in
exon 13
No White
British
Paternal 90 +0.07 Octreotide for 18 months,
dietary mgmt till 7 yrs
Not known
132 G92D Missense in
exon 2
No Other
Asian
Paternal 1 +1.6 Subtotal pancreatectomy Diffuse
97 A1263T Missense in
exon 31
Yes White
British
Paternal 1 +3.06 Subtotal pancreatectomy Diffuse
270 A1263T Missense in
exon 32
Yes White
British
Paternal 900 -1.82 Near total pancreatectomy Diffuse
87 IVS32-9G>A Splicing intron
32
No White
British
Paternal 1 +0.23 Octreotide Diffuse (PET
scan)
98 A113V Missense in
exon 3
No White
British
Paternal 1 Not known Near total pancreatectomy
x2
Diffuse
279 IVS38-2A>G Splicing in intron
38
No Other
White
Paternal 84 -1.59 Subtotal pancreatectomy Diffuse
Diazoxide unresponsive CHI due to a dominant mutation in ABCC8
300 M1514K Missense in
exon 37
Yes White
British
De novo 1 +1.01 Near total pancreatectomy Diffuse
295 D1506E Missense in
exon 37
Yes White Irish Maternal 1 +2.54 Subtotal pancreatectomy Diffuse
57 D1506E Missense in
exon 37
Yes White
British
De novo 1 +2.61 Near total pancreatectomy
x2
Diffuse
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9 G1485E Missense in
exon 37
Yes White De novo 1 +1.94 Subtotal pancreatectomy Diffuse
Transient CHI due to heterozygous ABCC8 mutation (diazoxide responsiveness not known)
281 R1539Q Missense in
exon 39
No White Irish Maternal 1 +0.07 Nil- Transient n/a
172 G1479A Missense in
exon 37
Yes White
British
De novo 3 +1.02 Nil- transient n/a
Diazoxide responsive CHI due to heterozygous mutations in ABCC8
15 L1390R Missense in
exon 34
Yes White
British
De novo 1 +3.22 Continuing diazoxide at 11
yrs of age
n/a
146 A1508P Missense in
exon 37
Yes White
British
Paternal 1 +4.09 Continuing diazoxide at 9.2
yrs of age
n/a
194 G1479R Missense in
exon 37
No White
British
Maternal 1 +1.37 Continuing diazoxide at 10.1
yrs of age
n/a
383 G1479R Missense in
exon 37
No White Irish Paternal 2 +1.65 Continuing diazoxide at 8.5
yrs of age
n/a
382 G1479R Missense in
exon 37
No White Irish Paternal 2 +2.23 Continuing diazoxide at 5.1
yrs of age
n/a
70 Q1459E Missense exon
36
Yes White
British
Maternal 1 +3.14 Continuing diazoxide at 5.9
yrs of age
n/a
50 R1539Q Missense in
exon 39
No White Irish Maternal 1 +2.19 Continuing diazoxide at 3.3
yrs of age
n/a
8 A1537V Missense in
exon 38
Yes White
British
Maternal 1 +4.66 Continuing diazoxide at 3.1
yrs of age
n/a
310 L1431F Missense in
exon 35
Yes Black
African
Paternal 365 -0.98 Continuing diazoxide at 2.5
yrs of age
n/a
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313 G1479R Missense in
exon 37
No White Irish Maternal 1 +2.82 Continuing diazoxide at 1.4
yrs of age
n/a
306 G1479R Missense in
exon 37
No White Irish Paternal 2 +1.93 Continuing diazoxide at 1.5
yrs of age
n/a
271 A355T Missense in
exon 7
Yes Not known Maternal 90 +0.88 Continuing diazoxide at 5.9
yrs of age
n/a
2 A309G Missense in
exon 6
Yes White
British
Maternal 1 -0.0 Continuing Diazoxide at 2.1
yrs of age
n/a
128 D1472N Missense in
exon 36
No Asian
Indian
Paternal 3 -1.91 Diazoxide for 1 year n/a
329 IVS32-9G>A Splicing in intron
32
No Not known Paternal 28 +0.11 Diazoxide stopped due to
severe hypertrichosis.
Continuing octreotide at 1 yr
n/a
344 V601I Missense in
exon 12
Yes White
British
Paternal 3 +1.19 Diazoxide for 9 months n/a
156 E1443D Missense in
exon 36
Yes Mixed-
White and
Black
African
Maternal 14 -1.41 Diazoxide for 9 months n/a
368 A1185E Missense in
exon 28
Yes White Irish Paternal 1 Not known Diazoxide for 8 months n/a
10 IVS32-9G>A Splicing in intron
32
No Other
White
Paternal 1 +3.43 Diazoxide for 5 months n/a
224 A726T Missense in
exon 16
Yes Other
White
Not
determined
1 +0.79 Diazoxide for 3 months n/a
186 A1303V Missense in
exon 32
Yes White
British
Not
determined
1 Not known Diazoxide for 4 weeks n/a
185 C418R Missense in
exon 8
No Other
White
Not known 1 +2.27 Diazoxide for 4 weeks n/a
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5.3.3 Ethnicity
The ethnic backgrounds of the 119 patients are summarized below. The five major groups
include White British (n= 42), Other Asian (n=21), White Irish (n= 14), Asian Pakistani (n=
12), and Asian Indian (n=10). The missense mutation G111R was found in 6/10 unrelated
patients from the Asian Indian background. This mutation was not found in patients in any
other ethnic group. Apart from this mutation, no other mutation was strikingly associated
with a particular ethnic background.
Ethnic background Number of patients
White British 42
White Irish 14
Other White 9
Asian Indian 10
Asian Pakistani 12
Asian Bangladeshi 2
Other Asian 21
Chinese 2
Black African 4
Mixed White and Black African 1
Not known 2
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5.4 Discussion
This is the largest cohort of patients with CHI due to mutations in the ABCC8 and KCNJ11
genes encoding the two subunits of the pancreatic ß-cell adenosine triphosphate (ATP)-
sensitive potassium (KATP) channel. The study confirms that recessive mutations in these
two genes are the most common cause of CHI (Thomas et al., 1995; Thomas et al., 1996).
It also confirms that these recessive mutations cause severe CHI that is unresponsive to
medical therapy with diazoxide and requires a near total pancreatectomy in the vast
majority of patients. Histologically, the recessive mutations in this study, as reported in the
literature, were associated with diffuse CHI. The study also confirms that dominant KATP
channel mutations are a cause of mild, diazoxide responsive CHI (detailed in chapter 9). In
addition, this study extends the clinical phenotype associated with recessive KATP channel
mutations to include transient CHI; and that of dominant KATP channel mutations to severe
CHI requiring near total pancreatectomy. These two novel phenotypic features associated
with KATP channel mutations are discussed in detail below.
Recessive mutations in the KATP channel genes have not been reported to cause transient
CHI. In this study, a neonate with transient CHI was identified to be compound
heterozygous for the R168C and S606T mutations in the ABCC8 gene. This patient (pt 88)
presented with severe HH at two hours of age and failed to respond to maximum doses of
diazoxide. However, he unexpectedly had complete resolution of his HH at eight weeks of
age. This is the first case of transient HH due to a compound heterozygous mutation in
ABCC8 (now published Kumaran et al., 2010).
Compound heterozygous mutations in ABCC8 and KCNJ11 account for approximately
13% of CHI mutations and are usually associated with medically unresponsive CHI (Suchi
et al., 2003). To date, there is one report of a patient with a compound heterozygous
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ABCC8 mutation who was responsive to diazoxide (Dekel et al., 2002). Dekel et al
described a patient with compound heterozygosity for two common mutations previously
associated with CHI in Ashkenazi Jews, the splicing mutation of intron 32(IVS32-9G>A)
and the deletion of phenylalanine at codon 1388 (F1388del) of the ABCC8 gene. The
patient had a relatively low glucose utilisation (<10mg/kg/min) and interestingly responded
to diazoxide. The authors postulate that the splicing mutation of intron 32 was responsible
for the diazoxide responsiveness as patients homozygous for F1388del have been
reported to have severe diazoxide resistant disease (Nestorowicz et al., 1996).
Greer et al (2007) have reported a patient who was compound heterozygote for the
R168C/R1421C mutations in the ABCC8 gene and had severe, medically unresponsive
CHI. No functional characterisation of the R168C mutation has yet been undertaken. Along
with the R168C mutation, our patient has a novel mutation S606T. The S606T mutation
results in a substitution of a G>C at the last base of exon 12 and is predicted to cause
aberrant splicing. Compound heterozygote mutations in CHI result in complex interactions
(Muzumbya et al., 2007) and it is possible that the combination of mutations and their
interactions may modify the potential disease pathogenesis and this requires further
evaluation using functional analysis.
Muzyamba et al (2007) studied a patient with diffuse disease who had inherited the
mutations D1193V and R1436Q in the ABCC8 gene. Channel complexes containing the
D1193V mutant were delivered to the plasma membrane and were functional and those
containing R1436Q were also present at the plasma membrane but were nonfunctional.
Combining the two mutations (SUR1D1193V/R1436Q) led to intracellular retention of the
channel complex. This suggests that mutations may interact to modify KATP channel
function and influence disease severity. Although the precise molecular mechanism/s
leading to transient CHI in this patient is/are not known it is possible that the interaction of
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the two mutations (R168C/S606T) may lead to transient impairment of KATP channel
function. In vitro studies will be needed to assess the functionality of the mutated protein
and the interactions of these two mutations.
This case illustrates that some patients with compound heterozygous mutations may have
resolution of CHI even as early as eight weeks. It also highlights the importance of
delaying pancreatic surgery (while maintaining normoglycaemia) even in genetically
confirmed diffuse disease unresponsive to diazoxide therapy, as the natural course of
many of the novel mutations is unknown.
This study also identifies three novel heterozygous ABCC8 missense mutations (G1485E,
D1506E and M1514K) in 4 patients from 3 families causing diazoxide unresponsive
disease. The mutations had arisen de novo in all four pedigrees. A second mutation was
not found in any of the 4 patients by sequence analysis. Histological examination of the
pancreatic samples was consistent with diffuse disease. In conclusion, G1485E, D1506E
and M1514K mutations are dominantly acting ABCC8 mutations associated with diffuse
disease with a 50% risk of HH in future offspring. This clinical presentation is very different
to that described in previous reports of dominant ABCC8 missense mutations which were
associated with a milder phenotype (Huopio et al., 2007, Pinney et al., 2008). These
mutations identified are novel, suggesting a genotype/phenotype correlation where
different missense mutations may result in a variable severity of CHI. This hypothesis is
supported by the identification of the same mutation, D1506E, in two individuals from
different families with diazoxide-unresponsive CHI.
Pancreatic ß-cell KATP channels are regulated by intracellular nucleotides (ATP and ADP).
SUR1 has two cytoplasmic nucleotide binding domains (NBD1 and NBD2) that sense
changes in intracellular [ATP]/[ADP] and transmit the signal to the pore. NBD1 appears to
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be the principal site for ATP binding, whereas NBD2 binds MgADP (Conti et al., 2001).
These binding domains cooperate with each other in mediating the nucleotide regulation of
the pore function (Ueda et al., 1999). MgADP and diazoxide activate KATP channels in the
presence of inhibitory concentrations of ATP, and both processes require Mg2+ (Shyng et
al., 1997; Dunne and Peterson 1986; Nichols et al., 1996). Mutations in NBD2 can abolish
channel activation by diazoxide or MgADP (Shyng et al., 1997). This loss of metabolic
inhibition by MgADP on KATP channel activity has been reported for patients with CHI due
to recessive ABCC8 mutations and seems to be a common molecular mechanism of CHI
(Nichols et al., 1996, Shyng et al., 1998).
Nine of the 11 previously reported dominant ABCC8 mutations affect residues within the
NBD2 region and functional studies have demonstrated that these mutations significantly
diminish or completely abolish the channels’ response to MgADP and diazoxide (Huopio,
et al., 2000; Pinney et al., 2008). Further studies on 10 of the ABCC8 mutations, under
simulated heterozygous conditions, indicated that while the mutant subunits do reduce
channel function, the wild type ABCC8 allele is sufficient to confer partial channel
response to changes in the ATP/ADP ratio expected during glucose metabolism and to
diazoxide (Pinney et al., 2008).
In this study, thirteen patients (from nine families) were identified to be heterozygous for
eight different dominantly inherited mutations occurring in NBD2 area of the SUR1 protein.
Six of these ABCC8 mutations (L1451F, L1390R, Q1459E, A1537V, A1508P and
Q1479A) are novel. The phenotype associated with these dominantly inherited mutations
(discussed in detail in chapter 9) confirms the reported phenotype associated with
dominant mutations in the NBD2 area (Pinney et al., 2008; Huopio et al., 2000), ranging
from asymptomatic macrosomia to persistent diazoxide responsive CHI. However, the
three mutations (G1485E, D1506E and M1514K) identified with diazoxide unresponsive
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CHI are also located in the NBD2 region of SUR1 and it is likely that they also abolish the
stimulatory effects of MgADP/ATP. However, the reasons underlying the lack of response
to diazoxide in the 4 patients with the G1485E, D1506E and M1514K mutations is not
known.
These findings suggest that the clinical presentation of patients with dominant inactivating
ABCC8 missense mutations is variable, ranging from mild medically responsive to severe
early onset CHI requiring a near total pancreatectomy. The clinical presentation of patients
at the time of diagnosis cannot distinguish between recessive and dominantly acting
ABCC8 mutations. A genetic diagnosis is important since finding a de novo dominant
mutation in a sporadic case with diazoxide unresponsive CHI confers a lower recurrence
risk for future siblings compared to a recessive mutation, but a higher risk of CHI (50%) for
the next generation.
In addition, this study demonstrates that a paternal mutation in the ABCC8/ KCNJ11 in
association with diazoxide unresponsive disease is not synonymous with a focal lesion. Of
the 23 patients with diazoxide unresponsive disease and an identifiable paternal mutation
(4- KCNJ11 and 19- ABCC8), 15 had confirmed focal disease, 7 had diffuse disease
(confirmed by an 18F-DOPA-PET scan or on histological analysis) and the histological
diagnosis was not confirmed in one. The mechanism of diffuse disease in these patients
is not understood. It is possible that the sequencing technique was unable to pick a
second ABCC8 mutation. It is also possible that there is a second hit within the pancreas
for e.g. loss of a part of the maternal 11p15 affecting the entire pancreas (leading to a
large focal lesion affecting the entire pancreas) or a second pancreatic specific mutation.
Genetic analysis of the pancreatic samples is warranted to test this hypothesis.
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Thirteen patients with diazoxide responsive CHI were heterozygous for a single mutation
in the ABCC8/ KCNJ11 gene. Four of these mutations are known to act recessively and it
is possible that the second mutation has not been identified by the sequencing technique.
However, the phenotype of these patients does not fit in with recessively inherited CHI that
is generally diazoxide unresponsive (as is also seen in this series). The remaining nine
mutations are novel. These have been classified as disease causing mutations as they
have not been found in control chromosomes and occur in residues that are conserved
across species. These mutations have not been classified as dominant mutations as they
are inherited from a parent unaffected by hypoglycaemia or diabetes or the parental origin
has not been determined. However, it is possible that they act dominantly (with variable
penetrance) as many of the adult mutation carriers in the only series of dominantly acting
mutations (Pinney et al., 2008) were asymptomatic. The identification of these mutations in
other pedigrees displaying recessive/ dominant patterns of inheritance would help in
establishing the inheritance of these mutations.
Finally, this series identified a missense mutation G111R in 6/10 unrelated families of
Indian background. Three of these patients were homozygous for the mutation; two were
compound heterozygous for the mutation and one patient with focal disease was
heterozygous for the mutation. All of these patients had severe, diazoxide unresponsive
disease. Two ABCC8 mutations, splicing mutation IVS32-9G>A in intron 32 and the
delF1388 mutation have been identified to be associated with CHI in the Ashkenazi Jewish
population (Nestorowicz et al., 1996) and the V187D mutation has been associated with
the Finnish population (Otonkoski et al., 1999). No mutation has yet been reported to be
associated with CHI in the Indian population. The recognition of the G111R mutation
exclusively in 6/10 patients from an Indian ethnic background suggests a founder effect.
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5.5 Conclusions
This is the largest study of patients with CHI due to mutations in the KATP channel genes.
This study confirms that the commonest known cause of CHI is mutations in the KATP
channel genes, of which the majority were inherited in a recessive manner. It also confirms
that recessively inherited mutations in the KATP channel genes are associated with
diazoxide unresponsive disease while the dominantly inherited mutations in these genes
are generally associated with mild, diazoxide responsive disease. In addition, the study
identified several novel mutations in the ABCC8 and KCNJ11 genes. Of the novel
mutations, the highlights of the study were the identification of dominant mutations in
ABCC8 as a cause of diazoxide unresponsive disease and the identification of a
compound heterozygous mutation in ABCC8 in association with severe CHI that was
transient in nature. The identification of these mutations would be important in future
patients in predicting the clinical course and in estimating the risk of CHI in their future
siblings and offspring. Finally, the study identified, for the first time, a known mutation
G111R to be a common mutation in the Indian population with CHI.
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Chapter 6
Congenital Hyperinsulinism due to mutations in the GLUD1 Gene
6.1 Background
The hyperinsulinism/hyperammonemia (HI/HA) syndrome is a form of CHI in which
affected children have recurrent symptomatic HH together with a persistently elevated
plasma ammonia concentration. It has been shown that this disorder is caused by
dominant mutations of the GLUD1 gene that encodes for the mitochondrial enzyme,
glutamate dehydrogenase (GDH) (Stanley et al., 1998). GDH is highly expressed in the
liver, pancreatic ß-cells, kidney and the brain (Hudson and Daniel, 1993). It catalyzes the
oxidative deamination of glutamate to α-ketoglutarate and ammonia. In the pancreatic ß-
cells, α-ketoglutarate enters the tricarboxylic acid cycle and leads to an increase in the 
concentration of cellular ATP. This rise in the cellular ATP causes closure of the ATP
sensitive potassium channel (KATP channel); resulting in cell membrane depolarisation,
Ca2+ influx via voltage gated calcium channels and insulin exocytosis.
GDH is allosterically regulated by a wide array of inhibitors (e.g. GTP) and activators (e.g.
leucine) (Fahein et al., 1980). Activating mutations in the GLUD1 gene reduce the
sensitivity of the enzyme to allosteric inhibition by GTP and ATP (Stanley et al., 2000) or
less frequently cause an increase in the basal GDH activity (Yorifugi et al., 1999). The loss
of inhibition by GTP leads to increased leucine induced glutamate oxidation to α-
ketoglutarate. Hence leucine sensitivity is manifested by postprandial HH (following
protein-rich meals) which is a classical feature of this condition (Hsu et al., 2001). The
mechanism of persistent hyperammonaemia, a striking and consistent feature of this
condition, is not completely understood.
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This chapter discusses the phenotype and genotype of twenty patients with HI/HA
syndrome. A patient with a normal serum ammonia concentration is described who has
severe leucine sensitivity with a novel GLUD1 mutation. The chapter also highlights the
high risk of epilepsy in patients with GLUD1 mutations.
6.2 Research design and methods
6.2.1 Patients
All the recruited patients with a raised serum ammonia concentration (n=19) had
mutational analysis of the GLUD1 gene. The exons of the GLUD1 gene which encode the
catalytic and allosteric domains of glutamate dehydrogense (exons 6, 7, 10, 11 and 12)
were amplified by PCR (for primer sequences see appendix 12.4 A) and sequenced using
Big Dye terminator v3.1 (Applied Biosystems, Warrington, UK). Sequencing reactions were
analysed on the ABI 3730 (Applied Biosystems, Warrington, UK) and compared to the
published sequence (M37154).
In one patient, GLUD1 analysis was requested in view of leucine sensitivity. This patient
(patient 12) presented at one year of age with a tonic–clonic seizure associated with HH
(serum insulin concentration of 9.6mU/L with a concomitant blood glucose concentration of
1.7mmol/L). She had a normal serum ammonia concentration (21µmol/L) on presentation
and on repeated measurements (30µmol/L and 41µmol/L) during childhood. She
responded to diazoxide and demonstrated a normal fasting tolerance on a moderate dose
of diazoxide (12-15mg/kg/day). However she continued to experience intermittent
hypoglycaemic episodes in the post-prandial period even on a high dose of diazoxide (15-
17mg/kg/day). Leucine sensitivity was hence evaluated at 13 years of age by an oral
leucine tolerance test.
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Oral leucine tolerance test: Following a fast of four hours, an oral dose of 0.15gm/kg of L-
Leucine was administered. Blood glucose and plasma insulin concentrations were then
measured at -30, 0, 30, 60, 90 and 120 minutes. Diazoxide was not discontinued for the
purpose of the test. The test was stopped at 60 minutes following the oral leucine load as
she developed symptomatic hypoglycaemia (sweating, disordered consciousness and
blurred vision) with a blood glucose concentration of 2.2mmol/L and simultaneous serum
insulin concentration of 69.5mU/L (table 6.1). Sequencing of the GLUD1 gene was
requested in view of the severe leucine sensitivity, a feature of HI-HA syndrome.
Table 6.1: Oral Leucine Tolerance Test in patient 12 demonstrating leucine induced
hyperinsulinaemic hypoglycaemia:
Time (minutes) Glucose (mmol/L) Insulin (mU/L)
-30 4.5 4.1
0 4.0 8.5
+60 2.2 69.5
Hence, a total of 20 patients had mutational analysis of the GLUD1 gene. Sixteen patients
were unrelated and four were related demonstrating vertical transmission of disease
consistent with a dominant pattern of inheritance. Along with the standard clinical
information (birth weight, age of presentation, treatment details, family history of
hypoglycaemia / diabetes) as outlined in chapter 3, information regarding seizure history/
epilepsy was also collated. Birth weight SDS was calculated for each patient. The clinical
characteristics are presented as mean. Comparison of the phenotypic characteristics (birth
weight, age of presentation) with patients with diazoxide responsive/ transient CHI and a
KATP mutation (n= 27), HNF4A mutation (n= 8) and a HADH mutation (n=3) was done
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using the one-way analysis of variance (ANOVA) followed by LSD post-test to test for
statistical significance. The comparative statistics are presented in chapter 8. Birth weights
of the three patients with the S445L mutation in GLUD1 was compared with the birth
weights of the rest of the cohort with a GLUD1 mutation using ANOVA followed by LSD
post-test.
6.2.2 Functional analysis of GDH activity (Performed by Dr Chadefaux at Necker
Hospital, Paris)
In order to confirm the pathogenecity of a novel mutation, P436L, GDH activity was
analysed (in collaboration with colleagues at the Necker Hospital, Paris) in lymphoblast
homogenates according to the method of Wrzeszczynski & Colman (Wrzeszczynski &
Colman, 1994). Lymphocytes were isolated from peripheral blood of the patient with the
novel P436L mutation and transformed with Epstein-Barr virus to establish lymphoblast
cultures. Lymphoblasts were harvested and washed with PBS. Cells were resuspended in
homogenising buffer (10mM Tris pH 7.4 + 0.1% Triton – X100) then homogenised using a
mechanical homogeniser for 3 x 30sec before being centrifuged at 18000g for 10 minutes.
The supernatant was retained to be used in the assay. An aliquot of lymphoblast
supernatant was added to the following reaction mixture made up in 10mM Tris buffer pH
8.0 to a reaction volume of 980µl (final concentrations: NH4Cl 35mM, NADH 90µM,
rotenone 2.5µM and EDTA 1mM.)
Assays were carried out at 30˚C in 1ml cuvettes .Absorbance was recorded at 340nM to 
establish a baseline. Another absorbance measurement was taken at 5 minutes. Then
8mM α-ketoglutarate was added and absorbance was recorded after a further 5 minutes. 
Blank cuvettes contained all the reaction mixture apart from α-ketoglutarate. Change in 
absorbance was recorded at all time points and the extinction coefficient for NADH
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(6.22x103M-1cm-1) was used to calculate a rate (de Lonlay et al., 2001). Enzyme activity
was expressed as nmol/min/mg protein. Protein was measured according to the method of
Lowry et al (Lowry et al., 1951).
To measure sensitivity of GDH to inhibition by GTP, a dose curve was set up using
concentrations of GTP from 50nM-1000nM and absorbance was measured. Absorbances
after addition of GTP were expressed as a percentage of basal absorbances and plotted
on a dose curve to establish the half-maximal inhibitory concentration (IC50).
6.3 Results
6.3.1 Molecular Genetics
16/20 patients were identified to be heterozygous for a mutation in the GLUD1 gene. Eight
different heterozygous mutations were identified in 13/17 probands (76%) screened. Three
mutations; N410D (c.1400A>G), D451V (c.1524A>T) and P436L (c.1479C>T) were novel.
These mutations were not present in the probands’ unaffected parents and affected
residues were conserved across species. Mutations at residue N410 have previously been
reported in patients with HI/HA, including 1 patient within this cohort, suggesting that N410
is a functionally important residue. The location of the novel mutations in context of
previously described mutations is demonstrated in figure 6.1.
Two mutations, S445L and R269H, were each identified in three unrelated families. All
other mutations were identified in a single proband. Testing of unaffected parents
demonstrated that the mutation had arisen de novo in 11/13 probands. For one patient,
with a S445L mutation, a spontaneous mutation could not be confirmed as DNA was
unavailable from the unaffected father. In a second patient, the R269H mutation was
inherited by the proband from their affected mother. Testing of further family members
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demonstrated that the R269H mutation was also present in the proband’s maternal uncle
and grandmother, all of whom have HI/HA.
Four patients referred with HI/HA were negative for a GLUD1 mutation. The mean serum
ammonium concentration of this group of patients was 66.7μmol/l (50-87μmol/l). All four 
patients had diazoxide responsive hyperinsulinism with no clinical symptoms suggestive of
protein/leucine sensitivity.
Figure 6.1: Cartoon showing location of mutations along a representation of the GLUD1
gene, the different colours signify the subunits of the protein (the purple region interacts
with NADP, the blue with GTP and ATP, the yellow structure is the pivot helix and the
green antenna region interacts with other proteins). The novel mutations identified in this
study are underlined and in bold.
1 2 3 3 5 6 7 8
S217C
R221C
F440L
Q441R
S445L
G446D
G446S
G446R
G446C
A447T
S448P
K450E
D451V
H262Y
R265K
R265T
Y266H
Y266C
R269H
R269C
E296AN410T
N410D
L413V2
9 10 11 12 13
G446VP436L H454T
113
6.3.2 Clinical characteristics of patients with GLUD1 mutation:
The clinical characteristics of the sixteen patients with a GLUD1 mutation is summarised in
table 6.2. The mean birth weight SDS of our cohort with a mutation was -0.11. Macrosomia
was not a common feature; with birth weight >90th centile in only three patients. All of
these three patients had the S445L mutation. The difference in the birth weights of these
three patients and the rest of the cohort with a GLUD1 mutation was statistically significant
(P=0.027).
The age of presentation was delayed (mean of 22.4 weeks), in comparison with the
patients with diazoxide responsive CHI due to KATP channel mutations (mean of 27 days,
P<0.005) and those due to HNF4A mutations (mean of 1 day, p=0.001), with only three
presenting in the neonatal period. Two patients were successfully managed with
manipulation of diet alone (low protein diet); all others required treatment with diazoxide.
Interestingly, two members of family M due to mutation R269H were successfully treated
with dietary management alone whilst two have required diazoxide therapy (figure 6.2),
suggesting a degree of clinical heterogeneity within the same family. None of our patients
required a pancreatectomy.
There was a high incidence of generalised seizures in the patients with a GLUD1 mutation.
15/16 patients presented with seizures and seven (43%) of them have developed epilepsy.
All of the patients who developed epilepsy had generalised seizures. 3/7 patients with
epilepsy had mutations in exons 6 and 7. The other four patients had mutation in exons 10
and 11, of which three had the mutation S445L in exon 11.
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Table 6.2: Clinical characteristics of the patients with a GLUD1 mutation (Kapoor et al., 2009b): The mean birth weight SDS
was -0.11 and the mean age of presentation was 22.4 weeks. None of the patients with a GLUD1 mutation required a
pancreatectomy.
Family No Sex Age Of
presentation
Current
age
Birth weight
SDS
Epilepsy Ammonia
(umol/L)
(<50umol/L)
Management Mutation Novel
A 1 F 52 weeks 13.8 yrs -0.58 No 21 Diazoxide
+protein
restriction
P436L
(c.1479C>T)
Yes
B 2 F 1 week 10 yrs +0.47 Yes 120 Diazoxide N410D
(c.1400A>G)
Yes
C 3 F 0.28 weeks
(2 days)
7 yrs +0.57 Yes 58-95 Diazoxide R221C
(c.833C>T)
No
D 4 F 6 weeks 18 yrs +1.2 Yes 244 Diazoxide S445L
(c.1506C>T)
No
E 5 F 1 week 1.6 yrs +1.73 Yes 125-161 Diazoxide S445L
(c.1506C>T)
No
F 6 F 32 weeks 2.5 yrs +0.29 Yes 128 Diazoxide R269H
(c.978G>A)
No
G 7 F 28 weeks 2.6 yrs -1.2 No 73-144 Diazoxide D451V
(c.1524A>T)
Yes
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H 8 M 24 weeks 1.6 yrs -1.3 Yes 258-307 Diazoxide R265K
(c.966G>A)
No
I 9 M 8 weeks 4.8 yrs +1.63 Yes 150-190 Diazoxide S445L
(c.1506C>T)
No
J 10 M 16 weeks 0.9 yrs -1.34 No 250 Diazoxide N410T
(c.1401A>C)
No
K 11 M 28 weeks 1.4 yrs -0.41 No 165 Diazoxide R269H
(c.978G>A)
No
L 12 M 72 weeks 5.9 yrs Not known No 60-100 Diazoxide R296H
(c.978G>A)
No
M 13 F 24 weeks 2.5 yrs -2.37 No 96 Diazoxide R269H
(c.978G>A)
No
M 14 F 52 weeks 35 yrs Not known No 78 Protein
restricted diet
R269H
(c.978G>A)
No
M 15 F Not known 56 yrs Not known No Not known Protein
restricted diet
R269H
(c.978G>A)
No
M 16 M 52 weeks 26 yrs -2.05 No 103 Diazoxide R269H
(c.978G>A)
No
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Figure 6.2: Family tree of patients 13-16 with the R269H mutation. Circles represent
females and squares represent males. Individuals with HI/HA and the R269H mutation in
GLUD1 are represented by filled symbols. Two members with HI/HA due to this mutation
were successfully treated with dietary management alone whilst two have required
diazoxide therapy.
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6.3.3 GDH activity in lymphoblasts:
The activity and allosteric response of GDH in lymphoblasts from patient 12 (with the
P436L mutation in GLUD1) is shown in table 6.3. She had normal basal GDH activities.
However, the half-maximal inhibitory concentration of GTP expressed in nmol/L (IC50)
was 470% higher than that of controls (n=20) i.e. a higher concentration of GTP
(625nmol/l) was required to inhibit 50% of the P436LGDH in comparison with the control
GDH (mean of 133nmol/l). This is consistent with a loss of GTP inhibition, a mechanism
known to cause HI/HA.
Table 6.3: Activity and allosteric responsiveness of GDH in lymphoblasts from patient 12
and normal subjects (n=20) (Kapoor et al., 2009b): The GTP concentration required to
inhibit GDH activity in patient lymphoblast was 470% higher than that of controls.
Patient 12 Normal subjects
Basal GDH activity
(nmol/min/mg protein)
Measured in the absence of effectors
11.2 13.2±3.2
(mean±SD)
IC50 GTP concentration
(nmol/L)
625 133±77
(mean±SD)
or <275
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6.4 Discussion
The phenotype of CHI due to mutations in the GLUD1 gene is well characterised. It is
reported to be milder, not usually associated with macrosomia at birth and tends to escape
recognition till later in infancy (Stanley et al., 2000; Hsu et al., 2001; de Lonlay et al.,
2002). This was confirmed in this study where the mean age of presentation was 22.4
weeks with only 3/17 patients presenting in the neonatal period. Interestingly, only three
patients had a birth weight of >90th centile and all three had the S445L mutation (P=0.027).
This may indicate that this mutation causes more severe fetal hyperinsulinism than the
other mutations identified in our cohort. This mutation, along with the R269H mutation, was
also the most prevalent mutation in our cohort. Three patients each were heterozygous for
these two mutations (S445L and R269H) accounting for 46% of our patients with CHI due
to mutations in the GLUD1 gene.
Missense mutations causing HI/HA were first described to occur in exons 11 and 12 that
form the hinge and antenna regions of GDH and lies close to the binding site for GTP
(Stanley et al., 1998 and Stanley et al., 2000). Mutations were then described in exons 6
and 7 that lie in the GTP binding region (Miki et al., 2000; Santer et al., 2001). Finally,
mutations in exon 10 were described located in the α-helix of the antenna like structure of 
the GDH (Fujioka et al., 2001; Yorifuji et al., 1999). Of the 13 probands with a GLUD1
mutation, 6 had mutations in the GTP binding domain (exons 6 and 7), 2 had mutations in
exon 10 while 5 had a mutation in exons 11/ 12.
Epilepsy has been frequently reported in association with HI/HA syndrome (Raizen et al.,
2005; Bahi-Buisson et al., 2008a). The increased frequency of epilepsy is thought to be
either the result of a) hypoglycaemic brain injury due to recurrent hypoglycaemia or b)
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chronic hyperammonaemia or c) decreased concentrations of glutamine and the
neurotransmitter GABA (gamma-aminobutyric acid) in the brain due to raised GDH activity
(Bahi-Buisson et al., 2008a). This study confirms that a high risk of epilepsy is associated
with hyperinsulinism due to mutations in the GLUD1 gene as 7/16 (43%) of the patients
developed epilepsy. The study by Bahi- Buisson et al (Bahi-Buisson et al., 2008b) reported
that epilepsy is associated more frequently with mutations in exons 6 and 7 (GTP binding
site). This was not confirmed in this study as 4/7 patients with epilepsy had mutations in
exons 10 and 11. Hence, no genotype-phenotype association according to the location of
the mutations was found in this study. However, all the three patients with the S445L
mutation developed epilepsy. Hence, this mutation was associated with an increased
frequency of epilepsy in this cohort.
The most consistent feature of the hyperinsulinism due to mutations in GLUD1 is the
persistent hyperammonaemia and hence the term ‘Hyperinsulinism/ Hyperammonaemia
Syndrome’ is used synonymously with CHI due to GLUD1 mutations (Stanley et al., 2000;
de Lonlay et al., 2001; Miki et al., 2000). It is proposed that hyperammonaemia is the
result of excessive GDH activity in the hepatocytes leading to a) either an increase in the
production of ammonia from glutamate and/ or b) depletion of glutamate with reduction in
the production of N-acetylglutamate, an allosteric activator essential for the first step of
ammonia detoxification (Stanley et al., 2004). However, the second mechanism is not
supported by results of a study by de Lonlay et al where they showed that the
administration of N-carbamylglutamate (an analog of N-acetylglutamate) does not
normalise the concentrations of venous ammonia (de Lonlay et al., 2001) in the patients.
Additionally, they also described a patient with the R265T mutation who had normal
venous ammonia concentrations during muscle relaxation (curarization) suggesting that
hyperammonaemia may have a muscular origin (de Lonlay et al., 2001). In summary, the
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exact mechanism causing hyperammonaemia remains unknown, but is an important
feature of CHI due to GLUD1 gene mutations.
In this cohort, patient 12 with the novel P436L mutation has a completely normal serum
ammonium concentration (highest being 41μmol/L). So far, there has been one other 
report of two patients (father and son) with hyperinsulinism due to the R269H mutation in
the GLUD1 gene and normal serum ammonia concentrations (35 and 28µmol/L) (Santer et
al., 2001). Six patients (4 from the same family) with HI/HA in this cohort who are
heterozygous for the R269H mutation have elevated ammonia concentrations proving that
the lack of hyperammonaemia is not mutation specific. A possible explanation for the lack
of hyperammonaemia is the occurrence of mosaicism. If the origin of the
hyperammonaemia is in the liver, it is possible that patients with lack of
hyperammonaemia and a GLUD1 mutation are mosaic for the mutation with the mutation
being absent or at <50% in the hepatic tissues. And hence this absence of
hyperammonaemia may not be genotype specific. However, this theory cannot be proved
or disproved without a liver/ pancreatic biopsy. Similarly, mosaicism may be the underlying
mechanism in the four patients with HI/HA syndrome and no GLUD1 mutation with the
mutation affecting the liver and pancreas, but not blood.
A genotype-phenotype correlation between serum ammonium concentration and
sensitivity to GTP inhibition (MacMullen et al., 2001) has been previously reported with
higher serum ammonia concentrations being measured in patients with higher GTP IC50.
This was not confirmed in this study where enzymatic analysis of the lymphoblastic GDH
from patient 12 with the P436L mutation showed a loss of GTP inhibition with the half-
maximal inhibitory concentration of GTP being 470% higher than that of controls despite
the absence of hyperammonaemia. Loss of GTP inhibition is known to increase glutamate
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oxidation in the presence of leucine causing leucine sensitive hyperinsulinism, a classical
feature of HI/HA syndrome. This was clinically evident in patient 12 with this novel P436L
mutation and was confirmed by the oral leucine tolerance test. The confirmation of leucine
sensitivity prompted the sequencing of the GLUD1 gene and led to the molecular
diagnosis. This suggests that analysis of the GLUD1 gene must be considered in all
patients with leucine sensitivity even in the absence of hyperammonaemia.
Leucine sensitivity in HI/HA syndrome is thought to be responsive to treatment with
diazoxide. However, anecdotal evidence suggests that some patients with HI/HA
syndrome may continue to have protein induced hypoglycaemic episodes even while on
diazoxide (Hsu et al., 2001). This study provides evidence to support these reports as
patient 12 is severely leucine sensitive despite normal fasting tolerance on a high dose of
diazoxide. This emphasises the importance of evaluating leucine tolerance in patients who
experience hypoglycaemic episodes on seemingly adequate diazoxide therapy with
normal fasting tolerance.
The study also reports two other novel mutations (N410D and D451V) in the GLUD1 gene.
N410 is located in the antenna-like structure connecting to the pivot helix of the GDH
structure. A mutation (N410T) previously described at the same residue is known to cause
HI/HA associated with a higher basal GDH activity (Yorifuji et al., 1999). D451 is located in
the allosteric domain of the GLUD1 gene; a common site for mutations causing HI/HA
syndrome and hence likely to be pathogenic by interfering with the allosteric binding sites.
Conservation data suggests that these residues are functionally important as they are both
well conserved among species.
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6.5 Conclusion
In conclusion, this study of 16 patients with GLUD1 gene mutations confirms that
mutations in this gene cause a mild form of CHI associated with normal birth weight,
delayed age at presentation and a high risk of epilepsy. The high risk of epilepsy was not
associated with the location of the mutation in this cohort of patients, as described
previously (Bahi- Buisson et al., 2008b). However, all three patients with S445L mutation
in this cohort were large at birth and developed epilepsy.
Most importantly, this study confirmed that mutations in the GLUD1 gene are not always
associated with hyperammonaemia. This raises the possibility that the current prevalence
of GLUD1 mutations in CHI, based on screening in the presence of hyperammonaemia
may be an underestimate.
The study also demonstrates that even in the absence of hyperammonaemia, patients with
GLUD1 gene mutations may be extremely leucine sensitive. Hence leucine tolerance test
(performed in an experienced centre due to the associated dangers) may give an
important clue to the genetic diagnosis and must be considered on all patients with
hyperinsulinism who have post-prandial hypoglycaemia/ intermittent hypoglycaemic
episodes. The prevalence of GLUD1 gene mutations in patients with leucine sensitive CHI
and normal serum ammonia concentrations is not known and further studies are required
to understand this.
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Chapter 7
Congenital Hyperinsulinism Due To Mutations in The HADH Gene:
Characterisation Of A Novel Mutation And Observation Of Severe
Protein Sensitivity
7.1 Background
The HADH gene encodes for the enzyme 3-hydroxyacyl-coenzyme A dehydrogenase
(HADH), which is an intra-mitochondrial enzyme that catalyses the penultimate reaction in
the ß-oxidation of fatty acids; the NAD+ dependent dehydrogenation of 3-hydroxyacyl–CoA
to 3-ketoacyl-CoA. Mutations in the HADH are a rare cause of recessively inherited CHI.
Four patients have been described with HH due to homozygous mutations in this gene
(Clayton et al., 2001; Molven et al., 2004; Hussain et al., 2005c). The clinical presentation
of all these reported patients was heterogeneous either with mild late onset hypoglycaemia
or severe neonatal hypoglycaemia. The blood acylcarnitine profile in all reported patients
revealed raised hydroxybutyrylcarnitine and urine organic acids analysis showed raised 3-
hydroxyglutarate. Functional analysis of the HADH enzyme in skin fibroblasts from all
these patients showed reduced expression and activity.
7.2 Protein sensitive hyperinsulinaemic hypoglycaemia
Protein sensitivity was first described in 1955 by Cochrane et al. (Cochrane et al.,1955)
who described three infants with hypoglycaemia exacerbated by a high protein diet and
demonstrated that these patients developed dramatic hypoglycaemia in response to a
leucine load. This hypoglycaemia was associated with an excessive rise in plasma insulin.
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Subsequently, leucine sensitivity was described in association with the hyperinsulinism-
hyperammonaemia syndrome (HI/HA syndrome) caused by missense mutations of
GLUD1 that reduce the sensitivity of the enzyme glutamate dehydrodgenase (GDH) to
allosteric inhibition by the high-energy nucleotide triphosphates GTP and ATP. GDH is
allosterically activated by leucine and inhibited by GTP (Fahein et al., 1990). Mutations
which cause loss of inhibition by GTP cause leucine to increase the oxidation of glutamate,
thereby raising the ratio of ATP/ADP in the pancreatic -cell. The increased ratio of
ATP/ADP then triggers closure of the KATP channel and triggers the release of insulin.
More recently Fourtner et al. (2006) described protein induced hypoglycaemia in a group
of patients with KATP CHI without leucine sensitivity and demonstrated that protein
sensitivity is not synonymous with leucine sensitivity. This protein sensitivity can be as
severe as that seen in the HI/HA syndrome and unlike the protein sensitivity seen in HI/HA
syndrome it does not respond to diazoxide.
This section describes the phenotype of the fifth case of CHI associated with a novel
missense mutation in the HADH gene. Unlike all other previously reported cases, this
patient has normal acylcarnitine and urine organic acid profile. In addition, the novel
observation of severe protein sensitivity (specifically due to leucine sensitivity) in patients
with mutations in the HADH gene is discussed.
7.3 Methodology
7.3.1 Clinical case
The index case, born to consanguineous parents of Bangladeshi origin presented at four
months of age with hypoglycaemic seizures. Investigations revealed a biochemical picture
125
consistent with hypoketotic HH with raised serum insulin concentration of 58mU/L and low
concentrations of serum fatty acids during hypoglycaemia (blood glucose concentration of
1.8mmol/L). The hypoglycaemia responded to diazoxide but she continued to have
episodes of HH especially when taking a meal rich in protein. Interestingly, results of
hypoglycaemia screens performed on two occasions were similar to the two patients
described previously (Clayton et al., 2001; Hussain et al., 2005c). During a controlled fast
she developed significant hypoglycaemia down to 2.4mmol/L within 5 hours of the fast with
undetectable insulin and presence of serum fatty acids and ketones. However, on another
occasion, she was admitted with a hypoglycaemic seizure and investigations revealed a
blood glucose concentration of 2.1 mmol/L with simultaneous insulin concentration of
3.9mU/L. On this occasion, she again had low but detectable levels of non esterified fatty
acids (0.9mmol/L) and ketone bodies (1.84mmol/L). However, no abnormal metabolites
were detected on repeated measurements of the acylcarnitine and urinary organic acids.
The hypoglycaemia responded to diazoxide but she continued to have episodes of HH
especially when taking a meal rich in protein.
Given the clinical suspicion, history of consanguinity and the absence of mutations in
ABCC8 and KCNJ11, the HADH gene was sequenced and in order to investigate the
intermittent nature of the hypoglycaemia, the patient was evaluated for protein sensitivity.
Apart from this patient, the two patients reported (Clayton et al., 2001; Hussain et al.,
2005c) previously from Great Ormond Street Hospital form the three patients with HADH
mutations in this cohort.
7.3.2 HADH sequencing (Analysed in Peninsula Medical School, Exeter)
The eight exons of the HADH gene were amplified from genomic DNA of the index case
and the products were sequenced at Peninsula Medical School in Exeter. The primer
126
sequences are outlined in appendix 12.4B. The sequences were compared to the
published sequence (NM_005327.2) using Mutation Surveyor version 2.61 (Softgenetics
PA, USA), as described in chapter 3.
7.3.3 Measurement of 3-hydroxyacyl-CoA dehydrogenase activity (Performed by Dr
Simon Eaton, ICH, London)
HADH enzyme activity was measured following the method of El-Fakhri & Middleton
(1982). Each measurement was performed on 6 fibroblast pellets from the index patient,
and on 12 different controls, and data were compared by Student’s t-test. Briefly,
fibroblasts were thawed and resuspended in 25mM phosphate, 0.2mM EDTA, pH 8. They
were then sonicated on ice (3 x 10sec). Triton X-100 was added to give a Triton:protein
ratio of 1:1, then samples were incubated on ice for 30 minutes before being centrifuged at
18000g in a bench microfuge for 10 minutes.
Assays were carried out at 30˚C in 1ml cuvettes in a Uvikon spectrophotometer. Fibroblast 
homogenate was added to assay buffer (0.1M potassium phosphate pH 7.0/ 0.1mg/ml
NADH/ 0.3mg/ml BSA (fatty acid free)). Baseline absorbance at 340nM was obtained and
then 40µM of substrate was added (2-methyl-acetoacetyl-CoA for short chain, 3-
ketooctanoyl-CoA for medium, 3-ketohexadecanoyl-CoA for long chain). Change in
absorbance was recorded at all time points and the extinction coefficient for NADH
(6.22x103M-1cm-1.) was used to calculate a rate. Enzyme activity was expressed as
nmol/min/mg protein.
7.3.4 Protein Tolerance Test
An oral protein load was carried out to investigate the possibility of protein induced
hypoglycaemia. Following a positive result, two previously described patients with CHI due
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to mutations in the HADH gene were investigated similarly (Clayton et al., 2001; Hussain
et al., 2005c). The results were compared with 3 control subjects with ketotic
hypoglycaemia. Patients with ketotic hypoglycaemia were selected as controls as the
cause of hypoglycaemia is not related to insulin action in these patients (as evidenced by
the presence of elevated ketone bodies during hypoglycaemia). All the patients had
previously demonstrated normal fasting tolerance on diazoxide. The diazoxide dose for
patients with HADH mutations was between 13-15mg/kg/day. Diazoxide was not
discontinued for the purpose of the test as stopping diazoxide in patients with
hyperinsulinism may itself lead to hypoglycaemia and false positive results. Following the
observation of severe protein sensitivity, GLUD1 was sequenced in all three patients and
no mutations were found.
The patients and controls were fasted for four hours prior to the test. Baseline bloods
(insulin, glucose) were collected prior to oral administration of the protein mixture. The oral
protein load was given in the form of a standard protein powder (Vitapro) dissolved in
water. The amount of amino acids present in 100 gram of this mixture is as follows: L-
Alanine 3.6g, L-Arginine 1.9g, L-Cystine 1.7g, L-Glutamine 14.8g, L-Glycine 1.4g, L-
Histidine 1.2g, L-Isoleucine 4.7g, L-Leucine 7.5g, L-Lysine 6.6g, L-Methionine 1.7g, L-
Phenylalanine 2.2g, L-Proline 4.9g, L-Serine 3.2g, L-Threonine 5.9g, L-Tryptophan 1.8g,
L-Tyrosine 1.9g, L-Valine 4.0g and L-Asparagine 8.9g. 1.5gm/kg of the mixture was
administered and bloods were collected at 30 minute interval post load. The test was
stopped at 180mins or earlier if hypoglycaemia developed; hypoglycaemia was defined as
blood glucose level of <3.0mmol/L for the purpose of the test.
Serum insulin and blood glucose measurements were performed in the biochemistry
department at Great Ormond Street Hospital by the laboratory staff.
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Serum insulin was measured using the IMMULITE 2500 immunoassay system (Siemens,
USA). IMMULITE 2500 insulin immunoassay is a chemiluminescent immunometric assay.
The procedure involves incubation of the patient’s sample with a bead coated with anti-
insulin antibody and a reagent containing alkaline phosphatise conjugated to anti-insulin
antibody for 60 minutes. During incubation, insulin forms a complex with the anti-insulin
antibody on the bead and the enzyme conjugated anti-insulin antibody in the reagent.
Unbound patient sample and enzyme conjugate are then removed by washes. The
chemiluminescent substrate is then added to the reaction which generates a light signal in
proportion to the bound enzyme which in turn is proportional to the amount of insulin in the
patient’s sample.
Blood glucose was measured using the VITROS Chemistry system (Johnson and
Johnsons Clinical Diagnostics, UK). First, the sample glucose is converted by glucose
oxidase in the presence of oxygen to hydrogen peroxidise and gluconate. Hydrogen
peroxidise then reacts with 4-aminophenazone and phenol to yield a coloured complex.
The intensity of the complex is measured at 505 nm and is proportional to the glucose
concentration in the patient’s sample.
7.3.5 Leucine Tolerance Test
To investigate whether the protein sensitivity was due to the leucine component in the
protein mixture as seen in patients with HI/HA syndrome, an oral leucine load test was
performed on the three patients. Following a fast of four hours, an oral dose of 0.15gm/kg
of L-Leucine was administered. Blood glucose and plasma insulin levels were then
measured at -30, 0, 30, 60, 90 and 120 minutes.
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7.4 Results
7.4.1 HADH mutation analysis
A novel homozygous missense mutation, M188V (c.562A>G, p.Met188Val) was identified
in exon 5 of the index patient’s HADH gene. Her parents and two unaffected siblings were
heterozygous for the M188V mutation. The approximate position of the mutation within the
HADH structure is depicted in figure 7.1. Both methionine and valine are nonpolar amino
acids, but the methionine residue at position 188 is conserved from human to Xenopus
tropicalis. 72 control ethnically matched chromosomes were sequenced and the
homozygous missense mutation, M188V (c.562A>G, p.Met188Val) was not detected.
The other two patients positive for a HADH mutation include a patient with the P258L
mutation in exon 7 (Clayton et al., 2001) and a splice site mutation IVS6-2a>g (Hussain et
al., 2005c).
Figure 7.1: Diagram depicting the location of the novel mutation M188V within the HADH
protein structure. The first 200 amino acids comprise the NAD+ binding domain and the
remaining residues comprise the C-terminal domain (Barycki et al., 2000). 3-
Hydroxybutyrl-CoA binds to the cleft between the two domains.The location of the P258L
mutation is also depicted.130
M188VP258L
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7.4.2 Activity of L-3-hydroxyacyl-CoA dehydrogenase (Performed by Dr Simon
Eaton, ICH, London)
Short chain L-3-hydroxyacyl-CoA dehydrogenase activity was significantly decreased
compared with controls (index patient mean 26.8 ± SEM 4.8 mU/mg protein vs. controls
48.0 ± 8.1; p=0.029), although the residual activity was much higher than in the other
reported cases (Clayton et al., 2001; Hussain et al., 2005c). Activities of medium and long
chain L-3-hydroxyacyl-CoA dehydrogenase were also mildly decreased compared with
controls although this difference was not significant (medium chain index patient 25.8 ±
4.2 vs. controls 40.1 ± 6.1; long chain index patient 28.8 ± 5.0 vs. controls 43.8 ± 6.2).
7.4.3 Protein induced hyperinsulinaemic hypoglycaemia with leucine sensitivity
The blood glucose response to the oral protein load in the patients with HADH deficiency
is illustrated in fig 7.2. As shown, all three subjects with HADH deficiency demonstrated a
dramatic decline in blood glucose concentration. In contrast, the control subjects had no
change in the blood glucose concentration in response to protein. Table 7.1 shows the
blood glucose and insulin responses to the oral protein load in subjects and controls. In
response to the oral leucine load, all the three patients demonstrated a fall in the blood
glucose concentrations with simultaneous increase in the serum insulin concentrations,
demonstrating leucine sensitivity (Table 7.2).
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Figure 7.2: Blood glucose concentrations in response to oral protein load in patients and
controls. All patients with mutations in the HADH gene demonstrated marked HH in
response to a standard protein load. In contrast, there was no hypoglycaemia in the
control patients (Kapoor et al., 2009a).
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Table 7.1: Comparison of blood glucose and insulin concentrations between subjects (Pt 1, Pt 2 and Pt 3) and controls (C 1, C 2 and
C 3) during protein load. All the three subjects with mutations in the HADH gene developed hypoglycaemia with a concomitant rise in
plasma insulin levels. In contrast, the control subjects had no change in blood glucose levels in response to a protein load (Kapoor et
al., 2009a).
Subject
Age at
testing
(yrs)
HADH
Mutation
Baseline
BG
(mmol/L)
Nadir
BG
(mmol/L)
Baseline
insulin
(mU/L)
Peak
insulin
(mU/L)
Time to
nadir
(mins)
Fasting
Tolerance
(hrs)
Pt 1 10.3 P258L 4.5 2.7 6.1 67.7 180 16
Pt 2 8.4
IVS6-
2a>g
5.2 2.9 <2.0 24 60 14
Pt 3 1.2 M188V 4.0 2.8 4.7 7.8 120 16
C 1 1.1 Nil 4.0 4.1 3.1 6.1 - 10
C 2 8.8 Nil 3.9 4.4 2.6 5.1 - 16
C 3 11 Nil 4.6 4.6 4.1 12.7 - 18
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Table 7.2: Oral leucine tolerance test in the three subjects with mutations in the HADH
gene showing development of HH with a concomitant rise in plasma insulin
concentrations.
Time (minutes) -30 00 15 30 45
Glucose (mmol/L) 4.4 4.4 4.1 3.4 2.7Patient 1
Insulin (mU/L) 9.5 6.6 25.4 34.7 45
Glucose (mmol/L) 4.4 4.4 4.1 1.7Patient 2
Insulin (mU/L) 6.5 3.5 26.5 63.8
Glucose (mmol/L) 5.1 4.8 4.2 2.7Patient 3
Insulin (mU/L) 8.6 3.4 27.4 31.7
7.5 Discussion
This data on the study of three patients with CHI due to mutations in HADH has
highlighted two important phenotypic features of patients with mutations in this gene.
Firstly, it suggests for the first time that CHI due to mutations in HADH may not be
accompanied by abnormalities in the urinary organic acids and plasma acylcarnitine
profiles. Secondly, it demonstrates that these patients are highly protein sensitive (and
leucine sensitive), a completely novel phenotypic feature of these patients. In the section
that follows, the implications of these results on the clinical management of the patients
and on the current understanding on the pathophysiology of the condition are discussed.
What is known about the role of HADH in the pancreatic ß-cell?
Mitochondrial HADH is involved in the second dehydrogenation step of the ß-oxidation
pathway. It catalyses the conversion of L3-hydroxyacyl CoA to 3-Ketoacyl CoA, and this
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reaction also utilises NAD+ as cofactor producing NADH. It is known that HADH is
expressed at high levels in pancreatic ß-cells (Agren et al., 1977). Two recent studies have
highlighted the pivotal role of HADH in ß-cell physiology: Firstly, Hardy et al (Hardy et al,
2007) showed that RNA interference-mediated gene suppression of HADH in insulinoma
cells and primary rodent islets caused enhanced basal insulin secretion. This
demonstrated for the first time that HADH is required directly in pancreatic ß-cells for the
regulation of basal insulin release. In a second study, Martens et al (Martens et al., 2007)
compared the expression of HADH and other enzymes of the ß-oxidation pathway in rat ß-
cells and in the ß-cell line INS1 with that of other cell types. They found that compared with
other cell types, pancreatic ß-cells express high levels of HADH mRNA and low levels of
other ß-oxidation enzymes. They also demonstrated that HADH suppression resulted in
increased basal and glucose stimulated insulin secretion and proved that this was not
caused by increased rates of glucose metabolism or an inhibition of fatty acid oxidation.
This study provides evidence for the existence of a crucial HADH dependent regulatory
pathway that is independent of ß-oxidation and KATP channel pathways. It also supports
the existence of dysregulated ß-cells as the cause of HH in patients with HADH mutations.
However the exact mechanism of regulation of insulin secretion by HADH remains to be
elucidated.
What has this data added to the understanding of insulin regulation by HADH?
It has been hypothesized that fatty acids increase insulin secretion by affecting the
concentrations of long-chain fatty acyl derivatives as a result of the inhibitory effect of
citrate and malonyl-CoA on the rate controlling enzyme carnitine palmitoyltransferase-1
(CPT1) (Eaton et al., 2003; Prentki et al., 1992; McGarry 2002). Various potential
mechanisms have been put forward to explain HH associated with HADH deficiency
(Eaton et al., 2003). The previously reported cases of CHI due to mutations in HADH have
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presented with increased 3-hydroxyglutarate in urine and hydroxybutyrylcarnitine in blood
(regarded as diagnostically useful markers for HADH deficiency). The presence of these
circulating abnormal acylcarnitine metabolites in the blood in all previously reported
patients led to speculations that accumulation of short chain acyl Co-A esters originating
from circulating metabolites or the metabolites themselves may lead to dysregulated
insulin secretion either by inhibition of CPT1, or via KATP channels or via the G-protein
coupled receptor GPR40 (reviewed by Eaton et al., 2003). The case described above now
demonstrates that hyperinsulinism associated with HADH deficiency in fact may not
always manifest itself with the presence of these abnormal metabolites. Hence the
accumulation of 3-hydroxybutyrylcarnitine may not be the trigger for insulin secretion in
patients with HADH deficiency. This supports the study by Martens et al. (Martens et al.,
2007) that demonstrated that knockdown of HADH in -cells increases insulin secretion
not as a consequence of a perturbation of -oxidation but possibly by another metabolic
mechanism that is currently unknown.
Interestingly, the residual enzyme activity in the patient described is higher than the
previously described cases of HADH deficiency with hyperinsulinism. The lack of
detectable abnormal acylcarnitines is indeed in keeping with the mild defect in enzyme
activity. This suggests that the mechanism of insulin dysregulation in patients with HADH
mutations (and/ or the mechanism of insulin regulation by HADH) may be unrelated to the
activity of the enzyme. The HADH protein has been previously shown to be associated
with other proteins which may be involved in insulin secretion e.g. GDH (Filling et al.,
2008) or complex I (Sumegi and Srere, 1984). Indeed, Filling et al (Filling et al., 2008)
conclude that protein interactions rather than changes in activity are likely to lead to the
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phenotype. It is thus possible that mutations in HADH resulting in minor changes in
enzyme activity can cause major changes in the interactions of HADH with other proteins.
This study also demonstrates for the first time that children with HH due to mutations in
HADH are severely protein/ leucine sensitive (table 7.1). This novel clinical observation
leads to the proposal that defects in HADH may reveal an unidentified biochemical
pathway by which leucine triggers insulin secretion. Leucine sensitive HH occurs in
patients with GLUD1 mutations whereas protein sensitive (without leucine sensitivity) HH
is observed in patients with defects in the KATP channel genes (Kelly et al., 2001; Fourtner
et al., 2006). However protein/ leucine sensitivity due to mutations in the HADH gene has
not been described before. This clinical observation implies that HADH inhibits leucine
induced insulin secretion.
Interestingly, the study by Filling et al. (Filling et al., 2008) proposes the existence of an
interaction between HADH and glutamate dehydrogenase (GDH) in the pancreatic ß-cell.
It could be hypothesized that mutations in HADH cause protein sensitive HH via the GDH
axis. In this model of HADH and GDH interaction, HADH would act as an inhibitor of GDH,
opposing leucine stimulated insulin secretion. This inhibition could be a direct inhibition of
GDH (like that exerted by GTP), or indirect via its effect on the interaction of GDH and its
inhibitors (such as GTP) or stimulators (such as leucine). Mutations in HADH could then
cause protein-induced hypoglycaemia due to enhanced sensitivity to leucine-mediated
insulin secretion as a consequence of:
i) impaired inhibitory control of GDH, as in patients with HI/HA syndrome or
ii) impaired inhibition of GDH itself or
iii) excessive stimulation by leucine
All of the above mechanisms (illustrated in figure 7.3) would lead to leucine sensitive HH,
as was seen in the patients in this study. Unravelling this biochemical pathway will provide
unique novel insights into fatty acid and amino acid induced insulin secretion.
Figure 7.3: Figure demonstrating the three hypothesised mechanisms linking GDH, HADH
and amino-acid stimulated insulin secretion. Glutamate is converted to α-ketoglurate + 
ammonia in the presence of GDH. GDH is activated by leucine and inhibited by GTP.
HADH may act by (A) direct inhibition of GDH, (B) inhibition of the inhibitory control of
GDH or (C) excessive stimulation of GDH by leucine
Leucine
NAD
AGlutamate -ketoglurate + ammoniaGDH
NADH? HADH
GTP138
/ other inhibitors
Glutamate -ketoglurate + ammoniaGDH
Leucine
NAD
? HADHGTP/ other inhibitors
Leucine
NAD
? HADH
NADH
B
CGlutamate
GTP
NADH139
-kGDH
/ other inhibitorsetoglurate + ammonia
140
7.6 Clinical Implications of this study
The observation that patients with HADH mutations do not necessarily have abnormalities
in the urinary organic acid or acylcarnitine profiles indicates that these markers can no
longer be used exclusively to screen for HADH mutations. It also implies that the current
prevalence of HADH mutations in CHI may be an underestimate. All the three patients had
diazoxide responsive CHI with marked leucine sensitivity, similar to patients with HI/HA
syndrome. Furthermore, there is considerable overlap between CHI due to mutations in
the HADH gene and GLUD1 gene in terms of other phenotypic features studied, such as
age of presentation and birth weight SDS (refer chapter 8). The only distinguishing feature
apparent so far is the mode of inheritance, with HADH mutations being inherited in a
recessive manner as opposed to GLUD1 mutations that are dominantly inherited. Hence, it
may be recommended that in patients with leucine sensitive, diazoxide responsive CHI;
HADH is sequenced (prior to GLUD1), if the patient belongs to a consanguineous family.
The second important clinical implication of this data relates to the observation of protein
induced hypoglycaemia in these patients. This novel observation has helped us in
understanding the basis of unpredictable hypoglycaemic episodes and in instituting the
right management strategy for the patients i.e. protein restriction in the diet. As in patients
with HI/HA syndrome, protein restriction is proving an invaluable aid in the clinical
management of these patients.
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7.7 Conclusions
This in-depth study of the phenotype of three patients with HADH gene mutations has
provided invaluable knowledge, both to the clinical management of patients with CHI and
to the further understanding of how HADH regulates insulin secretion. The observation of
severe protein/ leucine sensitivity in these patients has demonstrated that HADH somehow
regulates leucine induced insulin secretion. Further studies are required to understand the
link between HADH, ß-oxidation pathway, insulin secretion and protein sensitivity. This
may be investigated by studying the effects of HADH knockdown on ß-cell gene
expression and by identifying proteins that are closely associated with HADH, specifically
exploring protein-protein interaction between GDH and HADH. These studies will provide
invaluable insights into pancreatic ß-cell biochemistry and physiology.
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Chapter 8
Congenital Hyperinsulinism due to Mutations in the HNF4A Gene
8.1 Background
Hepatocyte nuclear factor 4 alpha (HNF-4 encoded by the HNF4A gene) is a transcription
factor of the nuclear hormone receptor superfamily and is expressed in liver, kidney, gut,
and pancreatic islets (Sladek et al., 1990). It plays a key role in the regulation of pancreatic
insulin secretion. Loss-of-function HNF4A mutations have been identified in MODY
(maturity-onset diabetes of the young) families, characterized by an autosomal dominant
inheritance pattern and impaired glucose-stimulated insulin secretion from pancreatic ß-
cells (Yamagata et al., 1996). In addition, variations in the ß-cell specific promoter (P2)
elements of the HNF4A gene in humans are associated with increased risk of type 2
diabetes (Silander et al., 2004).
HNF-4 plays an important role in regulating insulin secretion as well as interacting with
regulatory elements in promoters and enhancers of genes whose products are involved in
diverse functions, including cholesterol, fatty acid, amino acid, and glucose metabolism.
Heterozygous mutations in the transcription factor HNF-4 have recently been associated
with a mild form of transient HH and considerable risk of macrosomia (Pearson et al.,
2007). The finding of transient mild HH is unexpected as heterozygous mutations in the
HNF4A gene lead to loss of glucose induced insulin secretion with glucose intolerance in
patients.
143
This section discusses the clinical characteristics of the eight patients with CHI that have a
mutation in the HNF4A gene. This is the largest cohort of patients with CHI due to
mutations in this gene. The study of this group of patients extends the observations of
Pearson et al. (Pearson et al., 2007) reporting that heterozygous HNF4A mutations can
also cause severe and persistent CHI along with mild, transient CHI described previously.
8.2 Methodology
Of the patients with no mutations in the KATP channel genes (or features of GLUD1/ GCK/
HADH mutations), 111 patients had DNA sequence analysis of the HNF4A gene. This
included 105 patients with diazoxide responsive CHI and 6 patients with transient CHI, that
did not require treatment with diazoxide. HNF4A analysis included amplification of the
coding exons 1d-10 and the P2 pancreatic promoter using published primer sequences
(Thomas et al., 2001 (P2 promoter) and Yamagata et al., 1996 (exons 1d-10)). PCR
products were sequenced using standard methods as described in chapter 3, and
compared to the published sequence NM_000457.3 (Ellard and Colclough, 2006) using
Mutation Surveyor v3.2. The analysis was carried out at Peninsula Medical School, Exeter.
The phenotypic characteristics of the patients found to have a HNF4A mutation were
collated (as outlined in chapter 3) and compared with the phenotypic characteristics of
patients with transient and/ or diazoxide responsive CHI and a KATP mutation (n= 27),
GLUD1 mutation (n= 13) or a HADH mutation (n=3). The phenotypic data are presented
as mean and the one-way analysis of variance (ANOVA) followed by LSD post-test was
used to test for statistical significance.
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8.3 Results
8.3.1 Genetic results
A total of eight different HNF4A mutations were identified in the eight probands, all of
which are novel. These include a frameshift mutation L330fsdel17ins9
(c.987_1003del17ins9; p.Leu330fs), a mutation affecting the conserved adenine
nucleotide of the intron 2 branch site (c.264-21A>G), a nonsense mutation, Y16X
(c.48C>G, p.Tyr16X); and missense mutations R80W (c. 238C>T; p.Arg80Trp), M116I
(c.348G>A; p.Met116Iso), Y319Valfs (c.953dupA; p.Tyr319ValfsX2) and Q362X
(c.1084C>T; p.Gln362X). In addition, a mutation within the P2 promoter of the HNF4A
gene, c.-181G>A, was identified. This G>A mutation occurs within the HNF1A/HNF1B
transcription factor binding site (c.-181G>A) and has been shown to affect the transcription
of the HNF4A gene (Hansen et al., 2002). Analysis of 7 orthologous sequences
demonstrated that these 4 novel missense mutations occurred at residues that are
conserved through evolution and these mutations were not present in 300 Caucasian
control chromosomes.
8.3.2 Inheritance of HNF4A mutations
In 5/8 families the mutation was inherited from a diabetic parent (for pedigrees see figure
8.1). Two mutations (c.264-21A>G, c.-181G>A) were inherited from an affected mother
while three mutations (L330fsdel17ins9, R80W, Y16X) were inherited from an affected
father. One patient had inherited the mutation (Y319Valfs) from her unaffected father
(current age 39 years) but her paternal aunt who had gestational diabetes at 30 years was
also found to carry the Y319Valfs HNF4A mutation. Two mutations, M116I and Q362X,
were proven by microsatellite analysis to have arisen de novo.
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Figure 8.1: Family pedigrees: Partial pedigrees showing inheritance of HNF4A mutations
in the 8 families. Circles represent females and squares indicate males. Probands are
indicated by an arrow. Horizontal hatching denotes patients with HH, vertical hatching
represents gestational diabetes and filled symbols show diabetic individuals. The genotype
is given below each symbol: M/N denotes a heterozygous HNF4A mutation and N/N a
normal genotype. For each proband, birth weight SDS and duration of diazoxide treatment
are provided, >indicates the minimum duration when treatment is ongoing. The HNF4A
mutation identified in each family is shown above each pedigree.
L330fsdel17ins9
M/N
M/N
M/N
+4.92
34 months
c.264-21A>G
M/N
M/N
M/N
+2.85
18 months
R80W
M/N N/N
M/N
+0.52
3 months
c.181G>A
M/N
M/N
M/N
+1.64
1 week
M116I
N/NN/N
M/N
+1.51
18 months
MNot
Y16X
M/N
+2.97
32 months
M/N N/N
M/NY319Valfs
M/N/N
Not testedtested
>10 mo
N/N N/N
Q362XN/N
M/N
+2.49
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+2.38146
nths
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8.3.3 Clinical characteristics of HNF4A mutation carriers
The clinical characteristics of the patients with CHI due to a HNF4A mutation are
summarised in table 8.1. The mean birth weight SDS of the infants was +2.41 SDS (0.52-
4.92). All the infants presented with hypoglycaemia on the first day of life. The maximum
glucose requirement was 25mg/kg/min. Three infants required an intravenous infusion of
glucagon to stabilise blood glucose levels. Seven infants responded to diazoxide therapy
(1.5mg/kg/day – 10mg/kg/day). In the eighth infant, hypoglycaemia resolved within the first
week of life without diazoxide therapy. Hyperinsulinism resolved within six months in three
infants. However, five children developed more persistent hyperinsulinism with one child
continuing treatment at 48 months of age (table 8.2). There were no common mutations in
our cohort of patients.
The father carrying the L330fsdel17ins9 mutation was macrosomic (birth weight 2.79 kg)
at 26 weeks gestation. This raises possibility that HNF4A mutations lead to fetal
hyperinsulinaemia at an early gestational age, subsequently resulting in macrosomia.
Neonatal hypoglycaemia had not been reported in any of the heterozygous relatives.
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Table 8.1: Clinical characteristics of patients with CHI due to HNF4A mutations: The mean birth weight was +2.41 SDS and all the
infants presented at day 1. A history of diabetes in the parents was absent in 3/8 patients. The duration of HH varied between 1 week
and 48 months.
Pt Mutation Birth Weight
SDS
Age of
presentation
Diazoxide
Responsive
Duration Family history of diabetes Inheritance
1 c.181G>A +1.64 Day 1 Not Treated 1 Week Mother, Maternal Grandmother Maternal
2 R80W +0.52 Day 1 Yes 3 Months Father, Paternal Aunt,
Grandfather And Great Grand
Father
Paternal
3 M116I +1.51 Day 1 Yes 18 Months Nil De Novo
4 L330fsdel17
Ins9
+4.92 Day 1 Yes 34 Months Father, Paternal Aunt And
Grandmother
Paternal
5 c.264-21A>G +2.85 Day 1 Yes Continuing at
48 months
Mother, Maternal Grandfather Maternal
6 Y16X +2.97 Day 1 Yes 32 Months Father, Paternal Uncles,
Grandfather
Paternal
7 Q362X +2.49 Day 1 Yes Continuing
treatment at 39
months
Nil De novo
8 Y319Valfs +2.38 Day 1 Yes 6 months Paternal aunt- GDM Paternal
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Table 8.2: Clinical characteristics of the patients with persistent HH: The patients had
severe HH with requirements of high concentrations of intravenous glucose and
subcutaneous glucagon infusions.
Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Maximum
Glucose
Infusion
Rate
Not Known 25 Mg/Kg/Min 12.5
Mg/Kg/Min
11
Mg/Kg/Min
Not known
Glucagon
Infusion
Required
No Yes Yes Yes No
Diazoxide
Responsive
(Dose)
Yes,
1.5mg/kg/day
Yes, 10
mg/kg/day
Yes, 10
mg/kg/day
Yes, On 6
mg/kg/day
Yes, on
10mg/kg/d
Family
History Of
Diabetes
No Yes Yes Yes No
Attempted
Withdrawal
Of
Diazoxide
Successful
At 18 Months
Not Successful
At 7 Months
Not
Successful
At 18
Months
Successful
At 32
Months
Continuing
treatment
at 39
months
Mutation M116I L330fsdel17ins9 C.264-
21>G
Y16X Q362X
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8.3.4 Clinical characteristics according to genetic aetiology
The clinical characteristics of the probands according to genetic etiology were compared
(table 8.3). Patients with a HNF4A mutation presented earlier and were born heavier than
patients with a GLUD1 mutation (1 day vs 22.4 weeks, p = 0.001 and +2.41 birth weight
SDS vs -0.11 birth weight SDS, p = 0.001 respectively). In comparison to patients with an
HADH mutation, patients with an HNF4A mutation were heavier (birth weight SDS +2.41
(HNF4A) vs -1.09 (HADH), p= 0.001) and presented earlier (1 day vs 125 days), although
the difference in the age of presentation was not statistically significant (p=0.063). No
differences in the mean age at presentation were observed between patients with an
HNF4A or KATP channel mutations with diazoxide responsive CHI (the range varied from 1
day to 1 year for patients with a KATP channel mutation). The difference in the birth weights
between these two groups were also not significant (+2.41 birth weight SDS vs +1.47 birth
weight SDS, p = 0.141).
Within the other groups of patients, the age of presentation and birth weight SDS of
patients with a GLUD1 or HADH mutation were similar with no significant differences
(mean age of presentation 157 days vs 125 days and mean birth weight SDS -0.11 vs -
1.09, p values of 0.6 and 0.3 respectively). The mean birth weight SDS and age of
presentation of the patients with a GLUD1 mutation was significantly different from patients
with a KATP channel mutation (p=0.006 and p<0.005 respectively). Patients with a HADH
mutation were also significantly smaller at birth than patients with a KATP channel mutation
(p=0.008). The mean age of presentation of patients with a HADH mutation was 125 days
in comparison with 27.8 days in patients with KATP channel mutations; however the
difference was not statistically significant (p=0.1). These results are displayed in tables 8.4
(birth weight SDS) and 8.5 (age of presentation).
151
Table 8.3: Summary of the clinical characteristics for the patients with diazoxide
responsive CHI according to the genetic aetiology. The data are represented by the mean
(interquartile range).
HNF4A
mutation
positive
KATP channel
positive
GLUD1
mutation
positive
HADH
mutation
positive
Number of
patients
8 27 13 3
Sex (% males) 37.5% 73% 38.4% 33.3%
Age of
presentation
1
(1- 1)
27.8
(1-365)
157.3
( 2- 504)
125
(120-135)
Birth weight
(grams)
4153
(3360-5900)
3720
(1100- 5600)
3133
(2495- 3990)
3040
(2570-3450)
Gestational
age (weeks)
37
(35-40)
37
(31- 41.5)
38.6
(35-40)
40
(40-40)
Birth weight
SDS
2.41
(0.52- +4.92)
1.47
(-1.96- +4.66)
-0.11
(-2.37- +1.73)
-1.09
(0.01- -2.45)
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Table 8.4: Comparison of the birth weight SDS between different groups of patients using
the One Way Anova Post Hoc LSD test: Patients with an HNF4A or a KATP channel
mutation were significantly large at birth than patients with a GLUD1/ HADH mutation.
95% Confidence IntervalPt
group
(A)
Pt
group
(B)
Mean
Difference
(A-B)
Std.
Error Sig.
Lower
Bound
Upper
Bound
GLUD1 2.51917* .68334 .001 1.1381 3.9002
HADH 3.49667* 1.01355 .001 1.4482 5.5451
HNF4A
KATP .93524 .62201 .141 -.3219 2.1924
HNF4A -2.51917* .68334 .001 -3.9002 -1.1381
HADH .97750 .96638 .318 -.9756 2.9306
GLUD1
KATP -1.58393* .54177 .006 -2.6789 -.4890
HNF4A -3.49667* 1.01355 .001 -5.5451 -1.4482
GLUD1 -.97750 .96638 .318 -2.9306 .9756
HADH
KATP -2.56143* .92404 .008 -4.4290 -.6939
HNF4A -.93524 .62201 .141 -2.1924 .3219
GLUD1 1.58393* .54177 .006 .4890 2.6789
KATP
HADH 2.56143* .92404 .008 .6939 4.4290
*. The mean difference is significant at the 0.05 level.
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Table 8.5: Comparison of the age of presentation between different groups of patients
using the One Way Anova Post Hoc LSD test: Patients with an HNF4A or KATP channel
mutation presented significantly earlier than patients with a GLUD1 mutation. There was
no significant difference in the age of presentation between other groups.
95% Confidence Interval
Pt group
(A)
Pt group
(B)
Mean Difference
(A-B)
Std.
Error Sig.
Lower
Bound
Upper
Bound
GLUD1 -156.38462* 43.25264 .001 -243.4999 -69.2693
HADH -124.00000 65.16439 .063 -255.2478 7.2478
HNF4A
KATP -26.80000 39.09864 .497 -105.5487 51.9487
HNF4A 156.38462* 43.25264 .001 69.2693 243.4999
HADH 32.38462 61.65202 .602 -91.7889 156.5582
GLUD1
KATP 129.58462* 32.91317 <.005 63.2941 195.8751
HNF4A 124.00000 65.16439 .063 -7.2478 255.2478
GLUD1 -32.38462 61.65202 .602 -156.5582 91.7889
HADH
KATP 97.20000 58.81228 .105 -21.2540 215.6540
HNF4A 26.80000 39.09864 .497 -51.9487 105.5487
GLUD1 -129.58462* 32.91317 <.005 -195.8751 -63.2941
KATP
HADH -97.20000 58.81228 .105 -215.6540 21.2540
*. The mean difference is significant at the 0.05 level.
154
8.4 Discussion
CHI is clinically a very heterogeneous condition in terms of severity of disease, persistence
of disease and responsiveness to medical therapy. From this study, it was evident that the
heterogeneity was a feature of CHI within the group of patients with HNF4A mutations as
well. So far, it is known that mutations in HNF4A gene cause mild, transient HH. However,
at least 3 of the 8 patients with an HNF4A mutation had severe HH requiring large
amounts of intravenous glucose and subcutaneous glucagon infusions to maintain
normoglycaemia. With regards to persistence of disease, three patients had persistent
requirement of diazoxide therapy till 18 months, 32 months and 34 months and two are
continuing treatment at 39 months and 48 months (tables 8.1 and 8.2). These results
illustrate that heterozygous HNF4A mutations can cause severe and persistent
hyperinsulinism in addition to the mild, transient hyperinsulinism that has been reported
previously (Pearson et al., 2007).
The previous study examined families of patients with diabetes with HNF4A mutations and
concluded that CHI due to HNF4A mutations caused hypoglycaemia associated with
macrosomia and a family history of diabetes. This study of eight families confirmed that
CHI due to HNF4A mutations was associated with increased birth weight (mean birth
weight +2.41 SDS) which is likely to result from increased insulin secretion in utero.
However, three of the eight probands (37.5%) did not have a parent with diabetes and in
two cases a de novo mutation was confirmed. In the third case, the mutation was inherited
from an asymptomatic father and there was history of gestational diabetes in the paternal
aunt who also carried the same mutation (family 8). Therefore this study illustrates that the
absence of a history of diabetes in the parents should not preclude sequencing of the
HNF4A gene in patients presenting with diazoxide responsive HH.
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Neonatal hypoglycaemia has been reported in only a minority of patients (11%) with
HNF4A mutations who were ascertained by their family history of MODY (Pearson et al.,
2007; Fajans and Bell, 2007) and none of the other heterozygous relatives in this study
were known to have had neonatal hypoglycaemia. The reasons for the incomplete
penetrance of symptomatic hypoglycaemia are not known, but it appears to be a general
feature rather than mutation specific. The hyperinsulinaemic HNF4A phenotype hence,
ranges from increased birth weight, to neonatal hypoglycaemia managed by intravenous
glucose only (Pearson et al., 2007; Fajans and Bell, 2007) for 1-9 days, or neonatal
hypoglycaemia requiring diazoxide therapy for between 3 months and 3.3 years. It is
therefore likely that other environmental and genetic factors are influencing the severity of
the hyperinsulinaemic phenotype associated with HNF4A mutations.
It was striking that all the eight patients with HNF4A mutations presented on the first day of
life with hypoglycaemia. Also, the mean birth weight SDS of patients with HNF4A
mutations was the highest when compared to the patient groups of diazoxide responsive
CHI due to other aetiologies, with 5 out of 8 patients having a birth weight SDS of >2.
However, patients with a KATP channel mutation were also large at birth (birth weight SDS
ranged between -1.96 to +4.66) with an early age of presentation (ranging from 1 day to
365 days). Due to this overlap in the age of presentation and birth weight between patients
with an HNF4A mutations and KATP channel mutations, it is not possible to distinguish
between the two groups on the basis of these features. Although a family history of
diabetes is more likely to suggest an HNF4A mutation it is also not a distinguishing
feature. Hence, given the higher prevalence of KATP channel mutations and the high rate of
diabetes phenocopies in the population, it would be recommended to sequence KCNJ11
and ABCC8 first in all patients with diazoxide responsive CHI, followed by HNF4A in case
of a family history of diabetes.
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In contrast, patients with a GLUD1/ HADH mutation were diagnosed later (mean of 157
and 125 days respectively) and were of normal birth weight (mean birth wt SDS of -0.11
and -1.09 respectively). It was not possible to distinguish patients with a GLUD1 mutation
from those with a HADH mutation based on these two features. Patients with GLUD1
mutation or HADH mutation share further similarities in terms of being leucine sensitive
(chapter 7). In the vast majority of patients, a serum ammonia concentration would help in
distinguishing between the two aetiologies (raised in the majority of patients reported with
GLUD1 mutation). The other distinguishing feature would be a history of consanguinity as
HADH mutations reported so far have been recessively inherited and described to occur in
consanguineous families while GLUD1 mutations are dominantly inherited.
How do mutations in the HNF4A gene cause CHI?
HNF-4 has a key role in regulating the multiple transcriptional factor networks in the islet
and in combination with other hepatocyte nuclear factors (such as HNF-1α) has been 
proposed to form a functional regulatory loop in the adult ß-cell (Boj et al., 2001; Odom et
al., 2004). It interacts with regulatory elements in promoters and enhancers of genes
whose products are involved in diverse functions such as cholesterol, fatty acid, amino
acid, and glucose metabolism, as well as liver development and differentiation (Mietus-
Snyder et al., 1992, Hall et al., 1995). HNF-4 seems to be indispensable for development
as targeted disruption of this gene results in defective gastrulation of mouse embryos due
to abnormal development of the visceral endoderm (Chen et al., 1994). Since loss of HNF-
4 function leads to multiple defects (defective mitochondrial metabolism, impaired
mitochondrial tricarboxylic acid cycle enzyme activity and partial uncoupling of the
mitochondrial respiratory chain) (Wang et al., 2000) in glucose stimulated insulin secretion
it is unclear how heterozygous HNF4A mutations can also cause HH in the newborn
period. Using the conditional Cre-loxP-based inactivation system and deleting the HNF4A
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gene in ß-cells, Gupta et al. (Gupta et al., 2005) were able to show that fasted and fed
mice were hyperinsulinaemic but paradoxically also displayed impaired glucose tolerance.
These mice showed a 60% reduction in expression of the potassium channel subunit
Kir6.2 with cotransfection assays demonstrating that the Kir6.2 gene is a transcriptional
target of HNF-4 . However two further studies have reported no change in the expression
of Kir6.2 in Hnf4a- deficient mice (Pearson et al., 2007; Miura et al., 2006). This suggests
that the reduction in expression of the potassium channel subunit Kir6.2 may not be the
only mechanism responsible for the HH in Hnf4a- deficient mice.
HNF-4 also been shown to have an interaction with the nuclear receptor peroxisome
proliferator-activated receptor alpha (PPARα) with low levels of PPARα reported in HNF-
4 deficient ß-cells (Gupta et al., 2005). PPARα acts as a general sensor of overall tissue 
lipid supply and activates genes encoding enzymes of the ß-oxidation pathway of fatty
acids. A decrease in ß-oxidation of fatty acids results in the accumulation of lipids (such as
malonyl-CoA) in the cytoplasm. Increased malonyl-CoA inhibits the enzyme carnitine-
palmitoyltransferase 1 (CPT-1) thereby increasing cytosolic long-chain acyl-CoA (LC-CoA)
levels, which signal directly or indirectly via fatty acid esterification and/or protein acylation
processes to augment insulin release (Prentki et al., 2002).
Given the postulated role of PPARα in the regulation of ß-cell lipid metabolism, it is
possible that the lower level of PPARα in the HNF-4 mutants partially contributes to the
elevated basal insulin levels (Sugden and Holness, 2004). In support of this hypothesis
PPARα null mice develop fasting HH suggesting that PPARα is important for regulated 
insulin secretion during fasting (Gremlich et al., 2005). HNF-4 binds to the promoters of
11% of islet genes and it is quite likely that HNF-4 deficiency probably exhibits its
phenotype via abnormal expression of one or more of these target islet genes (Odom et
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al., 2004). Hence, further studies are required to study the effect of HNF-4 deficiency on
these genes.
Apart from understanding the mechanism of HH and diabetes due to HNF4A mutations, it
would be interesting to study the glucose tolerance of these patients in the interim period
after resolution of HH and development of overt diabetes. A long term prospective study
assessing glucose physiology in these patients may provide valuable clues in the further
understanding of the function of HNF4A and pancreatic insulin secretion.
8.5 Conclusions
Very little is known about CHI due to mutations in the HNF4A gene. Our previous
knowledge about the phenotype of the babies with a HNF4A mutation was limited to one
study that retrospectively studied the birth weights and history of hypoglycaemia in
children of patients with HNF4A MODY. These data have shown that CHI due to
heterozygous mutations in the HNF4A gene is not limited to mild, transient hypoglycaemia.
In fact, CHI due to this genetic aetiology can vary in severity and duration and must be
thought of even in cases with severe, persistent HH.
The study confirms that HNF4A mutations are associated with large for gestational age
babies, but this is not a distinguishing feature due to overlap of this feature with KATP
channel mutations. The data also points out that a history of MODY in the family is also not
an essential (though important) feature of CHI due to mutations in the HNF4A gene.
A genetic diagnosis is important for these patients as it predicts the likelihood of later
sulfonylurea-sensitive diabetes and a high risk of having macrosomic babies. Hence, on
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the basis of this study, it would be recommended that neonates with diazoxide responsive
CHI without a KATP channel mutation should be screened for mutations in the HNF4A
gene, especially in the presence of macrosomia and/ or a family history of young onset
diabetes.
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Chapter 9
Diabetes Mellitus and Congenital Hyperinsulinism due to
Dominant ABCC8/KCNJ11 Mutations
9.1 Introduction
Dominantly inherited mutations in the ABCC8/ KCNJ11 genes are known to cause mild,
diazoxide responsive CHI. The dominantly inherited mutations have been reported to
impair the ability of MgADP to stimulate channel activity with normal expression of the KATP
channels at the surface membrane (Pinney et al., 2008; Abdulhadi-Atwan et al., 2008).
Two reports suggest that CHI due to dominantly inherited mutations in the ABCC8 gene
may progress to diabetes mellitus in later life (Huopio et al., 2000, Abdulhadi-Atwan et al.,
2008). However, this was not supported by a case series by Pinney et al. where only 4 out
of 29 adults developed diabetes. Therefore, it is not yet clear whether the dominantly
acting mutations in these genes predispose to diabetes mellitus in adulthood or not.
In our cohort, there are 14 patients (from 10 families) with nine dominantly inherited KATP
mutations and diazoxide responsive CHI. This chapter focuses on the phenotype of these
10 families, with the aim to characterise the phenotype of the dominantly inherited
ABCC8/KCNJ11 mutations causing CHI and to study the prevalence of diabetes mellitus in
the adult mutation carriers. Of the nine mutations, six mutations are novel, not previously
described to be associated with CHI. In order to confirm the pathogenicity of these novel
mutations, functional studies were carried out at the Rayne Institute, UCL under the
supervision of Professor Andrew Tinker. This chapter gives details of these studies where
functional consequences of the mutations were examined by reconstituting the KATP
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channel in HEK293 cells and evaluating the effect of drugs (diazoxide, glibenclamide) and
metabolic poisoning on the channels using 86Rb flux assay.
9.2 Methodology
9.2.1 Patients
The phenotype of the fourteen children reported to be heterozygous for a dominantly
inherited mutation in the KATP channel genes were studied in detail. This includes thirteen
patients with eight different heterozygous mutations in the ABCC8 gene and one patient
heterozygous for a mutation in the KCNJ11 gene. Six of the eight ABCC8 mutations were
novel (L1390R; c.4169T>G, L1431F; c.4291C>T, Q1459E; c.4375C>G, G1479A;
c.4436G>C, A1508P; c.4522G>C, A1537V; c.4610C>T) and two have been reported
previously in patients with dominantly inherited CHI (G1479R; c.4435G>A and R1539Q
c.4616G>A) (Pinney et al., 2008). Each mutation was identified in a single family with the
exception of G1479R which was identified in two unrelated families. All mutations affected
residues that are highly conserved across several species and occurred within the
nucleotide-binding domain 2 (NBD2) of SUR1, a previously reported hotspot for
dominantly acting mutations. The remaining patient was heterozygous for an inframe
deletion (I284del; c.850_852delATC) in the KCNJ11 gene. The isoleucine at residue 284
in Kir6.2 is conserved across species.
Family member testing was undertaken when DNA was available (for the pedigrees see
figure 9.1). For two probands there was no family history of hypoglycaemia or diabetes
(family I, II-1 and family J, II-1). Testing of the unaffected parents demonstrated that the
L1390R and G1479A ABCC8 mutations had arisen de novo in the proband. In 7/8 families
the proband had inherited the mutation from a parent who was affected with
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hypoglycaemia or diabetes. In the remaining case (family C, III-2) although the mutation
had been inherited from the unaffected father, G1479R was shown to co-segregate with
HH in the family having been identified in the proband’s two affected siblings and maternal
cousin.
To understand the phenotype of the 14 patients with hyperinsulinism, data was collated
on:
1) birth weight,
2) age of presentation,
3) diazoxide-responsiveness and
4) duration of hyperinsulinism
For the adult mutation carriers (n=16), the phenotypic features studied, included:
1) birth weights (where available),
2) presence/ absence of hypoglycaemia (past and current),
3) duration of hypoglycaemia (where applicable),
4) presence/ absence of diabetes mellitus
5) type of diabetes mellitus (gestational or other)
6) age of presentation of diabetes mellitus (where applicable)
7) and treatment details, if diagnosed with non-gestational diabetes mellitus
Birth weight SDS of the patients and the adult mutation carriers was calculated. The
clinical characteristics (birth weight SDS and age of presentation) are presented as mean.
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Figure 9.1: Partial pedigrees showing inheritance of the dominant mutations in the 10
families. Circles represent females and squares indicate males. Probands are indicated by
an arrow. Vertical hatching denotes diabetic individuals and diagonal hatching represents
gestational diabetes. Filled symbols denote children with HH while symbols with square
hatching represent adults with past/ current hypoglycaemia. Individuals who progressed
from hypoglycaemia to diabetes are indicated by symbols that are half filled and half
hatched horizontally. The genotype is given below each symbol. M/N denotes a
heterozygous ABCC8/ KCNJ11 mutation and N/N a normal genotype.
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9.2.2 Functional analysis of novel mutations
Mutations were introduced into SUR1 or Kir6.2 using the Stratagene QuikChange site-
directed mutagenesis kit (Stratagene, La Jolla, CA). Mutated plasmid DNA was then
transformed into bacteria, purified and sequenced to ensure that the mutation had been
incorporated into the cDNA. Upon sequencing, the plasmid DNA was amplified in a large
scale culture providing large yields of mutated plasmid DNA. The functional consequences
of the mutations were then examined by expressing the mutant SUR1+WT-Kir6.2/ mutant
Kir6.2+ WT-SUR1 (by cell transfection) in HEK293 cell line and the effect on the KATP
channels was evaluated using 86Rb+ efflux assay. The details of each molecular biology
technique are described below.
9.2.2.1 Site directed mutagenesis
Mutations were introduced into hamster SUR1 cloned into the vector pcDNA3 (appendix
12.3, Invitrogen, Paisley, UK) (Giblin et al., 1999) and mouse Kir6.2 cloned into
pcDNA3.1+/Zeo (appendix 12.4, Invitrogen, Paisley, UK) (Giblin et al., 1999) with site-
directed mutagenesis using the QuikChange site-directed mutagenesis kit. Hamster SUR1
and mouse Kir6.2 proteins are very similar to the human counterparts and have been
extensively used to study the functional consequences of ABCC8/ KCNJ11 mutations
(Shyng et al., 1998; Taschenberger et al., 2002; Pinney et al., 2008). Moreover, we have
previous expertise in manipulating these clones (Muzumbya et al., 2007). The human
SUR1 sequence (NM_000352.2) was aligned to the hamster SUR1 sequence (L40623.1)
and the human Kir6.2 sequence (NM_000525) was aligned to the mouse Kir6.2 sequence
(NM_010602). It is worth clarifying that the mutations L1390R, L1431F, Q1459E, A1508P,
A1537V in human SUR1 are homologous to the L1390R, L1431F, Q1459E, A1508P,
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A1537V in hamster SUR1 and the mutation I284del in human Kir6.2 is homologous to the
I284del mutation in mouse Kir6.2.
Site directed mutagenesis utilizes two oligonucleotide primers, complementary to the
opposite strands of the cDNA, both containing the desired mutation. The primers are
extended during temperature cycling by PfuUltra HF DNA polymerase which results in a
mutated plasmid containing staggered nicks. The product is then treated with Dpn I, an
endonuclease that specifically digests the methylated and hemimethylated DNA. Since
DNA isolated from G dam (+) E. coli strain is dam methylated, Dpn I digestion selectively
digests parental DNA. The nicked vector DNA containing the desired mutations is then
transformed into XL1- Blue supercompetent cells (Stratagene, La Jolla, CA) in which the
nicks are repaired and the DNA amplified.
9.2.2.2 Primer design
Individual oligonucleotide primers containing the mutation and complementary to the
opposite strands of the cDNA, were designed according to the desired mutation. Each
primer was between 25-45 bases and designed such that the mutation was in the middle
of the primer with 10-15 bases of sequence on both sides. The melting temperature (Tm)
of each primer was >/= 78oC, using the formula
Tm= 81.5 + 0.41 (%GC)- 675/N- %mismatch
where, N is the primer length in bases and values for %GC and % mismatch are whole
numbers. For calculating Tm for primers introducing deletions, the formula was modified
to: Tm= 81.5 +0.41(%GC) -675/N, where N does not include the bases that are being
deleted.
The mimimum GC content of each primer was 40% and the primers terminated in one or
more C or G bases.
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The following primers were designed to create point mutations in the hamster SUR1
cDNA:
1. L1390R (Tm- 85.48)
SENSE: GGGAAGTCCTCCTTCTCCCGGGCCTTTTTCCGAATGGTG
ANTISENSE: CACCATTCGGAAAAAGGCCCGGGAGAAGGAGGACTTCCC
2. A1537V (Tm- 86.7)
SENSE: CGCACGGTGGTCACCATCGTGCATCGTGTGCACACCATC
ANTISENSE: GATGGTGTGCACACGATGCACGATGGTGACCACCGTGCG
3. Q1459E (Tm- 86.7)
SENSE: GAGGCCCTGGAGATCGCCGAGCTGAAGCTGGTAGTGAAG
ANTISENSE: CTTCACTACCAGCTTCAGCTCGGCGATCTCCAGGGCCTC
4. L1431F (Tm= 85.48)
SENSE: CTACAGGACCCCGTCTTCTTCAGCGGCACGATCAG
ANTISENSE: ATCGTGCCGCTGAAGAAGACGGGGTCCTGTAGGATG
5. A1508P (Tm=81.32)
SENSE: ATCTTCATCATGGATGAACCAACCGCCTCCATCGACATG
ANTISENSE: CATGTCGATGGAGGCGGTTGGTTCATCCATGATGAAGAT
A1508P mutation primers (Tm 85.2) were redesigned as mutagenesis reaction with the
above primer pair was unsuccessful (2 attempts):
SENSE: CAGCATCTTCATCATGGATGAACCAACCGCCTCCATCGACATGG
ANTISENSE: CCATGTCGATGGAGGCGGTTGGTTCATCCATGATGAAGATGCTG
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The following primers were designed to create the I284del mutation in the mouse Kir6.2
cDNA:
6. I284del (Tm=87.7)
SENSE: CACCAGGACCTCGAGATCGTCATCCTGGAAGGCGTG
ANTISENSE: CACGCCTTCCAGGATGACGATCTCGAGGTCCTGGTG
I284del primers were also re-designed (Tm=88.3) following two unsuccessful attempts
at mutagenesis with the above primers:
SENSE: CACCACCAGGACCTGGAGATCGTCATCTTGGAAGGCGTG
ANTISENSE: CACGCCTTCCAAGATGACGATCTCCAGGTCCTGGTGGTG
The mutagenesis reaction was prepared in a thin-walled PCR tube as below:
5μl 10x reaction buffer 
50ng of dsDNA template
125ng of primer #1
125ng of primer #2
1μl dNTP mix 
ddH2O to a final volume of 50μl 
Finally, 1μl of PfuUltra HF DNA polymerase was added and the reaction was cycled as 
follows:
Step 1: Initial denaturation 95oC for 30 seconds
Step 2: Denaturation 95oC for 30 seconds
Step 3: Annealing of primers to template 55oC for 60 seconds
Step 4: Elongation of mutant primers 68oC for 2 minutes per kilobase (kb) of
plasmid length
Step 2 to step 4 was repeated for 16 cycles and the reaction was cooled to 4oC.
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Following temperature cycling, 1μl of Dpn I restriction enzyme was added to each reaction 
and thoroughly mixed by pipetting the reaction several times. The reaction mix was then
spun in a microcentrifuge for 1 minute and incubated at 37oC for 1 hour to digest the
parental DNA.
9.2.2.3 Glycogen precipitation of DNA
Glycogen is insoluble in ethanol and forms a precipitate that traps nucleic acids. After Dpn
I treatment, 0.5μl of glycogen (20mg/ml) and 120μl of cold 100% ethanol was added to the 
reaction. The reaction was mixed and stored in -20oC for 2-3 hours. The mix was then
centrifuged for 15 minutes at 14,000xg at 4oC to pellet the precipitated nucleic acids. The
supernatant was discarded and the pellet was re-dissolved in 5μl of molecular biology 
grade water after air drying at room temperature for 10 minutes.
9.2.2.4 Transformation of XL1- Blue Supercompetent Cells
Transformation is the process by which foreign DNA is introduced into bacteria. 50μl of 
XL1- Blue supercompetent cells gently thawed on ice, were incubated with 2.5μl of DNA 
after glycogen precipitation. This reaction was incubated on ice for 30 minutes and then
heat shocked at 42oC for 45 seconds to introduce the DNA into the bacterium. Immediately
after heat shocking, the cells were placed on ice for 2 minutes, followed by incubation at
37oC for 1 hour after adding 500μl of Lucia-Bertani (LB) broth. LB broth was prepared by 
adding 1 LB tablet (Sigma- Aldrich, USA) per 50mls of ddH2O. The cells were then pelleted
and re-suspended in 100μl of warm LB before plating. LB plates containing carbenicillin at 
a final concentration of 80μg/ml were used. Discrete colonies were observed after the 
plates were incubated for 12-16 hours at 37oC.
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9.2.2.5 Purification of plasmid DNA
Following bacterial transformation, a single colony was picked and added to 5mls of LB
broth containing 5μl of carbenicillin (100 mg/ml). The culture was incubated overnight with 
orbital shaking (~225rpm) at 37oC. The following morning, the cells were harvested by
centrifugation at 6,000xg for 15 minutes at 4oC. The supernatant was discarded and the
plasmid DNA was purified using the QIAGEN plasmid purification Mini-prep kit (QIAGEN,
Crawley, Sussex) according to the manufacturer’s guidelines.
The QIAGEN purification kits use an anion-exchange resin to bind to plasmid DNA. It
removes the impurities, dyes, proteins and RNA by washing with a medium-salt buffer and
then eluting plasmid DNA with a high salt buffer. Plasmid DNA is then concentrated and
desalted by isopropanol precipitation. Various QIAGEN purification kits are available that
yield different quantities of DNA. Generally, 10-20μg DNA is obtained using the Mini-prep 
kit; 100μg of DNA is obtained using the Midi-prep kit and up to 500μg may be obtained 
using the Maxi-prep kit.
9.2.2.6 Sequence analysis
After purification of the plasmid DNA, the DNA was sequenced (Geneservice, UCL,
London) to confirm that mutagenesis was successful.
I designed the following primers to sequence the regions:
For mutations L1390R, L1431F, Q1459E (ABCC8):
AGCGTGCGCTATGACAGC
For mutation A1537V (ABCC8):
CGGGCCTTCGTGAGGAAG
For mutation A1508P (ABCC8):
ACACTGTGGGAGGCCCTG
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And for mutation I284del (KCNJ11):
GAGGGCGAAGTTGTGCCTCTC
9.2.2.7 Re-transformation and DNA purification
Following confirmation of the DNA sequences, the mutated plasmid DNA was re-
transformed and purified using the QIAGEN Maxi-prep kit as large quantities of DNA were
required for subsequent experiments.
100μl of thawed Top10 competent E.coli cells were incubated with 1μl of purified plasmid 
DNA on ice for 30 minutes and then heat shocked at 420C for 90 seconds. The reaction
was then chilled on ice for 2 minutes and 800μl of warm LB media was added.  
As described above, the reaction was then centrifuged at 14,000xg for 1 minute and the
cell pellet was re-suspended in 100μl of warm LB broth before plating on LB-carbenicillin 
agar plates. Discrete colonies from transformed bacteria were observed after the plates
were incubated for 12-16 hours at 370C. Following re-transformation, a single colony was
picked and cultured as before. Mutated plasmid DNA was then purified using the QIAGEN
Maxi-prep kit according to the manufacturer’s guidelines.
9.2.2.8 Cell culture
Studies were performed using the HEK293 cell line, an immortalised human cell line
derived from primary embryonic kidney cells (obtained from Dr LY Jan, UCSF).
Growth and maintenance of the cell line:
The cells were grown in a T75 (75cm2) (VWR, Merck House, UK) tissue culture flask in
humidified atmosphere of 95% oxygen and 5% CO2 in Minimum Essential Medium (MEM)
containing Earle’s salt and L-Glutamine (Invitrogen, Paisley, UK). The medium was also
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supplemented with 10% Foetal Bovine Serum (FBS, Invitrogen, Paisley, UK) and 1%
penicillin- streptomycin (from a stock of 1mg/ml streptomycin and 10,000 units/ml
penicillin). The cells were subcultured when 90% confluent (generally once a week).
Preparation of cells for Rb flux experiments: Splitting cells into 35mm dishes-
To prevent contamination, the cells and media were handled in a vertical laminar air flow
hood, using sterile techniques. After removing the media from the T75 flask, the cells were
washed twice with 10mls of Ca2+, Mg2+ free Dulbeccos’ phosphate buffered saline (PBS,
Invitrogen, Paisley, UK). The cells were then treated with 2mls of 0.25% trypsin EDTA mix
in PBS buffer for 2-4 minutes to detach the cells. To stop trypsinisation, 8mls of MEM was
added and the cells were then transferred in the media to a 50ml tube (Strastedt, UK). The
cells were then pelleted by centrifugation for 2-3 min at 340g. After discarding the
supernatant, the cell pellet was re-suspended in 31mls of MEM. 1ml each of the cells was
added to each well of a 6 well plate (with wells of 35mm diameter, Triple Red, UK),
resulting in 30 wells. To each well, a further 1ml of the medium was added so that the
volume was 2mls/ well. The remaining 1ml of cells was used to seed a new T75 flask, to
which 9mls of MEM was added.
9.2.2.9 Transfection
Transfection is the process by which foreign DNA is introduced into a cell line. Once in the
cytoplasm, DNA uses the host cell’s transcriptional and translational machinery to express
proteins. For these studies, FUGENEHD (Roche, UK) was used which is a nonliposomal
transfection reagent that uses a polycationic head group to attach to the negatively
charged DNA. The complex is then taken up by the cell via endocytosis.
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Since the KATP channel is an octameric compound comprising of SUR1 and Kir6.2
components, mutant SUR1 was co-transfected with WT Kir6.2 and a small amount of the
enhanced variant of the green fluorescent protein (eGFP) cloned into peGFP-n1 (appendix
12.5, Clontech laboratories). Similarly, while studying the effect of a mutant Kir6.2 protein,
it was co-transfected with WT SUR1 and eGFP. Control cells were transfected with WT
SUR1, WT Kir6.2 and eGFP. The co-transfection of eGFP enabled me to assess the
transfection efficiency using epifluorescence.
Transfection was carried out 24 hours after sub-culturing the HEK293 cells in the 6 well
plates. Individual transfection mixtures were prepared containing 2μg of SUR1, 500ng of 
Kir6.2, 50ng of eGFP, 94μl of serum free MEM and 6μl of FUGENE HD in 1.5mls 
centrifuge tubes. The mixtures were vortexed thoroughly and left at room temperature for
30 minutes to allow complex formation. The individual mixtures were then added directly to
individual wells and incubated overnight.
9.2.2.10 Loading of 86Rb and 86Rb Flux assay
If transfection was successful (>80 % efficiency, as evidenced by >80% cells expressing
eGFP), the cells were loaded with 86Rb 24 hours after the transfection of cells. The existing
medium was removed from each well and replaced by MEM containing 0.037 MBq/ml of
86Rb. The cells were then left for 24 hours in optimum conditions (5% CO2, 37oC) in a
Perspex box. The lid of the box was left slightly open to allow for gas exchange.
86Rb Flux assay
86Rb is an ideal element to study the conductance of K+ via the K+ channels as it is similar
in size and charge and is handled by the channels in a manner similar to K+. The 86Rb
efflux assay is based on the principle that when cells are loaded with rubidium, its
174
distribution between intracellular and extracellular spaces is an indicator of channel
activity. Hence, the function of the channel can be studied by measurement of Cherenkov
radiation following exposure of cells to channel activators, inhibitors or genetic
manipulations (Muzyamba et al., 2007).
The 86Rb flux assay experiment was carried out in a designated area for handling
radioactive substances. It was necessary to handle 86Rb in a specific room behind a lead
shield to minimise exposure to ß-radiation. Whole body dosimeters were worn to monitor
the exposure to 86Rb. A Geiger-Mueller detector was used during the experiment to
monitor spillage. Solid waste was collected in sealed, shielded containers and liquid waste
was disposed in the designated sinks. Detailed records were maintained throughout each
experiment regarding the amount of 86Rb in the vial (by calculating decay), amount used
for each experiment and the amount of solid/ liquid waste disposed.
Procedure: First, the loading media was removed from each well and the cells were
washed twice with 2mls of HEPES Buffered Saline (HBS). The constituents of HBS
included 10mM HEPES, 10mM anhydrous Glucose, 130mM Nacl, 7mMKCl, 2mM CaCl2
(2H2O) and 1mM MgCl2, (6H2O) adjusted to a pH of 7.4 (using NaOH) and autoclaved prior
to use. The cells were then incubated with 2ml of HBS medium with or without channel
stimulants and/ or inhibitors. The following conditions were used:
 control cells,
 cells treated with 100μM diazoxide,  
 cells treated with 100μM diazoxide plus 10μM glibenclamide, 
 cells treated with 2.5mM NaCN and 20mM 2-deoxy-D-glucose (metabolic
inhibition, MI) and
175
 cells treated with 2.5mM NaCN, 20mM 2-deoxy-D–glucose and 10μM 
glibenclamide
The concentrations of the drugs stated have been shown to be effective on this cell line
(Muzyamba et al., 2007). The supernatant was aspirated after 5 minutes into 6mls
polyethylene scintillation vials (Packard Biosciences) for counting. The cells were then
lysed with 2% Triton/HBS solution and the cell lysates were aspirated into separate
scintillation vials. Cherenkov radiation in the supernatant and cell lysates was measured in
a liquid scintillation counter (TriCarb, Packard 2000CA). The percentage efflux was
calculated using:
86Rb content of the medium
(86Rb content of medium + 86Rb content of cells)
Three wells of cells were individually transfected for exposure of each drug per
experiment, which was repeated three times (n=9).
Statistical analysis:
The data were analysed in Microsoft Office Excel 2003 and Graph Pad Prism 4 (Graph
Pad Software, San Diego, CA, USA, www.graphpad.com). All data are presented as mean
+/- SEM. Significant differences were tested for by employing the one-way ANOVA and
Bonferroni post-test. Significant differences are reported as: * indicated P</= 0.05, **
indicates P</= 0.01 and *** indicates P</=0.001.
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9.2.2.11 SDS-PAGE and Western Blotting
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and Western
blotting were used to detect the level of mutant protein expression.
Principle: Gel electrophoresis separates proteins by molecular weight. The proteins are
then transferred onto a stable membrane that is probed with an antibody specific to the
protein of interest. A secondary antibody (conjugated to horseradish peroxidase (HRP)) is
then used to detect the bound (primary antibody) which itself can be detected using
enhanced chemiluminescence (ECL). The ECL technique is based on the principle that the
light emitting chemical ‘luminol’ is oxidised by HRP conjugated to the secondary antibody.
ECL is achieved by activating oxidation of luminol by HRP in the presence of chemical
enhacers (such as phenol) which enhances the emission of light by 100 fold, making it
easier to detect light. The light from the reaction is captured on a photographic film
creating an image of the antibodies bound to the blot.
Method:
Sample preparation:
HEK293 cells were first transfected with 2μg of WT SUR1 (control) or SUR1 mutants 
(A1537V, Q1459E, L1431F, L1390R), 500ng of WT Kir6.2 and 50ng of eGFP in 6-well
dishes (35mm diameter). Untransfected HEK293 cells were used as control. After 24
hours, the cells were harvested in Phosphate Buffered Saline or PBS (PBS tablets, Sigma-
Aldrich, USA) and resuspended in 50μl of PBS + 50μl of 2x SDS loading buffer (0.0625M 
Tris-HCl (pH 6.8), 2%SDS, 10%glycerol, 0.001% bromophenol blue. 0.1M dithiothreitol
(DTT)). The samples were then sonicated for 15 seconds and the protein denatured by
heating to 95oC for 5 minutes.
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SDS-PAGE:
Each sample was then resolved on an 8% polyacrylamide gel. The resolving gel was first
prepared (6.66 mls acrylamide 29:1 (30%), 5mls 1.5M Tris pH 8.8, 200μl 10% ammonium 
persulphate, 200μl 10% SDS, 10μl TEMED, 7.9mls ddH2O) and allowed to set. Then a 4%
stacking gel (1.7mls acrylamide 29:1 (30%), 1.25mls 1.5M Tris pH 8.8, 100μl 10% 
ammonium persulphate, 100μl 10% SDS, 10μl TEMED, 6.8mls ddH2O) was prepared and
poured on top of the resolving gel. Combs were inserted and the gel was allowed to set.
The protein samples were then loaded in the wells and separated by electrophoresis
(120V for 90 minutes). On application of the voltage, the proteins travel towards the anode
at different speeds based on their size. To help determine the molecular weight of the
seperated protein, a ladder was also loaded onto each gel which is a commercially
available mixture of proteins with defined molecular weights (Biorad plus protein
standards).
Western Blotting:
The proteins were then transferred by blotting to nitrocellulose membrane in transfer buffer
(25mM Tris, 192mM glycine, pH 8.3). The gels were sandwiched with a nitrocellulose
membrane between filter paper and sponges. Transfer was performed at 100V for 60
minutes at 4oC.
Antibody detection:
Remaining nonspecific binding sites on the membrane were blocked using 5% skimmed
milk blocking buffer (5% skimmed milk powder in PBS + 0.1% Tween 20 (PBST)) for 1
hour at room temperature. Membranes were then probed with a sheep anti-SUR1 NBD2
polyclonal antibody raised to the peptide sequence ETLLSQKDSVFASFVRADK(C)
(developed at The University of Dundee) (1:1000 dilution in PBST+ 5% non fat milk) or
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mouse anti-GFP monoclonal antibody (Roche, UK) (1:1000 dilution in PBST+ 5% non fat
milk) overnight at 4oC. The membranes were then washed 1 x 15 minutes in PBST and 2 x
5 minutes. The primary antibody was then incubated with an HRP-conjugated secondary
antibody for 1 hour at room temperature. An anti-sheep IgG raised in donkey (Sigma-
Aldrich, USA) was used to probe the primary anti-SUR1 antibody at 1:5000 dilution and an
anti-mouse IgG raised in goat (Jackson Immunoresearch, USA) was used to probe the
primary anti-GFP antibody at 1:10,000 dilution. The membrane was finally washed with
PBST 1x 15 minutes and 4 x 5 mins, prior to detection.
ECL Detection:
Protein-antibody complexes were detected using an ECL plus western blotting detection
system as per the manufacturer’s instructions (Amersham Biosciences UK Ltd). Molecular
masses were determined by comparison to the Bio-Rad Precision Plus protein standards.
9.3 Results
9.3.1 Phenotype of the patients with CHI
The clinical characteristics of the 14 children are summarised in table 9.1. The mean age
of presentation with hypoglycaemia was 27.3 days, with all except one presenting within
the first week of life. The mean birth weight SDS of the children was +2.06. 12/14 patients
responded to diazoxide and have persistent HH, while two others had resolution of
hypoglycaemia within the neonatal period and hence were not treated with diazoxide. Two
siblings who were heterozygous for the same mutation (R1539Q) in the ABCC8 gene had
varying duration of HH, with one persisting at 3.2 years whilst resolving within a week after
birth in the other.
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Table 9.1: Clinical characteristics of the 14 children with HH: The mean birth weight was
+2.06 SDS. The patients presented early at a mean age of 27.3 days. The duration of HH
was variable between few days to 11 years.
Patient Family Mutation/
gene
Birth
wt SDS
Age of
presentation
Diazoxide
responsive
Length of treatment
with diazoxide
1 A A1537V/
ABCC8
+4.66 1 day Yes Continuing at 4 years
2 B G1479R/
ABCC8
+1.37
(twin II)
1 day Yes Continuing at 11 years
3 C G1479R/
ABCC8
+2.82 1 day Yes Continuing at 1.4 years
4 C G1479R/
ABCC8
+1.65 2 days Yes Continuing at 8.5 years
5 C G1479R/
ABCC8
+2.23 2 days Yes Continuing at 5.1 years
6 C G1479R/
ABCC8
+1.93 2 days Yes Continuing at 1.5 years
7 D Q1459E/
ABCC8
+3.14 1 day Yes Continuing at 5.8 years
8 E I284del/
KCNJ11
+1.48 1 day Yes Continuing at 1.8 years
9 F R1539Q/
ABCC8
+2.19 1 day Yes Continuing at 3.2 years
10 F R1539Q/
ABCC8
+0.07 1 day n/a n/a
11 G L1431F/
ABCC8
-0.98 1 year Yes Continuing at 2.5 years
12 H A1508P/
ABCC8
+4.09 1 day Yes Continuing at 9.2 years
13 I L1390R/
ABCC8
+3.22 1 day Yes Continuing at 11 years
14 J G1479A/
ABCC8
+1.02 3 days n/a n/a
n/a: not applicable, as had transient HH that did not require treatment with diazoxide
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9.3.2 Phenotype of the adult mutation carriers
Birth weight SDS data were available for 10 adult mutation carriers. The mean birth weight
SDS of the adult mutation carriers was +0.88 (range -2.1 to +3.05) and five adults were
macrosomic. Figure 9.1 shows the pedigrees of the 10 families with a dominant KATP
channel mutation. As shown in figure 9.1, of the sixteen mutation carriers identified, two
adults have persisting hypoglycaemia at 28 and 39 years of age (family A, II-2 and family
F, III-2) whilst one adult has a history of neonatal hypoglycaemia (family E, II-1). Two other
adults have a past history of hypoglycaemia progressing to overt diabetes mellitus at 30
and 38 years of age (individuals II-2 and III-2 in families B and H respectively). Of the
remaining eleven adult mutation carriers, three were diagnosed with diabetes mellitus at
20, 47 and 50 years of age (family G, III-5; family F, II-4 and family H, II-2 respectively)
whilst three other adult mutation carriers have developed gestational diabetes (II-3, II-2
and III-4 in families A, D and F respectively). The remaining five adults (family A I-2,
Family C I-2, II-2, II-3 and family F III-3) have remained asymptomatic at ages 57, 73, 32,
37 and 35 years respectively.
9.3.3 Functional analysis of mutant channels
Expression and functional effects of six novel mutations were studied using SDS-PAGE
and western blot and 86Rb flux assays. Of the remaining three mutations, ABCC8 R1539Q
and G1479R mutations have been functionally characterised previously (Pinney et al.,
2008) and hence these mutations and another mutation (G1479A) occurring at the same
residue were excluded from the functional studies. 85% of transfections carried out were
successful. 86Rb flux assay showed that the channels expressing the mutant proteins
(SUR1- A1508P, L1431F, L1390R, Q1459E and A1537V or Kir 6.2- I284del) were non-
functional (figure 9.2) as evidenced by the lack of 86Rb efflux on exposure to the channel
agonist diazoxide or metabolic inhibition. Expression of the mutant SUR1 proteins L1431F,
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L1390R, Q1459E and A1537V did not differ from the WT SUR1 protein on western blot
analysis (figure 9.3).
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Figure 9.2: The effects of SUR1/ Kir6.2 mutants on KATP channel function studied with 86Rb efflux. The 86Rb efflux was assayed in
control cells (red; no drugs), cells treated with 100μM diazoxide (green), cells treated with 100μM diazoxide plus 10μM glibenclamide 
(blue), cells treated with 2·5mM NaCN and 20mM 2-deoxy-D-glucose (MI) (purple) and cells treated with MI and 10μM glibenclamide 
(yellow). Efflux was calculated as %efflux of initial 86Rb content. Data are shown as +/- SEM, whereby n=9. Significant differences
are reported as: * indicates P</= 0.05, ** indicates P </= 0.01 and *** indicates P </=0.001.
A: Channel agonist diazoxide and MI activated the wild-type (WT) channels, evidenced by an increase in the 86Rb efflux from
baseline. In contrast, there was no significant increase in the 86Rb efflux when the mutant channels (expressing the ABCC8
mutations L1431F, A1508P or the KCNJ11 mutation I284del) were stimulated, suggesting a loss of function of the KATP channels.
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Figure 9.2B: The effect of the ABCC8 mutations Q1459E, A1537V and L1390R on the function of the KATP channels as shown by
86Rb efflux. As opposed to the wild-type (WT) channels, there was no significant increase in the 86Rb efflux when the mutant
channels were exposed to channel agonist diazoxide or metabolic inhibition, suggesting a loss of function of the KATP channels. Data
are shown as +/- SEM, whereby n=9.
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9.4 Discussion
This case series confirms the mild, diazoxide responsive HH reported with dominantly
inherited mutations in the ABCC8 and KCNJ11 genes (Pinney et al., 2008; Huopio et al.,
2000; Abdulhadi-Atwan et al., 2008). 12/14 children that were heterozygous for a mutation
in these genes and developed HH responded to diazoxide; whilst the remaining two had
transient hypoglycaemia limited to the neonatal period. This includes a pair of siblings
(family F- figure 9.1) heterozygous for the previously described R1539Q mutation in the
ABCC8 gene who had hypoglycaemia for varying durations. The elder sibling required
brief treatment with intravenous glucose after birth while the younger sibling continues to
require diazoxide therapy at 3 years of age, demonstrating that the phenotype of HH can
be varied within the same family.
Of the 16 adult mutation carriers, two were recognized to have hypoglycaemic episodes
after the diagnosis of the children with HH. Three others have a previous history of
hypoglycaemia of which one (family E) had transient hypoglycaemia requiring intravenous
glucose in the neonatal period while the other two (families B and H) had more persistent
hypoglycaemia that remitted in young adulthood. The remaining adult mutation carriers
(11/16) have no current/ past history of hypoglycaemia. This is consistent with the study by
Pinney et al. (Pinney et al., 2008) where 14/29 adults were asymptomatic. The incomplete
penetrance of symptomatic hypoglycaemia was a general feature rather than mutation
specific. This variability in the phenotype may be the effect of environmental factors or
modifying genes. It may also be related to the number of mutant channels expressed on
the pancreatic ß-cell membrane in different individuals. The KATP channels are hetero-
octameric complexes and the combination of mutated and wild type SUR1 and Kir6.2
proteins on the pancreatic ß-cells may differ in different individuals. Nevertheless, in-utero
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hyperinsulinism was evident by the increased birth weights of 5/10 mutation carriers.
Hence the hyperinsulinism phenotype of these dominant mutations varies from
asymptomatic macrosomia to transient hypoglycaemia that requires brief supportive
treatment to persistent HH requiring diazoxide for prolonged periods. The heterogeneity in
the clinical picture due to these mutations is comparable to the heterogeneity observed in
HH due to recessive mutations in the KATP channel genes (Nestorowicz et al., 1998).
It has been debated whether dominant mutations in the KATP channel genes causing HH
predispose to the development of diabetes mellitus in adulthood (Pinney et al., 2008;
Abdulhadi-Atwan et al., 2008; Huopio et al., 2000; Huopio et al., 2003, Magge et al., 2004).
Huopio et al. first reported a dominant inactivating ABCC8 mutation, E1506K that caused
HH progressing to hypoinsulinemic diabetes during middle age (Huopio et al., 2000;
Huopio et al., 2003). In their study of 11 adult individuals heterozygous for this particular
mutation; four had overt diabetes, five had impaired glucose tolerance, one had impaired
fasting glucose, and only one individual had normal glucose tolerance (Huopio et al.,
2003). Assessment of glucose tolerance of the adult mutation carriers showed severe
blunting of the first phase of glucose stimulated insulin secretion and reduced maximal
glucose stimulatory insulin capacity, suggesting that the primary defect lay in the insulin
secretory capacity. The individuals who developed diabetes showed a 15% reduction in
insulin sensitivity in comparison with those without diabetes with three of the four diabetic
individuals being overweight. The authors hypothesized that the primary insulin secreting
defect may be related to ß-cell apoptosis due to raised intracellular calcium concentrations
and that the accompanying insulin insensitivity may be the reason for conversion from
impaired glucose tolerance to diabetes. In support, insulin deficiency (attributed to
apoptosis) is seen in transgenic mice with congenital hyperinsulinism over expressing a
dominant negative form of Kir6.2 in pancreatic ß-cells (Miki et al., 1998). A recent report
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(Vieira et al., 2009) also confirms the association of this mutation (E1506K) with CHI in
childhood and diabetes mellitus in adulthood. In addition, Abdulhadi-Atwan et al.
(Abdulhadi-Atwan et al., 2008) have also described a patient with HH who was
heterozygous for a de novo mutation in the ABCC8 gene (R370S) and presented with
diabetes at 10.5y of age. This child was significantly obese (BMI of 30.2kg/m2), supporting
the hypothesis that insulin insensitivity in conjunction with a dominant mutation in the KATP
channel genes can predispose to the development of diabetes mellitus.
However, a recent study that looked at the prevalence of diabetes mellitus in a large group
of families with dominant KATP hyperinsulinism mutations (Pinney et al., 2008) did not
report an increased prevalence of diabetes mellitus in the adult mutation carriers. Only
13.8% of the carrier adults in this study were diagnosed with overt diabetes mellitus and 3
of 13 women were diagnosed with gestational diabetes during pregnancy. This prevalence
of diabetes in the adult mutation carriers was comparable with the estimated prevalence of
type 2 diabetes in adults in the United States, which ranges from 9.6% to 21% (Signorello
et al., 2007).
In contrast to the study by Pinney et al. (Pinney et al., 2008), our study found an increased
prevalence of diabetes in the adult mutation carriers. Two of the adult mutation carriers
(family B, II-2 and family H, III-2) have a clear progression of hypoglycaemia in early life to
diabetes in adulthood, with one of them being treated with insulin while the other is being
treated with metformin. Three others were diagnosed with diabetes at ages 20, 47 and 50
years. Of these three adults, individual II-5 in family G is being treated with insulin while
the other two are on oral hypoglycaemic agents. Interestingly, there is a strong family
history of young onset diabetes spanning three generations typical of MODY in family G.
Co-segregation of diabetes in this family would have confirmed the association of this
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mutation with early onset diabetes mellitus. However, unfortunately it has not been
possible to recruit the family members into the study. Apart from these five adult mutation
carriers who have developed overt diabetes mellitus, three other mutation carriers have
developed gestational diabetes. Excluding the two adults who currently have symptoms of
hypoglycaemia, the prevalence of diabetes (gestational or other) is high at 57% (8/14) in
the adult mutation carriers of our cohort. This may even be an underestimate as some of
these adults who do not have diabetes mellitus may go on to develop it later (two adults in
this cohort are < 30 years of age).
Studies looking at the functional consequences of dominant mutations in ABCC8/KCNJ11
so far have shown that these mutations cause decreased KATP channel responses to
MgADP/ diazoxide or impaired channel opening as opposed to the trafficking/ biogenesis
effects of recessive ABCC8/KCNJ11 mutations (Pinneyet al., 2008; Huopio et al., 2000).
Western blotting carried out on the four mutant SUR1 proteins demonstrated that the
mutant SUR1 proteins were expressed in the cell (Fig. 9.3). Using homozygous mutants
expressed in HEK293 cells I studied the effects of SUR1/ Kir6.2 mutants on KATP channel
function with 86Rb efflux. Neither the KATP channel agonist diazoxide nor metabolic
inhibition stimulated the mutant channels confirming that these mutations are disease
causing and not rare polymorphisms. However in-vivo it is likely that the pancreatic ß-cell
contains a combination of channel hetero-octamers (a mixture of mutated and wild type
SUR1 and Kir6.2 channels with ratios of 0 to 4 SUR1 or Kir6.2 mutant subunits) thus
explaining the in-vivo responsiveness to diazoxide. Further studies are required to
understand the molecular mechanism of disease due to these mutations. Along with 86Rb
efflux studies under heterozygous conditions (to mimic patient conditions), it would be
beneficial to study the effect of metabolic regulators (viz. MgADP, ATP) and drugs by
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inside out patch clamp studies (Pinney et al., 2008, Muzyamba et al., 2007; Cartier et al.,
2001).
9.5 Conclusions
This study demonstrates that dominant mutations in ABCC8/ KCNJ11 cause a varying
phenotype ranging from asymptomatic macrosomia to medically responsive HH in
childhood. In the adult mutation carriers the prevalence of diabetes mellitus (gestational or
other) was significantly high at 57% (8/14). Hence, dominant mutations in ABCC8/
KCNJ11 may be an important cause of MODY X i.e. MODY where no genetic aetiology
has been found. This has important implications for follow up of the children diagnosed
with dominant ABCC8/KCNJ11 mutations and the management of the adult carriers.
This study also opens up further avenues for translational research. Further studies are
required to establish the molecular mechanism of HH and diabetes due to these novel
mutations. It is also important to study why certain individuals heterozygous for loss of
function mutations in these genes develop diabetes mellitus and whether these individuals
have additional predisposing factors that lead to the development of diabetes. Clinical
studies looking at the glucose physiology of the adult mutation carriers would help in
classifying whether the diabetes is due to insulinopenia (due to ß-cell exhaustion) or
insulin insensitivity or a combination of both, as hypothesized by Huopio et al. (Huopio et
al., 2000). This cohort of adult mutation carriers hence forms a unique group of individuals
which could give further insights into the development of a common and important health
issue –diabetes mellitus. Finally, this study may have implications for the diagnosis of
patients with MODY-X. Screening a cohort of patients will help determine whether
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mutational analysis of the ABCC8/KCNJ11 genes should be incorporated into the
molecular diagnostic work-up of patients with MODY.
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Chapter 10
Summary and Future Work
This is the largest study of patients with Congenital Hyperinsulinism that have been
genotyped and phenotyped. The phenotype of the patients recruited in this study was
studied in detail with regards to age of presentation, birth weight, biochemical features,
family history of hypoglycaemia/ diabetes, responsiveness to treatment with diazoxide,
persistence of disease and histopathological outcome (in cases where surgery was
performed). Sequence analysis of genes known to cause CHI was conducted following the
strategy detailed in chapter 3. The clinical features were then correlated to the results of
the genetic analysis. A genetic diagnosis was possible in 48.6% of study subjects
providing further evidence to the literature that the genetic cause of CHI is not known in
approximately 50% of patients (Hussain, 2008a).
In this cohort, the commonest identifiable cause of CHI was a mutation in ABCC8/
KCNJ11 genes that encode the components of the KATP channel in the pancreatic ß-cells.
Mutations in these genes accounted for 119/146 (81%) patients with an identifiable cause
and 87.6% of all patients with diazoxide unresponsive CHI. Recessively inherited
mutations in these genes were confirmed to cause diazoxide unresponsive CHI (chapter
5). So far, dominantly inherited mutations have been described in association with
diazoxide responsive disease. Apart from identifying novel dominant mutations that lead to
diazoxide responsive CHI, the study also identified novel dominant mutations that led to
diazoxide unresponsive disease (Flanagan et al., 2010). This novel finding has
implications for the prognosis of children identified to be heterozygous for a mutation in the
KATP channel genes and for genetic counselling of the patient and family. Interestingly, the
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dominant mutations causing diazoxide responsive CHI were associated with a high risk of
adult onset diabetes in our study (Chapter 9) with important implications for the follow up
of the children with these mutations and also for pathogenesis of a common condition such
as diabetes. Our findings are in contrast with a previous study by Pinney et al., (Pinney et
al., 2008) where the prevalence of diabetes mellitus in a large cohort of families with
dominantly inherited CHI was not increased. Interestingly, not all of the adult mutation
carriers in our study developed diabetes raising the question as to why only certain
individuals with these mutations develop diabetes. The study demonstrates that the
association of diabetes was not mutation specific. However, the effect of body mass index
(BMI) or any other additional factors was not studied. Future studies looking at the type of
diabetes (insulinopenia or insulin resistance or both) and effect of BMI on this unique
cohort of patients will help understand the pathogenesis of diabetes. These studies could
include an oral glucose tolerance test to assess the glucose tolerance, an intravenous
tolerance test and hyperglycaemic clamp to study the insulin secretory capacity and a
hyperglycaemic euglycaemic clamp study to assess the insulin sensitivity. Functional work
in this study was limited to proving the pathogenecity of the six novel dominant mutations
identified that cause diazoxide responsive CHI. Previous studies have shown that the
dominant mutations cause impairment of the responses of the KATP channel to MgADP and
diazoxide. Further patch-clamp studies (Muzumbya et al., 2007) are required to
understand the functional consequences of these novel dominant ABCC8/ KCNJ11
mutations that cause diazoxide responsive and unresponsive CHI. In the long term,
understanding molecular mechanisms of disease would inform development of novel
therapeutic strategies; especially required in the management of the severe, medically
unresponsive CHI.
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Chapter 5 also discusses the case study of a patient with compound heterozygous
mutations in the ABCC8 gene and transient CHI (Kumaran et al., 2010). This novel
association of transient, diazoxide unresponsive disease with recessively inherited
mutations in the KATP channel mutations has important clinical implications. It highlights the
importance of delaying pancreatic surgery (while maintaining normoglycaemia) even in
genetically confirmed diffuse disease unresponsive to diazoxide therapy, as the natural
course of many of the novel mutations is unknown.
Chapter 6 discusses the phenotype of 16 patients with CHI due to GLUD1 gene mutations
(published Kapoor et al., 2009b). The study confirms that mutations in this gene cause
diazoxide responsive CHI associated with normal birth weight, delayed age at presentation
and a high risk of epilepsy. Although the small number of patients limit the study of the
correlations between genotype and phenotype, interestingly all the three patients with
S445L mutation in this cohort were large at birth and developed epilepsy, suggesting that
this mutation may be associated with a severe phenotype. The highlight of the study was
the identification of a mutation in the GLUD1 gene in a patient with a normal serum
ammonia concentration as mutations in this gene are known to cause the Hyperinsulinism-
Hyperammonaemia (HI/HA) syndrome. Like other patients with HI/HA syndrome, this
patient was extremely leucine sensitive suggesting that GLUD1 mutational analysis may
be indicated in patients with leucine sensitivity; even in the absence of hyperammonaemia.
The study raises the possibility that the current prevalence of GLUD1 mutations based on
screening patients with hyperammonaemia might be an underestimate. Further studies are
required to study the prevalence of GLUD1 mutations in patients with leucine sensitive CHI
and normal serum ammonia concentrations.
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In chapter 7, a case of CHI due to a novel missense mutation in the HADH gene, a rare
cause of CHI, is discussed. Unlike all other previously reported cases of CHI due to this
genetic aetiology, this patient has normal acylcarnitine and urine organic acid profile,
previously thought to be diagnostic biochemical markers of CHI due to HADH mutations. In
addition, the novel observation of severe protein sensitivity (due to leucine sensitivity) in
patients with mutations in the HADH gene is described (published Kapoor et al., 2009a).
These novel clinical findings have implications for the diagnosis and management of
children with CHI. Additionally, the occurrence of severe protein/ leucine sensitivity in
these patients has provided a novel link between HADH and leucine induced insulin
secretion. In view of the reported interaction between HADH and GDH proteins (Filling et
al., 2008), it is possible that HADH causes leucine induced insulin secretion via the GDH
axis. Studies looking at direct protein-protein interactions involving HADH would help
confirm this hypothesis. This could be achieved by performing protein pull-down
experiments using anti-HADH or anti-GDH antibodies in ß-cells, followed by mass
spectrometric analysis of the pull-down proteins. It would also be interesting to study the
activity of GDH enzyme in patients with HADH mutations and confirm if there is a loss of
inhibitory effect of GTP on GDH (as in patients with HI/HA syndrome). This could be
determined by measuring the basal GDH activity and the concentration of GTP required to
inhibit GDH by 50% (IC50) in patient lymphoblast homogenates. These studies would help
in understanding the link between HADH, GDH and regulation of insulin secretion and will
provide invaluable insights into pancreatic ß-cell biochemistry and physiology.
Chapter 8 discusses the clinical characteristics of the eight patients with CHI that have a
mutation in the HNF4A gene. The study of this group of patients extends the observations
of Pearson et al. (Pearson et al., 2007) reporting that heterozygous HNF4A mutations can
also cause severe and persistent CHI along with mild, transient CHI described previously
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(published Kapoor et al., 2008). The only other previous study on HNF4A mutation causing
CHI examined families of patients with diabetes due to HNF4A mutations and concluded
that CHI due to HNF4A mutations caused hypoglycaemia and was associated with a
family history of diabetes. In this study, three of the eight probands did not have a diabetic
parent, illustrating that the absence of a history of diabetes in the parents should not
preclude sequencing of the HNF4A gene in patients presenting with diazoxide responsive
CHI.
In chapter 8, the clinical characteristics of the four groups of patients with diazoxide
responsive CHI (with a KATP channel, GLUD1, HNF4A and HADH mutation) were also
compared. There was overlap in the birth weight and age of presentation between the KATP
channel and the HNF4A groups, with patients in these two groups presenting earlier and
being heavier at birth than the patients with a mutation in the GLUD1 and HADH gene.
Similarly, these two clinical characteristics were not statistically different between the
HADH and GLUD1 group. This extends the phenotypic similarities shared by the patients
with a mutation in the HADH or GLUD1 genes, in addition to the leucine sensitivity
described previously. Additionally, the association of diabetes in the adult carriers of a
dominant KATP channel mutation (Chapter 9) suggests that a family history of diabetes is
not a feature exclusive to patients with HNF4A mutations.
The mechanism of CHI due to HNF4A mutations is not known. It is likely that HNF-4
deficiency probably exhibits its phenotype via abnormal expression of one or more of its
many target islet genes. Further studies are required to study the effect of HNF-4
deficiency on the genes expressed in the ß-cells of the pancreatic islets, to help
understand the molecular mechanism underlying the opposite phenotypes of CHI and
diabetes caused by mutations in this gene.
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Finally, the genetic mechanisms causing CHI are yet to be elucidated in the remaining 152
(51.4%) patients from this cohort. This cohort forms a unique group of patients for future
research. The majority of the patients in this group with an unidentified genetic aetiology
are diazoxide responsive (132/ 152). Within this large group of patients with diazoxide
responsive CHI, there are unique and rare groups of patients with unusual types of CHI
where the phenotypic features are not limited to hyperinsulinaemic hypoglycaemia. These
include:
a) Renal cysts and CHI (n=6): These patients have clinical and imaging
features of autosomal recessive polycystic kidney disease along with
diazoxide responsive CHI.
b) Hypopituitarism and CHI (n=5). These patients have hypopituitarism,
ranging from isolated growth hormone deficiency to multiple pituitary
hormone deficiencies.
c) Cerebellar dysfunction and CHI (n=4). Four patients with cerebellar signs
(structurally normal brain on MRI scan) and CHI have been identified,
indicating a possible genetic link between the cerebellum and pancreas.
Two candidate genes (NEUROD1 and Kv2.1 gene) expressed in the
cerebellum and the pancreas, have been sequenced in these patients so
far (Kv2.1 gene sequencing was performed by me).
The occurrence of groups of patients with additional phenotypic features suggests that a
genetic aetiology may link these rare phenotypes. Future studies including candidate gene
studies, homozygosity mapping studies (in consanguineous families) and the use of next
generation sequencing techniques may lead to discovery of novel genetic aetiologies and
may give novel insights into the development of organs such as the cerebellum, pituitary,
kidney and pancreas.
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Chapter 12
Appendices
12.1 Proforma and consent forms:
PLEASE RETURN THIS FORM WITH EDTA BLOOD OR DNA WHEN GENETIC TESTING FOR
HYPOGLYCAEMIA IS REQUESTED
Defining phenotype-genotype correlations in patients with hypoglycemia
Consultant Paediatric Endocrinologist: Dr Khalid Hussain (02079052128 or
K.Hussain@ich.ucl.ac.uk)
Consultant Molecular Geneticist: Prof S. Ellard (01392-402910 or
Sian.Ellard@rdeft.nhs.uk)
Please contact Dr Ritika Kapoor, Clinical Research Fellow at the Institute of Child Health
(07814149531, 0207 2429789/ Extn 2274, r.kapoor@ich.ucl.ac.uk) as soon as diagnosis is
established.
Please fill in as fully as possible and circle Yes/ No where appropriate.
Patient details Requestor details
Surname..............................…..………. Clinician name............................
First name(s).......................……......... Telephone ................................
Date of birth........................…………….. Email Address…………………………………..
Gender...............................…… ………. Address for report.......................
Hospital No.........................……………… ..............................................
Address………………………...........……………….
Tel No……………………………………………………….. Type of Test: NHS Research
Ethnic origin …………………………………………….. If NHS referral, has consent for
research been obtained? Yes/No
Clinical information
Age at presentation (weeks): ......................
Duration of hyperinsulinism:……………………………
Insulin level: ……….. (mU/L) C-peptide: .......... (pmols/l) Glucose level: …………
(mmol/L)
Details of Treatment
Current Treatment: …………………………..
Responsive to current treatment? : Yes/No
Any other medications tried? Please give details (name of drug, duration tried):
…………………………………………………………………………………………………………………………………
Pancreatectomy performed? : Yes/No
If yes, focal/diffuse disease: ……………………………..
Neonatal History
Birth weight (g): ………….……………….Gestation (weeks): ............................
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IUGR: Yes/No
Perinatal Asphyxia: Yes/No
Any syndromic features (e.g. Beckwith Weidemann Syndrome). Please give details:
……………………………………………………………………………………………………………………………………..
Hyperammonaemia? : ………………………………………………………(give level and normal range)
Any other medical problems? : ……………………………………………………………………………………….
Family history
Are parents related? If yes – how? : ………………………………………………………
Any family history of hypoglycaemia? : ………………………………………………………
Any family history of diabetes? Please give details of affected family members (age of
onset, treatment and duration of diabetes):
………………………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………
(NB. A pedigree showing clinical details of affected family members would be very
helpful).
Testing required (If no boxes are ticked, testing will be performed according to the
clinical information provided)
SUR1 sequencing KCNJ11 (gene encoding Kir6.2) sequencing GCK
(glucokinase) sequencing
GLUD1 sequencing LOH analysis for 11p15 (paraffin-embedded pancreatic tissue
required + blood DNA)
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DNA sample taken from patient: Yes/No
Consent form
Consent by parent or guardian for genetic testing to determine the cause of
hypoglycemia in a child less than 16 years old
Date:…………………………………………………………...
Child’s full name:……………………………………………..
Date of birth:…………………………………………………..
Parent or guardian’s full name:………………………………………..
I have given permission for a blood sample to be taken from my child to allow genetic
testing to be performed. I understand that this testing will be only for the purpose of
determining the cause of hypoglycaemia in my child or a member of my family. The
sample will not be used for any other purpose. The testing will be performed in the
molecular genetic laboratory, Peninsula Medical School, Exeter UK.
The details of the testing have been explained by …………………………………….
Signed …………………………………………………
Consent for genetic testing to determine the cause of hypoglycemia (patient)
Date:…………………………………………………………...
Name of the person:……………………………………………..
Date of birth:…………………………………………………..
I have given a blood sample to allow genetic testing to be performed on my blood. I
understand that this testing will be only for the purpose of determining the cause of
hypoglycaemia that affects myself or a member of my family. The sample will not be
used for any other purpose. The testing will be performed in the molecular genetic
laboratory, Peninsula Medical School, Exeter UK.
The details of the testing have been explained by …………………………………….
Signed …………………………………………………
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If samples from other family members have been sent previously please give details:
.............................................................................................................
Consent for genetic testing to determine the cause of hypoglycemia (family member,
if applicable)
I have given a blood sample to allow genetic testing to be performed on my blood. I
understand that this testing will be only for the purpose of determining the cause of
hypoglycaemia that affects a member of my family. The sample will not be used for any
other purpose. The testing will be performed in the molecular genetic laboratory,
Peninsula Medical School, Exeter UK.
The details of the testing have been explained by …………………………………….
1) Name of the person:………………………………………
Date of birth:…………………………………………………
Relationship with the patient:………………………………..
Signed …………………………Date……………………….
2) Name of the person:………………………………………
Date of birth:…………………………………………………
Relationship with the patient:……………………………….
Signed …………………………Date……………………….
3) Name of the person:………………………………………
Date of birth:…………………………………………………
Relationship with the patient:……………………………….
Signed …………………………Date……………………….
4) Name of the person:………………………………………
Date of birth:…………………………………………………
Relationship with the patient:……………………………….
Signed …………………………Date……………………….
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Samples taken
The samples should be labeled with name and date of birth and can either be:
1. Our preferred option is Blood 5 mls: taken in tubes containing EDTA and couriered
fresh (not frozen). This should be sent in a package with at least two layers of wrapping
and include absorbent material to absorb any blood that leaks out of the tube.
2. Or made into DNA and 2-10 micrograms (to allow repeats) sent at room temperature.
Again please make sure the tube is very securely sealed.
Where should samples be sent?
Please discuss with Dr Ritika Kapoor (r.kapoor@ich.ucl.ac.uk/ 07814149531/
02072429789, Ex 2274) before sending samples.
The samples should be sent to:
Dr. Ritika Kapoor
NIHR Clinical Research Associate
Institute of Child Health
1st Floor, Clinical & Molecular Genetics Unit
30, Guilford Street
London
WC1N 1EH
Email: r.kapoor@ich.ucl.ac.uk
Other questions
Please do contact me if there are any other questions. We would be very keen to help
in any way we can.
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12.2 Parent/Guardian Information Sheet:
Project Title: Defining genotype-phenotype correlations in patients with
hypoglycemia.
1. The aim of the study
The aim of this project is to investigate the genetic causes of hypoglycaemia (low blood
glucose) in newborns, infants and children.
Previous research has already identified a number of abnormalities in certain genes that can
cause hypoglycaemia, but we still don’t know the cause in the majority of children.
Recently, we found a new genetic cause of hypoglycaemia due to excessive insulin
secretion (hyperinsulinism). The aim of this study is to characterize this novel type of
hyperinsulinism along with trying to unravel further genetic causes.
2. Why is the study being done?
A normal blood glucose level is important for brain function. Hypoglycemia (low blood
glucose levels) can cause significant brain injury. We currently have very little
understanding as to the genetic mechanisms that cause hypoglycaemia in childhood. This
study will allow us to understand why hypoglycaemia develops in some children and the
genetic basis of this. This will have important implications for the future treatment of our
children.
3. How is the study being done?
If you agree to participate in this study, your child will have an additional blood sample
taken when they are having their routine investigations. We will use this blood sample to
extract DNA (genetic material). The DNA will then be used to analyze certain genes. The
extra blood sample that we take will do no harm to your child, as the amount of blood that
we will take is extremely small (5 mls). As a part of the study, we might request blood
samples from you or other related family members; especially if there is a family member
affected with diabetes mellitus/ hypoglycemia. This blood sample will be used to extract
DNA that will be used only for the purpose of establishing a genetic cause for
hypoglycaemia.
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4. What are the risks and discomfort?
No risk to the child can be foreseen. Your child will have a cannula inserted for routine
medical treatment and we will then take the blood sample from the cannula. There is
discomfort from the insertion of the cannula but we would normally numb the skin anyway
with a local anaesthetic cream.
5. Who will have access to the case/research records?
Only the researchers and a representative of the Research Ethics Committee will have
access to the data collected during this study.
6. What are the arrangements for compensation?
An independent Research Ethics Committee who believes that it is of minimal risk to your
child has approved this research. However, research can carry unforeseen risks and we are
required to tell you that if your child is harmed and this is due to someone’s negligence,
you may have grounds for legal action for compensation in respect of any harm arising out
of participation in the study.
7. What are the potential benefits?
This study will not bring any immediate benefits to your child. However, if we find the
genetic mechanism that is causing the hypoglycaemia in your child we will explain this to
you and it will give us a better understanding of why some children do develop this
condition.
8. Do I have to take part in this study?
No, you do not have to take part in the study if you do not wish to. If you decide, now or at
a later stage, that you do not wish to participate in this research project, that is entirely your
right and will not in any way prejudice any present or future treatment.
9. Who do I speak to if problems arise?
If you have any complaints about the way in which this research project has been, or is
being conducted, please, in the first instance, discuss them with the researcher (Dr. Ritika
Kapoor: 07814149531; 02072429789/ Extn 2274; r.kapoor@ich.ucl.ac.uk).
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12.3: Letter of approval from the Research Ethics Committee
Institute of Child Health/Great Ormond Street Hospital Research Ethics
Committee
The Institute of Child Health
30 Guilford Street
London
WC1N 1EH
Tel: 020 7905 2620
Fax: 020 7905 2201
27 April 2007
Dr Khalid Hussain
Consultant Paediatric Endocrinologist
Unit of BEM, 30 Guilford Street
London
WC1N 1EH
Dear Dr Hussain
Study title: The genetics of childhood hypoglycaemia
REC reference: 06/Q0508/58
Amendment number: 1
Amendment date: 22 March 2007
The above amendment was reviewed at the meeting of the Sub-Committee of the REC
held on 24 April 2007.
Ethical opinion
The Subcommittee asked for extra clarifications which were dealt with by Dr Kapoor in
writing. The further information was considered by Chairman's action.
When they are available, the Subcommittee asks for copies of the ethical approval from
the countries outside the UK.
The Chairman on behalf of the Subcommittee present gave a favourable ethical opinion of
the amendment on the basis described in the notice of amendment form and supporting
documentation.
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Approved documents
The documents reviewed and approved at the meeting were:
Document Version Date
Protocol new - The genetics of childhood
hypoglycaemia
Participant Information Sheet new Parent/ Guardian
"Pro-forma" entitled Defining
phenotype-genotype
correlations in patients with
hypoglycemia
new
Notice of Substantial
Amendment (non-CTIMPs)
22 March 2007
Covering Letter 22 March 2007
Participant Consent Form:
Consent Form
new
Protocol old protocol
Participant Information Sheet old information sheet
Participant Consent Form old consent form
Protocol Version II March 2007
Parent/ Guardian Information
Sheet
Version II March 2007
Participant Consent Form, “Pro
forma” entitled Defining
phenotype-genotype
correlations in patients with
hypoglycaemia
Version II March 2007
Email from Dr Kapoor with
further clarifications
26 April and 27 April 2007
Membership of the Committee
The members of the Committee who were present at the meeting are listed on the
attached sheet.
R&D approval
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All investigators and research collaborators in the NHS should notify the R&D office for the
relevant NHS care organisation of this amendment and check whether it affects R&D
approval of the research.
Statement of compliance
The Committee is constituted in accordance with the Governance Arrangements for
Research Ethics Committees (July 2001) and complies fully with the Standard Operating
Procedures for Research Ethics Committees in the UK.
06/Q0508/58: Please quote this number on all correspondence
Yours sincerely
Taki Austin
Research Ethics Co-ordinator
E-mail: t.austin@ich.ucl.ac.uk
Enclosures List of names and professions of members who were present at the
meeting and those who submitted written comments
Copy to: Great Ormond Street Childrens Hospital NHS Trust/ Institute of Child
Health R&D Department
Institute of Child Health/Great Ormond Street Hospital Research Ethics Committee
Attendance at Sub-Committee of the REC meeting on 24 April 2007
Name Profession Capacity
Dr V Larcher Consultant Paediatrician
Mr R Selby Lay member
Also in attendance:
Name Position (or reason for attending)
Taki Austin Research Ethics Co-ordinator
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12.4 DNA Extraction -Promega Wizard Genomic DNA purification Kit
The following DNA extraction protocol is used by staff at Peninsula Medical School,
Exeter for volumes of blood greater than 1ml
Safety precautions
Standard laboratory precautions apply and powder free gloves should be worn at all times.
Please refer to COSHH forms/safety data sheets for other chemicals utilised in this
protocol and risk assessments for procedures employed. The extraction should be carried
out in a Class II cabinet.
Materials
Product Supplier
Promega Wizard Genomic DNA
Purification kit
Promega
Cat. No. A1620
Ethanol (99.7-100%) BDH
Cat. No. 10107
Isopropanol Sigma Aldrich
Cat. No. 190764
Notes:
Ensure all reagents are mixed before using.
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Methods
1. Place blood samples to be extracted into a rack in the order that they are on the
extraction workbatch. Check details on blood tube against workbatch.
2. Label 50ml centrifuge tubes with the patient name as per workbatch.
3. Transfer 1-7.5ml blood to the centrifuge tube. Add Cell Lysis Solution to make a total
volume of 30ml. Invert tube twice to mix.
4. Incubate at room temperature for 10 minutes, inverting 2-3 times during this period.
5. Centrifuge at 3,000rpm in Sigma 4-15 centrifuge for 10 minutes.
6. Tip off supernatant carefully (into 2% bleach solution) without disturbing the visible
white pellet.
7. Add 5ml Cell Lysis Solution, vortex to mix and repeat steps 7-8. Proceed to step 10.
8. Vortex the tube vigorously until the white blood cells are resuspended.
9. Add 5ml Nuclei Lysis Solution to the cells. Using a pasteur, pipette the solution 5-6
times to lyse the white blood cells. The solution should become very viscous.
10. Add 1.65ml Protein Precipitation Solution to the nuclear lysate and vortex vigorously
for 10 seconds.
11. Centrifuge at 3,000rpm in Sigma 4-15 centrifuge for 10 minutes. A dark brown protein
pellet should be visible.
12. Label a 15ml centrifuge tube with the patient name as per workbatch. Add 5ml
isopropanol.
13. Transfer the supernatant to the 15ml centrifuge tube containing the isopropanol. Gently
mix the solution by inversion until the white thread-like strands of DNA form a visible
mass.
14. Centrifuge at 3,000rpm in Centaur 2 for 2 minutes.
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15. Carefully decant the supernatant into a beaker. Add 1ml 70% ethanol to the DNA.
16. Centrifuge at 3,000rpm in Centaur 2 for 2 minutes.
17. Carefully decant the ethanol into a beaker. Air-dry the DNA pellet for 10-15 minutes.
18. Add 500µl DNA Rehydration Solution (0.1mM EDTA see Appendix 12.3.1) to the tube
(100µl if there is little visible DNA) and rehydrate the DNA by placing samples in the
waterbath for a maximum of 1 hour at 65oC then leave samples overnight to rehydrate
DNA. For samples extracted at the end of the day put in the waterbath the following
morning. For samples run on Friday afternoon leave for the weekend at room
temperature.
19. Generate labels for each patient according to the workbatch. The label should have
the patient name, lab number and location (as per DNA data sheet, column N).
20. Nanodrop the DNA sample (refer to Nanodrop SOP – MG/SOP/SPE017) and record
concentration and ratio on DNA data sheet (columns B and C) and workbatch.
21. If DNA concentration is <300ng/ul for any test (excluding FVL/PROTH, B27,
Haematology tests, HCHRO) then a repeat extraction should be carried out on a spare
blood sample if possible. For all other tests, if the concentration is <50ng/ul notify a
scientist who will decide whether this is sufficient for the test requested.
22. A second person should now be present to witness the transfer. Read out the details
on the blood tube, 50ml tube and 15ml tube and the witness should check the details
against the workbatch. Pick up the 15ml tube.
23. Obtain a 2D barcode tube and scan barcode number into column L of DNA data sheet.
24. Transfer entire DNA sample from 15ml tube to 2D barcode tube.
25. Obtain label and check details on label by reading out to witness. If correct stick label
on 2D barcode tube.
26. DNA can now be put in appropriate location in -20oC freezer.
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Any blood remaining from extraction should be stored (maximum 1 tube per patient).
Samples for Clinical Genetics patients are stored for one year and then destroyed. Non-
Clinical Genetics patients’ spare bloods should be destroyed after 3 months. Any surplus
blood tubes should be placed in the autoclave bin.
Appendix 12.3.1:
DNA Rehydration buffer (0.1mM EDTA)
5ml Kit Rehydration Buffer
1ml 1M Tris-HCl (Sigma T2788)
44ml Baxter water
249
12.5: Primer sequences for amplification of GLUD1 gene and HADH genes:
A) Primer sequences for amplification of GLUD1 genes which encodes the catalytic
and allosteric domains of glutamate dehydrogenase:
Exon Forward Reverse
6 TTAAATGAGAATGTGCTTTGACTT TGAATTTGGTGATAGTTTGGTTG
7 GCCCGCTCATCACATTCTT CTCTGGGTGCGTTGGATTT
10 GTGGGATGGGAAGGAGTGT TTGTGCATTTTTGGTCTAAGTTTC
11 TCTGTTAGCAATATCTTGATCTCTTG CAAAGACTATGCCGCAGATG
12 GTTCTGTGTGGTGTCCCTGTT GGCTGAGATAGCATGGTTGAG
B) Primer sequences for amplification of the eight exons of HADH gene:
Exon Forward Reverse
1 CGTGTATACCCGCTCAACG GTGAAAACTCCCTGGTGTCG
2 TCGGTATTTTGAATGGAATGG AACCTCAAATCCCACCCAAC
3 GAACAGATAGGGTAGGCCAAT GCATGGAACAAAACTGCAC
4 CCCAATGGGTCAGGACAAC TATGAGGCTCAGGGACAACC
5 TTGTTTCTGGCTTGAGATTCC AACTAGAACAGGAGGCACGG
6 TGTACAGCTTGATAAATGGGG TCACAAAGCTAGAAAACAGACACTG
7 CCAAGCCAGAAAGTCTCAGTC GTGAGGCAGGATTTTGGAAG
8 CACCAGCACAGCCTTCCT TGCTGTAACTGGTGTAATAATCACTTC
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12.6: Map of the vector pcDNA3, a commercially available vector (Invitrogen,
Paisley, UK).
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12.7: Map showing the main features of the vector pcDNA3.1/Zeo (Invitrogen,
Paisley, UK).
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12.8: Map of the pEGFP-N1 vector (CLONTECH Laboratories), showing the multiple
cloning site (MCS) and the various restriction sites.
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12.9 Presentations at National and International Conferences
2009
1. Diabetes Mellitus and Hyperinsulinaemic Hypoglycaemia (HH) due to Dominant
ABCC8/KCNJ11 Mutations- Oral Presentation at the British Society of Paediatric
Endocrinology and Diabetes (BSPED) meeting, Reading, November
2. Diabetes Mellitus and Hyperinsulinaemic Hypoglycaemia due to Dominant
ABCC8/KCNJ11 Mutations- Poster Presentation at the UCL Partners Symposium,
London, September
3. 3-Hydroxyacyl-Coenzyme A Dehydrogenase (HADH) Deficiency and
Hyperinsulinaemic Hypoglycaemia: Characterization of a Novel Mutation and
Severe Protein Sensitivity. Oral Presentation at the Congenital Hyperinsulinism and
Pancreatic Tumors in Childhood International Congress, Greifswald, Germany,
September
4. Clinical and Molecular Characterisation of 300 Patients with Congenital
Hyperinsulinism- Oral Presentation at the Lawson Wilkins Pediatric Endocrine
Society- European Society of Paediatric Endocrinology (LWPES-ESPE)
Conference, New York, September
5. Prevalence of HNF4A gene Mutations in Patients with diazoxide Responsive
Hyperinsulinism- Poster Presentation at the LWPES-ESPE Conference, New York,
September
6. Hyperinsulinism-Hyperammonaemia (HI/HA) Syndrome: Novel Mutations in the
GLUD1 gene and Genotype-Phenotype correlations- Poster Presentation at the
LWPES-ESPE Conference, New York, September
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2008
1. Hyperinsulinism-Hyperammonaemia (HI/HA) syndrome: Novel mutations in the
GLUD1 gene and genotype phenotype correlations- Poster presentation at the
BSPED Conference, Swansea, November
2. Genotype-Phenotype Correlations in Patients with Hyperinsulinaemic
Hypoglycaemia due to Mutations in the HNF4A Gene- Oral presentation at the
ESPE Conference, Turkey, September
3. Persistent Hyperinsulinaemic Hypoglycaemia and Maturity Onset Diabetes of the
Young (MODY) due to Heterozygous HNF4A Mutations- Poster Presentation at the
International Update in Paediatric Endocrinology, Mumbai, India, February
2007
1. Severe Hyperinsulinaemic Hypoglycemia and Maturity Onset Diabetes Of the
Young -due to mutations in the HNF4A gene. BSPED Conference, Cambridge, UK
– September
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12.10 Honours and Awards
 Clinical Research Associate Award for the research project entitled ‘Congenital
Hyperinsulinism: Understanding the Genotype-Phenotype Correlations, Molecular
Mechanisms and Relationships with Diabetes Mellitus’. Funding awarded by the
NIHR- Biomedical Research Centre at the Institute of Child Health, London for 2
years commencing September 2009.
 President’s Best Poster Prize awarded for ‘Prevalence of HNF4A gene Mutations
in Patients with diazoxide Responsive Hyperinsulinism’ presented at the
LWPES/ESPE Conference, New York, September 09
 ESPE Travel Grant awarded for the abstract ‘Genotype-phenotype Correlations in
Patients with Hyperinsulinaemic Hypoglycaemia due to Mutations in the HNF4A
Gene’, presented at the ESPE (European Society of Paediatric Endocrinology)
Conference, Turkey- September 08.
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12.11 Publications in peer reviewed journals
1. Flanagan SE, Kapoor RR, Banerjee I, Hall C, Smith V, Hussain K, Ellard S (2010).
Dominant ABCC8 mutations in patients with medically unresponsive
hyperinsulinemic hypoglycaemia. Clinical Genetics (in press).
2. Kumaran A, Kapoor RR, Flanagan SE, Ellard S, Hussain K. Congenital
hyperinsulinism due to a compound heterozygous ABCC8 mutation with
spontaneous resolution at eight weeks. Horm Res Paediatr. 2010;73(4):287-92
3. Flanagan S, Kapoor RR, Mali G, Cody D, Murphy N, Schwahn B, Siahanidou T,
Banerjee I, Akcay T, Rubio-Cabezas O, Shield J, Hussain K, Ellard S. Diazoxide-
responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations. Eur
J Endocrinol. 2010 Feb 17.
4. Kapoor RR , Flanagan SE, Fulton P, Chakrapani A, Chadefaux B, Banerjee I,
Julian Shield, Ellard S, Hussain K. Hyperinsulinism-Hyperammonaemia (HI/HA)
syndrome: Novel mutations in the GLUD1 gene and genotype phenotype
correlations- European Journal of Endocrinology 2009 Nov;161(5):731-5.
5. Kapoor RR , Flanagan SE, James C, Eaton S, Ellard S, Hussain K. 3-Hydroxyacyl-
Coenzyme A Dehydrogenase (HADH) Deficiency and Hyperinsulinaemic
Hypoglycaemia: Characterization of a Novel Mutation and Severe Protein
Sensitivity. JCEM 2009 Jul;94(7):2221-5.
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6. Kapoor RR, Colclough K, Flanagan S, Wales J, Conn J, Ellard S, Hussain K.
Persistent Hyperinsulinaemic Hypoglycaemia and Maturity Onset Diabetes of the
Young (MODY1) due to Heterozygous Mutations in the HNF4A gene. Diabetes.
2008 Jun;57(6):1659-63
